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ABSTRACT 
 
 β-lactamase enzymes catalyze the irreversible hydrolysis of the four-membered 
cyclic amide ring characteristic of β-lactam antibiotics rendering them inactive and 
useless against pathogenic bacteria. Understanding structure activity relationships 
between β-lactam antibiotics and β-lactamases is important for designing novel β-
lactams, β-lactamase inhibitors, and β-lactam-based fluorescent probes for rapid 
diagnosis of β-lactam antibiotic resistant infections.  
 The first half of this study focuses on the class A β-lactamase BlaC from 
Mycobacterium tuberculosis (Mtb) and addresses intermolecular interactions between 
BlaC and substrates, inhibitors, and biosensors that influence their kinetic parameters 
with BlaC and activities against Mtb. The substrate structure activity relationship 
explained the molecular basis for differential innate resistance of Mtb to faropenem, 
biapenem, and tebipenem by showing the interactions between BlaC and the lactams that 
govern differential acyl-intermediate stability and affinity. The inhibitor structure 
activity relationship revealed features of the BlaC active site that can be exploited to 
enhance binding and inhibition of BlaC by benzoxaboroles, and demonstrates their 
utility as potentiators of β-lactam antibiotic activity against Mtb. BlaC-specific β-lactam 
based fluorescent probes were designed and optimized for Mtb detection. Their utility 
was demonstrated by detecting down to 10 colony forming units of bacillus 
Mycobacterium bovis Calmette–Guérin (BCG) in human sputum. 
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 The second half of this study focuses on the New Delhi Metallo-β-lactamase-1 
(NDM-1), which is rapidly generating bacterial resistance to nearly all β-lactams. The 
NDM-1 gene encodes a class B1 metallo-β-lactamase enzyme. Purified recombinant 
NDM-1 was biochemically and biophysically characterized. The crystal structures of apo 
and monometalated NDM-1 provided structural insight into metal binding and the 
promiscuous enzymatic activity of NDM-1. Mechanistic details of the NMD-1 reaction 
were examined by comparing crystal structures of NDM-1 in complex with an 
unhydrolyzed β-lactam substrate and with hydrolyzed products. These structures were 
used for quantum mechanics / molecular mechanics simulations to estimate the free 
energy along the β-lactamase reaction coordinate. The results suggest that NDM-1 uses 
bulk water as the nucleophile that attacks the β-lactam ring, and a coordinated hydroxide 
ion or water molecule as the catalytic base depending on pH. 
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CHAPTER I  
 
INTRODUCTION AND LITERATURE REVIEW 
 
 Drug resistance presents a formidable threat to human health and modern 
medical practices. Pathogenic microorganisms possess many drug resistance 
mechanisms. Whether the genes that code for such mechanisms are innate or acquired, 
they have the ability to evolve and enhance the fitness of the organism by overcoming or 
disarming antibiotic threats to the cell.   
β-lactam antibiotics are the most widely used antibiotic class in the world 
because of their broad spectrum activity against bacterial pathogens and relatively low 
toxicity to humans. They are routinely used as prophylactics during surgeries, and to 
treat existing infections. β-lactamase enzymes are the primary mechanism of resistance 
to β-lactam antibiotics. The first section of this record of study addresses ways to combat 
β-lactamase mediated β-lactam antibiotic resistance due to the chromosome-encoded β-
lactamase of Mycobacterium tuberculosis (BlaC) through multidisciplinary biochemical 
and biophysical approaches spanning the molecular to organismal levels. The resulting 
structure activity relationships revealed the structural basis for differential resistance of 
Mtb to several β-lactams, structural insights into the mechanism of inhibition of BlaC by 
benzoxaboroles, and aided in the design of a BlaC specific probe for tuberculosis 
detection. The second section of this record of study identifies the biochemical, 
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biophysical, and mechanistic determinants for the extreme promiscuity of the recently 
discovered plasmid encoded New Delhi metallo-β-lactamase (NDM-1). 
The serendipitous discovery of penicillin by Alexander Fleming in 1928 marked 
the beginning of an era where bacterial infections became routinely treatable. Fleming 
noticed a zone of staphylococci growth inhibition surrounding a mold that had 
contaminated the culture plates. The contaminant species was identified as mold from 
the Penicillum genus, which Fleming hypothesized released a substance that possessed 
the antibiotic activity. He named the active substance penicillin, and modern day β-
lactam antibiotics were born
1,2
. 
Since the isolation, mass production, and clinical implementation of penicillin in 
the 1940’s, several new β-lactams emerged from natural, semi-synthetic, and eventually 
full synthetic sources
3,4. By the late 1990’s, β-lactams were estimated to comprise 
greater than 65% of the world’s antibiotic market5. 
Identification of the cell wall components and the penicillin-sensitive 
transpeptidase, carboxypeptidase and endopeptidase activities
6,7
 and the mechanism of 
action of penicillin have been studied and reviewed extensively
8
. A variety of 
phenotypic effects and observations alluded to the mechanism of action of β-lactam 
antibiotics. Penicillin treated bacteria exhibited increases in metabolic precursors to the 
cell wall component murine, or peptidoglycan, and also had altered cell morphology 
suggesting that the target performed a cell wall biosynthetic function
9-11
. Experiments 
with radiolabeled penicillin were able to trace the antibiotic activity to a set of enzymes 
localized in the inner membrane of Escherichia coli
12
 that were able to bind penicillin, 
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thus emerging the moniker penicillin binding proteins (PBP). The structural mimicry of 
penicillin to the D-alanyl-D-ala peptide substrate of transpeptidases suggested that 
penicillin and other β-lactams function through inhibition of essential cell wall 
biosynthetic transpeptidase enzymes
13,14
. The target of penicillin was confirmed when 
inhibition of the transpeptidase and carboxypeptidase enzyme activities was 
demonstrated in vitro
15
. D-D-transpeptidases function by cleaving the bond between D-
Ala4 and D-Ala5 of the substrate pentapeptide, and subsequently cross-linking D-Ala4 to 
the amino group of the third residue of the acceptor stem peptide
16
. Targeting the 
peptidoglycan cross-linking activity of essential transpeptidases enzymes with β-lactam 
antibiotics has proven to be an excellent strategy for anti-infective therapy
17
. 
 β-lactam antibiotics exhibit extended spectrum antibiotic activity against gram-
positive and gram-negative pathogens
1,18,19
. The general structure of a gram-positive cell 
wall is composed of an inner membrane surrounded by a thick peptidoglycan layer, 
where the cell wall of gram-negative organisms is composed of inner and outer 
membranes with a relatively thin peptidoglycan layer in the middle
20
. The mycobacterial 
cell wall is generally considered as gram positive, though it contains an extra layer of 
mycolic acids covalently linked to arabinogalactan, which is linked to the peptidoglycan 
layer
21
.  Irreversible disruption of the peptidoglycan by inhibition of PBPs by β-lactams 
compromises the structural integrity of the cell wall eventually leading to cell death
8,22
. 
Orally available β-lactams are commonly used either alone or in combination with other 
antibiotics for the treatment of the following pathogenic bacterial infections: 
Staphylococcus aureus, Streptococcus species, Haemophilus influenza, Moraxella 
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catarrhalis, Listeria monocytogenes, Proteus mirabilis, Escherichia coli, Klebsiella 
species, Proteus vulgaris, and Enterococcus species
17
. Mycobacterial species are also 
susceptible to the deleterious effects of β-lactam antibiotics, but they are less sensitive 
due to one or more resistance mechanisms preventing clinical utility of β-lactams for 
these infections
23
. 
 Stresses imposed on the bacteria by environmental conditions are the driving 
force for selection of mutations that increase organismal fitness. This is the basis for 
evolution by natural selection, and is also at the heart of bacterial resistance to antibiotics 
where humans have introduced selective pressure. In addition to the acquisition of 
compensatory mutations that decrease the efficacy of antibiotics, bacteria have innate 
resistance mechanisms that help evade antibiotic action. These include pumping the drug 
outside of the cell, modifying or swapping the target protein, or enzymatically changing 
the antibiotic
24
.  For example, L-D-transpeptidases, a more recently discovered member 
of the PBP family, have been found to bypass conventional D-D-transpeptidation by 
forming alternative peptidoglycan crosslinks with L-Lys3 instead of D-Ala4
25
. Since β-
lactam antibiotics target D-D transpeptidases by mimicking their polypeptide substrates 
D-Ala4 D-Ala5, not L-Lys3 D-Ala4, the switch from D-D transpeptidation to L-D 
transpeptidation is accompanied by resistance to β-lactam antibiotics25.  
 Mycobacteria possess both D-D-transpeptidase as well as L-D-transpeptidase 
functions
26
. Experimental evidence suggests that β-lactam antibiotics target both D-D 
and L-D-transpeptidases
27
 
28
, albeit with differential specificity. It was discovered that 
the peptidoglycan of stationary phase Mtb primarily contains crosslinks generated by L-
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D-transpeptidation, which suggests that remodeling of the D-D peptidoglycan crosslinks 
may be involved in resistance to β-lactam antibiotics. The gene that encodes the L-D-
transpeptidase, LdtMt1, is upregulated in response to nutrient starvation. Notably, the 
enzyme LdtMt1 is inactivated by carbapenem-type β-lactams, suggesting that 
carbapenems, and structurally similar β-lactams, can function to target both D-D and L-
D transpeptidases in actively dividing and persistent MTB infection
28
.  
 The most common and often primary mechanism of resistance to β-lactam 
antibiotics is the expression of β-lactamase enzymes. These enzymes catalyze the 
irreversible hydrolysis of the active chemical moiety of β-lactams, the four membered 
cyclic amide or β-lactam ring. Cells expressing β-lactamase have a significant 
evolutionary advantage over those without β-lactamase. However, β-lactamase have very 
distinct substrate specificities, some narrow and some broader than others. 
 β-lactamases are non-essential enzymes related to the PBP family, and sequence 
similarity lends credence to the hypothesis that they evolved from a common ancestral 
enzyme
29,30
. The driving force behind selection and maintenance of β-lactamase function 
is likely interspecies competition
31
. It is assumed that β-lactams including penicillins, 
cephalosporins, and others are natural product weapons secreted by microorganisms 
competing for resources; therefore the evolution of β-lactamase genes was essential for 
co-existence
30
. 
 In addition to chromosome-encoded β-lactamase genes, they are also maintained 
among bacterial populations as transmissible genes on plasmid DNA. These may be the 
most threatening of all types of β-lactamase because of the constantly changing 
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environment and selective pressure that facilitates evolution and expansion of their 
substrate specificities to become highly potent, promiscuous β-lactamases. 
 β-lactamase enzymes are historically classified based on their primary structure 
(classes A-D)
32
 but have also been functionally classified based on their substrate 
specificity
33,34
. They are also further grouped into families, whose members are nearly 
identical to each other but may have single or multiple mutations, insertions, or deletions 
that change their substrate specificities, or confer resistance to inhibitors. Their diverse 
acronym-based nomenclature of β-lactamase families is representative of their origin, 
while the numeric portion distinguishes derivative mutants of each type
35
. 
 Classes A, C, and D of β-lactamase are serine hydrolases36, and class B enzymes 
are mechanistically distinct in that they require metal cofactors for function
37,38
. Though 
they may have evolved from a common ancestor, mechanistic studies indicate that β-
lactamase classes evolved separately in response to different environmental stresses
39
. 
The mechanisms of serine β-lactamases have been extensively characterized by 
biochemical and biophysical means. Despite the fact that the first step of the reaction, 
acylation of the lactam at the catalytic serine, is conserved, each mechanism (class A, 
class C, and class D) has distinct features
30,39,40
. 
 Class A, C, and D β-lactamase share a common reaction pathway that initiates 
with base catalyzed deprotonation of an active site serine that nucleophilically attacks 
the β-lactam carbonyl forming the acyl-enzyme intermediate complex. The reaction is 
terminated through hydrolysis of the acyl-intermediate complex to free the irreversibly 
inactivated β-lactam and regenerated enzyme. Class A and C β-lactamase differ in the 
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final step of the reaction, which is deacylation. For class A β-lactamase, the second half 
of the reaction proceeds through activation of a hydrolytic water molecule by a 
conserved active site base E166
41-43
. For class C β-lactamase, this conserved base is 
absent and it is hypothesized that the hydrolytic portion of the reaction proceeds through 
substrate assisted catalysis
30,39
. Class D β-lactamase rely on a conserved carbamylated 
lysine residue to act as the catalytic base for both serine activation and hydrolytic water 
activation
40,44
. 
Class B metallo-β-lactamase enzymes (MBLs) are less common than the other β-
lactamase, and represent the most evolutionarily distant β-lactamase class evidenced by 
sequence alignment
30
. MBL enzymes are further divided into 3 subclasses based on their 
sequence similarity. Crystal structures of MBLs have played a major role in sub-
classification because the modest primary structural similarity prevented facile 
assignment of conserved structural elements
38
. MBLs function through assisted catalysis 
from either one or two zinc cofactors that are coordinated within the active site. The 
mechanism of β-lactam hydrolysis by MBLs is hypothesized to proceed through 
nucleophilic attack of the lactam carbonyl carbon atom by a metal coordinated 
hydroxide ion and subsequent protonation of the lactam nitrogen
38
. One hypothesis 
suggests that an active site aspartate plays a role as a catalytic base
45
. Also, the distances 
between the metal ligand cofactors in MBL crystal structures and spectroscopic studies 
suggest potential alternative mechanisms
46-52
. 
In addition to the classical sequence based classification scheme of β-
lactamase
32
, the substrate profile-based classification scheme is especially useful to 
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describe drug resistant infections in clinical settings
33,53
. The β-lactamase are divided 
into groups named based on their ability to break down specific classes of β-lactams; 
some examples are penicillinases, cephalosporinases, carbapenemases, oxacillinases, and 
extended spectrum β-lactamase (ESBLs). The evolution of β-lactamases with highly 
variable activities is a reflection of the selective pressure imposed by the antibiotics used 
to treat infections in the past
31,54
. 
Clinical isolates carrying transmissible plasmids or resistance factors with 
penicillinase genes were reported as early as the 1960’s55,56. The most clinically 
prevalent plasmid encoded β-lactamase are the TEM, SHV, CTX-M, CMY, OXA, IMP, 
and VIM families
57
. The fact that these β-lactamase are carried on plasmids and passed 
from organism to organism
58
 affords them a great deal of functional diversity through 
independent evolution within the same family. The class A TEM family is by far the 
most common with 172 variants and the capacity to hydrolyze nearly all classes of β-
lactams except carbapenems. The next most common is the class D OXA family 
composed of 158 members. These enzymes have an even more extended spectrum 
activity than TEM type in that they are also carbapenemases. The SHV family of class A 
β-lactamase has 127 members and has a similar substrate profile to the TEM family. The 
population of TEM, OXA and SHV families has been rapidly and steadily increasing in 
number since the late 1980’s relative to other β-lactamase families53. Slightly less 
common are the class A CTX-M and class C CMY families with 90 and 50 members, 
respectively. These families have the increased ability to hydrolyze cephalosporins over 
penicillin. Some of the more prevalent class B enzyme families IMP (26 members) and 
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VIM (23 members) have extended spectrum activity against all β-lactams except 
aztreonam, though they are much less common relative to the class A, C, and D 
enzymes
53
. 
With β-lactamase on the rise and the continuous widespread use of β-lactam 
antibiotics, it is easy to imagine a future where β-lactam antibiotics no longer work. It is 
possible for a single organism to carry multiple plasmids that encode different β-
lactamase enzymes. The combination of two extended spectrum β-lactamase could 
literally prevent treatment with β-lactams. Moreover, many infectious organisms are 
already resistant to other classes of antibiotics. This is the case for Mycobacterium 
tuberculosis, which is the causative pathogen of tuberculosis
59,60
. Essentially, we are in a 
perpetual antibiotic arms race with infectious microorganisms as evolution is inevitable. 
Generating new antibiotics is essential to compete with the ever evolving 
infectious microorganisms, but we can also extend the utility of existing antibiotics by 
combatting the resistance mechanisms. For β-lactam resistant infections, one approach is 
to administer a β-lactam antibiotic that is outside the infectious organism’s β-lactamase 
activity spectrum. An even more effective approach is to pair a β-lactam antibiotic with a 
β-lactamase inhibitor. Both approaches require prior knowledge of the sensitivity of the 
organism to β-lactam antibiotics and of the type of β-lactamase they may carry. The 
differences in the catalytic mechanisms and active site architecture between β-lactamase 
classes and families require careful selection of the appropriate combination. 
There are three mechanism-based β-lactamase inhibitors that are clinically used: 
clavulanic acid, tazobactam, and sulbactam
61
. Clavulanic acid is a natural product that 
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was originally isolated from Streptomyces clavuligerus
62
. Sulbactam and tazobactam are 
sulfone derivatives of penicillin
63,64
. Clavulanic acid, tazobactam, and sulbactam are β-
lactams themselves, and inhibit by forming stable acyl-intermediates with the catalytic 
serine residue of class A, B, and D enzymes
65-68
, and are ineffective against class B 
MBL enzymes because they do not have a catalytic serine
30,61
. Mechanism-based 
inhibitors can be considered as poor β-lactamase substrates because they are eventually 
hydrolyzed and enzymatic activity is restored
69
. As of 2010, six inhibitor-resistant 
variants of the SHV family have already been clinically isolated, and dozens for the 
TEM family
57
. The lack of clinically approved inhibitors for MBL enzymes, and the 
alarming emergence of inhibitor resistant variants makes novel β-lactamase inhibitor 
discovery essential to maintaining the utility of existing and future β-lactam antibiotics. 
Non-β-lactam β-lactamase inhibitors have yet to enter the clinic but are in 
development. Drawz and Bonomo provide an extensive review of β-lactamase 
inhibitors
61
. The classes of inhibitors that possess greater potential for clinical utility 
include molecules that can bind reversibly (boronic acids), irreversibly (hydroxamates), 
or are very slowly hydrolyzed as substrates
61,70
. 
 The boronic acids are a unique class of inhibitors due to their ability to form 
reversible covalent bonds with the active site serine of proteases
71-77
 and β-
lactamase
78,79
. Boronic acids were originally identified as subtilisin protease inhibitors
76
. 
Later, the crystal structures of boronic acid covalent adducts in complex with subtilisin
73
 
and of alpha-lytic protease with peptide boronic acids helped to elucidate that the serine 
protease mechanism proceeds through a tetrahedral intermediate
77
. The tetrahedral 
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intermediate structure of a boronic acid inhibitor in complex with class A β-lactamase 
TEM-1 revealed similar mechanistic insights
80
. Extensive biochemical and biophysical 
characterization of boronic acids with the class C β-lactamase AmpC led to the 
development of low nanomolar inhibitors
81-83
. A fragment based approach to optimizing 
AmpC boronic acid inhibitors resulted in subnanomolar inhibitors that are active in vivo 
84
. Recently, the benzoxaborole scaffold was identified as a new class of β-lactamase 
inhibitor with activity against class A β-lactamase CTX-M and TEM-1, and class C β-
lactamase CMY-2 and AmpC
85
. These studies signify that boronic acids continue to 
show potential for pairing with β-lactam antibiotics for treatment of infectious disease. 
The recent discovery that O-aryloxycarbonyl hydroxamates can inactivate class 
C β-lactamase P99 and AmpC, and class A enzyme TEM-1 suggests that this novel class 
of β-lactamase inhibitor may be useful against many infectious organisms86. The 
mechanism of inactivation is similar to the mechanism of substrate catalysis in that the 
molecule forms an acyl-intermediate with the catalytic serine which is subsequently 
hydrolyzed. Alternatively, a second aminolysis reaction occurs with catalytic lysine 
resulting in crosslinking of the active site with the inhibitor
87
. It is possible that these β-
lactamase inhibitors may also inhibit PBPs, but studies have yet to be reported. 
 NXL-104, or Avibactam, is a broad spectrum non-β-lactam β-lactamase inhibitor 
of class A, C, and D enzymes
88
. Biochemical characterization of NXL-104 with TEM-1, 
KPC-2, CTX-M, demonstrate potent inhibition of β-lactamase activities and the ability 
to form extremely stable covalent intermediates with the enzyme due to the slow 
decarbamylation reaction
89-91
. Co-crystal structures with CTX-M and BlaC show that 
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NXL-104 forms several conserved hydrogen bonds with the active site residues that 
substrates contact
70,91
. NXL-104 in combination with ceftazidime has demonstrated 
efficacy against Klebsiella pneumonia and Enterobacteriaceae species in murine 
infection models
92,93
.The stability of the NXL-104 adducts with β-lactamase is an 
improvement over classical mechanism-based inhibitors. 
The distinct mechanistic difference between MBLs and serine β-lactamase 
precludes the use of the aforementioned β-lactamase inhibitors for MBL inhibition. 
MBL inhibitors primarily utilize carboxylate or thiol/mercapto functional groups to 
chelate the active site zinc cofactors that are required for MBL activity. Some examples 
include mercaptocarboxylates, pyridine carboxylates, thiomandelates, mercaptoacetic 
esters, and succinic acid derivatives
61
.  Biochemical and biophysical characterization of 
thiol derivatives with MBLs demonstrate their modest micromolar affinities and function 
by chelating the active site zinc cofactor
61
. Unfortunately many of these inhibitors are 
promiscuous metal chelators, which present a challenge to designing specificity and 
limit their practical utility for treatment of infections. However, increasing the number of 
contacts that the inhibitors make with active site residues via rational design is a strategy 
to increase their potency and specificity.  
 Continuous advances to combat β-lactamase mediated β-lactam resistance 
through the design of β-lactamase inhibitors and more effective β-lactams is the reason 
that we are able to still use β-lactam antibiotics today. However, the arms race is never 
ending. Therefore, it is imperative that we continue to stay ahead of the drug resistance 
curve by developing novel inhibitors and antibiotics that evade established resistance 
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mechanisms. 
 Tuberculosis (TB) remains one of the world’s most deadly infectious diseases. 
According to the World Health Organization (WHO) Global Tuberculosis Report 2012, 
1.4 million people died from TB, and it was estimated that 8.7 million new cases 
emerged in 2011. While the number of new cases is slowly declining (2% from 2010 to 
2011), the number of multidrug-resistant TB (MDR-TB) cases is still increasing with 
over 60,000 new cases reported in 2011
94
.  
 MDR-TB is defined as being resistant to both frontline drugs isoniazid and 
rifampicin, at least one fluoroquinolone, and at least one second line aminoglycoside 
injectable. Major factors contributing to MDR-TB include genetic factors such as 
acquired compensatory mutations that confer resistance and poor patient compliance
59,95
. 
Innate resistance mechanisms also prevent the use of existing FDA approved drugs such 
as β-lactams. 
 The increase of MDR-TB demands the development of new therapeutic 
strategies. Mutagenesis studies revealed several essential Mtb genes that code for 
potential drug targets.  Alternatively, repurposing of existing FDA approved drugs for 
tuberculosis treatment is of particular interest, especially in the case of β-lactams. β-
lactams, the most widely used antibiotics in history, have the potential to treat one of the 
world’s most infamous diseases. The main obstacle to using β-lactam antibiotics for TB 
chemotherapy is overcoming the primary mechanism of β-lactam resistance in Mtb. 
 The role of the blaC gene of Mtb in innate resistance to β-lactam antibiotics was 
confirmed by disc diffusion assays with the ΔblaC strain. No β-lactamase activity was 
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detected, suggesting that the blaC gene encoded the primary β-lactamase that conferred 
resistance to β-lactam antibiotics96. The crystal structure of the BlaC enzyme revealed a 
conserved class A β-lactamase architecture with a flexible active site loop97. Kinetic 
analysis of BlaC with multiple classes of β-lactams demonstrated the extended spectrum 
activity of BlaC, including the ability to slowly hydrolyze tight binding carbapenems, 
and to be inhibited by clavulanic acid
69,97
. These observations suggested that the 
sensitivity of Mtb to β-lactam antibiotics may be restored by inhibition of the BlaC 
enzyme. 
 The effectiveness of combining the β-lactamase inhibitor clavulanic acid with the 
β-lactam meropenem at killing extensively drug resistant Mtb (XDR-TB) was eventually 
demonstrated
98
. This observation was extremely significant because it essentially opened 
the door to potentially utilizing β-lactam antibiotics to combat MDR and XDR-TB. 
Meropenem and other carbapenems are particularly potent relative to other β-lactam 
classes because of their dual function of targeting essential PBPs as well as inhibiting β-
lactamase
99
. Carbapenems binding tightly to BlaC (meropenem Ki = 1.1 ± 0.8 µM) to 
form transient acyl-intermediates. However, because carbapenems are BlaC substrates, 
they are eventually hydrolyzed and inactivated by the enzyme
98,100
. This results in 
depletion of active β-lactam that could be used to target essential PBPs. Moreover, the 
activity of BlaC is completely restored to further degrade active β-lactams. 
 These preliminary investigations show marked capacity for the treatment of Mtb 
with β-lactams, but there is still room for improvement. Fighting Mtb with combinations 
of β-lactamase inhibitors and β-lactams is a two-part equation. Both the β-lactam 
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antibiotics and on the β-lactamase inhibitors need to be as effective and efficient as 
possible. The ability of β-lactams to elicit their antibiotic activity is determined by 
several factors including the potency against their essential PBP enzyme targets. In the 
case of Mtb, innate β-lactam resistance is due to the BlaC enzyme96. 
 The main drawback to carbapenem scaffold is that they lack selectivity. An ideal 
target selective β-lactam would bind preferentially to its essential target PBP over BlaC. 
If the main hurdle to combatting Mtb with β-lactams is innate β-lactamase mediated 
resistance, it would be advantageous to use a β-lactam that is potent against Mtb cells 
and evades BlaC mediated resistance. A structure activity relationship (SAR) focused on 
identification and characterization of Mtb active β-lactams that evade β-lactamase 
mediated resistance would be a step toward designing new target selective β-lactams that 
resist binding to BlaC. 
 Chapter 2 of this investigation addresses the structural relationship between β-
lactams and the BlaC active site to understand how specific intermolecular interactions 
influence β-lactamase activity and ultimately resistance of Mtb cells to these β-lactams. 
In order to identify target selective β-lactams, the contribution of BlaC to resistance to 
individual β-lactams was determined using whole cells of Mtb. The results showed 
variation in the magnitude of resistance due to BlaC. Biochemical and biophysical 
characterization of the β-lactams with BlaC lead to the identification of the structural 
basis for the observed differential magnitudes of resistance of Mtb to the β-lactams, and 
specifically shed light on how faropenem evades BlaC mediated resistance more than all 
other β-lactams investigated. The results demonstrate the biological repercussions of a 
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hydrophobic interaction between BlaC and β-lactams that increases resistance on the 
organismal level. 
 Previous studies with existing clavulanic acid demonstrated the ability to 
inactivate BlaC and to potentiate the activity of β-lactams antibiotics against Mtb in vitro 
and in vivo
69,98,101
. Clavulanic acid inhibits BlaC (Ki = 12.1 µM) by forming a covalent 
acyl-enzyme adduct, but because it is a β-lactam it is eventually hydrolyzed by the 
enzyme and β-lactamase activity is restored69,70,102.  More recently, a non-β-lactam 
mechanism-based inhibitor of BlaC was reported to form a more stable inhibitor 
complex than clavulanate, but the authors report the poor affinity of NXL-104 for BlaC 
prevents practical implementation until derivatives are designed
70
. The continuous 
advancement of inhibitors of Mtb BlaC holds promise for future treatment of Mtb with 
β-lactams. 
 Chapter 3 of this investigation illustrates a biochemical and biophysical inhibitor 
SAR with BlaC that identifies the structural features of the active site that are important 
for potent inhibition by boronic-acids, and demonstrates their utility as potentiators of β-
lactam antibiotic activity against Mtb. Boronic acids have recently proven to be 
extremely potent β-lactamase inhibitors with demonstrated activity in vivo84, and remain 
an untapped class of inhibitors for BlaC and combination with β-lactams to combat 
Mtb
85
. Boronic acids are also not degraded by β-lactamase. 
 To identify boronic acid inhibitor scaffold for rational design of BlaC inhibitors, 
a boronic acid library was enzymatically screened with BlaC. The results from the 
screen identified benzoxaborole as an inhibitor scaffold, and several benzoxaborole 
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derivative molecules were synthesized for SAR generation. The derivative inhibitor 
molecules were enzymatically characterized with BlaC which enabled identification of 
the structural features of the benzoxaborole inhibitors that drive potent inhibition of 
BlaC. The co-crystal structures of BlaC with three benzoxaborole inhibitors revealed 
how the functional moieties of the derivative inhibitors interact with the BlaC active site, 
and how those interactions influence affinity for the enzyme inhibitory activity. The 
most potent benzoxaborole competitively inhibited BlaC (Ki = 0.7 µM), and the SAR 
offered insights to further improve affinity. Moreover, preliminary experiments 
demonstrate the ability of the benzoxaboroles to potentiate the antibiotic activity of 
amoxicillin on Mtb cells. Cumulatively, the results demonstrate the utility of 
benzoxaboroles as BlaC inhibitors and potential to be paired with a β-lactam antibiotic 
for combating Mtb. 
 Chapter 4 of this study addresses the challenge of early tuberculosis diagnosis 
through the design and optimization of BlaC-specific molecular probes
103
. The WHO 
estimated that nearly 9 million new cases of tuberculosis appeared in 2011, and more 
frightening is that the number of MDR-TB cases is increasing
94
. Without diagnosis, 
infected persons may remain unknowingly contagious and exponentially transmit 
disease. Early detection and diagnosis of tuberculosis would reduce dissemination and 
mortality rates. Diagnostics must be specific enough to discriminate between pathogens, 
and sensitive enough to prevent false negatives. Many of the commonly used diagnostics 
including smear tests, skin tests, and chest X-rays are not sensitive or specific enough to 
rule in or rule out tuberculosis alone
104-106
.  Several probes were synthesized and 
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enzymatically characterized to identify characteristics that enhance probe specificity and 
selectivity for BlaC over TEM-1
103
. Crystal structures of BlaC and the fluorescent 
probes illustrate the structural determinants for the observed selectivity. The efficacy of 
a BlaC specific β-lactam-based fluorogenic probes was demonstrated by detecting down 
to 10 colony forming units of bacillus Mycobacterium bovis Calmette–Guérin (BCG) in 
human sputum
103
. 
 The New Delhi Metallo-β-lactamase-1 (NDM-1) gene is rapidly spreading to 
pathogenic microorganisms all over the world
107
. NDM-1 is a potent, broad spectrum 
class B1 metallo-β-lactamase that confers bacterial resistance to all classes of β-lactams, 
except for monobactams
108
. Since the first reported isolation of NDM-1 producing 
Klebsiella pneumoniae in Sweden in
109
, NDM-1 has surfaced in several countries around 
the globe in multiple pathogenic microorganisms
110-125
. Many of the infectious 
organisms are already resistant to several frontline therapeutics, which suggests the 
possibility of a future with many untreatable infectious diseases. 
 Chapter 5 of this investigation describes the biochemical and biophysical 
characterization of the class B β-lactamase NDM-1 that identified the structural and 
molecular basis for the promiscuous activity of NDM-1
48
.  The results show the flexible 
nature of the NDM-1 active site, which is comprised of 5 loops that donate residues that 
form the catalytic triads that coordinate the zinc cofactors. The flexible NDM-1 active 
site loops and the enlarged active site relative to other MBL’s contribute to the observed 
promiscuous extended spectrum substrate specificity of NDM-1. 
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 The diverse sequences of MBLs and inconsistency with the number of zinc 
cofactors required for activity make the mechanism of MBLs a controversial 
subject
126,127
. Crystal structural data from multiple MBLs suggests that a zinc 
coordinated solvent molecule, likely a hydroxide serves as the nucleophile that attacks 
the β-lactam carbonyl for ring opening45,127. Spectroscopic data suggest three reaction 
species including substrate, ring-opened intermediate, and product
51
. Reaction 
completion requires protonation of the lactam amide nitrogen, and the origin of the 
proton has not been elucidated. The catalytic base is also subject of debate. One 
hypothesis suggests that a conserved aspartic acid residue participates in the reaction 
mechanism as the general base, but mutation of the conserved aspartate to alanine in 
CphA decreased but did not abolish β-lactamase activity128,129, excluding the conserved 
aspartate as the catalytic base.  
 Chapter 6 of this investigation reveals the mechanism of NDM-1 β-lactamase 
activity and identifies additional factors that give NDM-1 the capacity to hydrolyze 
substrates without discrimination
52
. The biochemical activity of NDM-1 and the distance 
between the zinc cofactors in crystal structures were determined to be pH dependent. As 
the pH increased, the distance between the zinc cofactors in crystal structures decreased, 
and the catalytic activity of NDM-1 increased. The distances between the zinc cofactors 
were consistent with coordination of a catalytic water molecule at lower pH and a 
hydroxide ion at higher pH, emphasizing the role of pH in the NDM-1 reaction 
mechanism
52
. Crystal structures of NDM-1 were solved in complex with an 
unhydrolyzed β-lactam substrate and with hydrolyzed products. These structures were 
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used for quantum mechanics / molecular mechanics (QM/MM) simulations to estimate 
the free energy along the β-lactamase reaction coordinate using several mechanistic 
models. The results suggest that the most energetically favorable reaction mechanism 
uses bulk water as the nucleophile that attacks the β-lactam for ring opening by NDM-
1
52
. The proposed mechanism is in accordance with biochemical and biophysical pH 
dependence data in that the reaction is energetically favorable using either zinc 
coordinated water molecule or hydroxide ion as the base. Taken together, the flexibility 
of the active site loops, the lack of specific interactions between the substrates and 
NDM-1 active site, the ability to utilize multiple divalent cations to recognize substrates, 
catalyze hydrolysis of β-lactams over a wide pH range, and use a coordinated water 
molecule or hydroxide ion as the catalytic base all contribute to NDM-1’s extreme 
promiscuity
52,108
. 
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CHAPTER II  
 
STRUCTURAL AND FUNCTIONAL INSIGHTS INTO DIFFERENTIAL 
RESISTANCE OF Mycobacterium tuberculosis TO BETA-LACTAMS FAROPENEM, 
BIAPENEM, AND TEBIPENEM BY BlaC 
 
OVERVIEW 
 
Mycobacterium tuberculosis (Mtb) is innately resistant to β-lactam antibiotics 
because the bacilli express the broad spectrum class A β-lactamase, BlaC. β-lactamase 
inhibitors like clavulanate potentiate the activity of β-lactams that are susceptible to 
inactivation by BlaC. We show that the MIC of faropenem on Mtb does not change with 
the addition of the β-lactamase inhibitor clavulanate. Inhibition of BlaC by clavulanate 
did not potentiate the activity of faropenem like other β-lactams, suggesting that the 
structure activity relationship of BlaC with faropenem is distinct. Faropenem, biapenem, 
and tebipenem form covalent adducts that inhibit BlaC; their stabilities were monitored 
with mass spectrometry. BlaC acyl-intermediate (AI) crystal structures with β-lactams 
show specific active site interactions that explain the difference in the affinity of BlaC 
for the lactams and the difference in the stability of the AI complexes. The results 
provide structural and functional insight into the differential resistance of Mtb to these 
antibiotics by BlaC. To test faropenem’s activity in vivo, the bacterial burden in the lung 
of Mtb infected mice was assessed. Faropenem treatment reduced lung cfus by 0.7 logs 
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within 6 days, demonstrating faropenem’s potential utility as a therapeutic, possibly 
alone or in combination with other antibiotics. 
 
INTRODUCTION 
 
 The β-lactam antibiotics are the most widely used antibiotics in history5 because 
their essential microbial targets are not present in humans
4
. β-lactams elicit their 
antibiotic activity by binding to and inactivating essential cell wall biosynthetic 
enzymes, penicillin binding proteins (PBPs)
6-8
. Resistance mechanisms include 
upregulation of PBP that are less susceptible to β-lactams130, and upregulation of PBPs 
that change the peptidoglycan structure of the cell wall
131
. The primary mechanism of 
resistance can be attributed to the dissemination of plasmid encoded β-lactamase genes 
among infectious microorganisms
36,37,53
. β-lactamase mediated drug resistance has been 
the subject of detailed investigation for decades; however, research is increasingly 
important due to the emergence of totally drug resistant infections
132
, and the evolution 
of β-lactamase that can inactivate nearly all β-lactam antibiotics133. β-lactams are not 
used to treat Mtb infection because the bacilli express a chromosome-encoded broad 
spectrum class A β-lactamase, BlaC. Investigation of the anti-mycobacterial properties 
of β-lactams goes back several decades134,135, but still no orally available or FDA 
approved β-lactams exist for tuberculosis treatment. 
 The role of the blaC gene of Mtb in innate resistance to β-lactam antibiotics was 
confirmed by disc diffusion assays with the ΔblaC strain. No β-lactamase activity was 
 23 
 
detected, suggesting that the blaC gene encoded the primary β-lactamase that conferred 
resistance to β-lactam antibiotics96. The crystal structure of the BlaC enzyme revealed a 
conserved class A β-lactamase architecture with a flexible substrate specificity loop97. 
Thorough kinetic analysis of BlaC with multiple classes of β-lactams demonstrated the 
extended spectrum activity of BlaC, including the ability to slowly hydrolyze tight 
binding carbapenems, and the ability to become inactivated by the mechanism based 
inhibitor clavulanate
69
. More recently, a non-β-lactam mechanism-based inhibitor of 
BlaC was reported to form a more stable inhibitor complex than clavulanate
70
. 
 Carbapenems are effective β-lactam antibiotics that inhibit essential PBP targets. 
They also potentiate their activity by transiently inhibiting class A β-lactamase. The 
combination of meropenem with the β-lactamase inhibitor clavulanate has activity on 
Mtb in vitro, and even has modest activity against a chronic infection model of murine 
tuberculosis
101
. Combining carbapenems with β-lactamase inhibitors is effective because 
carbapenems only transiently inhibit β-lactamase, and eventually become hydrolyzed 
and inactivated
69,99
. 
 Ideally, a more efficient β-lactam would selectively bind to essential PBP targets 
over β-lactamase, which would reduce resistance and eliminate the requirement for a 
combination with a β-lactamase inhibitor.  Carbapenems do not fit this description 
because they characteristically bind very tightly to class A β-lactamase like BlaC69,98-100. 
The structural similarity that provides PBPs, transpeptidases, and β-lactamase the ability 
to bind to and hydrolyze the same β-lactams, makes designing a selective molecule 
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challenging
29,30
. A recently reported β-lactam probe demonstrated selectivity for BlaC 
over the very similar β-lactamase, TEM-1103. 
 Screening for a target-selective β-lactam antibiotic for tuberculosis can be done 
by comparing the minimum inhibitory concentrations (MIC) of β-lactams on Mtb cells in 
presence and absence of active BlaC enzyme. β-lactams with no change in MIC would 
theoretically be less affected by innate resistance due to β-lactamase. We found that Mtb 
is less resistant to faropenem than all β-lactams tested. Biochemical and biophysical 
characterization of the β-lactams with BlaC elucidated the molecular basis of decreased 
resistance that distinguishes faropenem from structurally similar β-lactams biapenem and 
tebipenem. 
 
RESULTS 
 
Whole cell assays 
 The potency of β-lactam antibiotics against Mtb may be severely decreased by 
the presence of active BlaC enzyme. Clavulanate, potentiates the whole cell activities of 
β-lactams against Mtb by inhibiting BlaC and preventing the depletion of active β-lactam 
available to target essential PBP’s. Except for faropenem, the potency of each β-lactam 
was enhanced when clavulanate was added (Table 2.1). We interpreted the magnitude of 
change between the MIC in the presence and absence of clavulanate to reflect the 
amount of degradation of each β-lactam by BlaC. For example, the MIC of β-lactams 
reported to be rapidly turned over by BlaC, e.g., amoxicillin ( kcat = 600 ± 20  
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Table 2.1. Activity of β-lactams on Mycobacterium tuberculosis. Minimum inhibitory concentration 
(MIC) of β-lactam antibiotics to inhibit growth of Mtb.  aMIC assayed in presence of 2.5µg mL-1 
clavulanate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
β-lactam MIC (µg mL-1) aMIC (µg mL-1) 
Amoxicillin >10.0    1.3  
Biapenem     2.5    0.6 
Cefotaxime     1.3      0.6 
Faropenem     0.6    0.6 
Imipenem     5.0    0.6 
Meropenem     2.5    0.6 
Tebipenem     0.6 < 0.3 
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min-1), were expected to decrease with the addition of clavulanate more than β-lactams 
that are not rapidly turned over by BlaC, e.g., imipenem (kcat = 10 ± 1 min-1) and 
meropenem  (kcat = 0.08 ± 0.01 min-1)
69
.  When clavulanate was added, amoxicillin’s 
MIC decreased from >10 µg mL-1 to 1.3 µg mL-1, imipenem’s MIC decreased 8-fold 
from 5 µg mL-1 to 0.6 µgmL-1, and meropenem’s MIC decreased 4-fold from 2.5 µg 
mL-1 to 0.6 µg mL-1. 
 
Fourier transform ionization cyclotron resonance mass spectrometry 
 The class A β-lactamase reaction proceeds to form a covalent acyl-intermediate 
(AI), which is hydrolyzed by a nucleophilic hydroxyl radical generated by deprotonation 
of the hydrolytic water coordinated by catalytic base Glu166
61. If the reaction doesn’t 
complete, the covalently bound AI stalls the enzyme in a catalytically incompetent state. 
The characteristic R1 hydroxyethyl group of carbapenems is responsible for the 
formation of stable AIs that inhibit β-lactamase98,100,136,137.  
 Faropenem, a penem, is structurally distinguished from carbapenems by the 
presence of a sulfur atom at the 4 position of the dihydrothiazole ring, but shares the AI 
stabilizing R1 hydroxyethyl group (Figure 2.1). The MIC of faropenem on Mtb did not 
change when clavulanate was added, which may partially be due to inhibition of BlaC by 
formation of a stable AI analogous to carbapenems. To test this, the stabilities of the 
BlaC AI complexes with faropenem, biapenem, and tebipenem were monitored using 
Fourier transform ion cyclotron resonance mass spectrometry (FTICR-MS). The raw 
mass spectra showed two reaction species for each AI complex in the early time  
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Figure 2.1. Chemical structures of β-lactam scaffolds.  (a) carbapenem, (b) penem, (c) penam, and (d) 
cephalosporin β-lactams. 
 
 
 
 
 
 
a b 
c d 
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points, which corresponded to the masses of AI complexes with BlaC (Appendix Figure 
A1). The masses of the first AIs corresponded to the BlaC-biapenem complex (30886 
Da), BlaC-faropenem complex (30820 Da), and BlaC-tebipenem complex (30918 Da). 
The masses of the second AIs corresponded to the BlaC-biapenem complex – 44 Da 
(30842 Da), BlaC-faropenem complex – 44 Da (30776 Da) and BlaC-tebipenem 
complex – 44 Da (30874 Da). The masses of the second AI reaction species (– 44 Da) 
were consistent with the proposed model of deacetylation
98
. 
 As the reactions reached completion, the AI reaction species decreased 
concomitantly with the appearance of regenerated BlaC (30535 Da). To reduce the data 
sets for comparison, regenerated BlaC enzyme was plotted as a function of time for each 
reaction (Figure 2.2).  Regeneration of the free BlaC enzyme is dependent upon the 
stability of the AI complex. The more stable the AI complex, the longer it takes to 
regenerate the free BlaC enzyme. The graph shows that BlaC’s reaction with tebipenem 
took the longest time to regenerate free BlaC enzyme, followed by biapenem and 
faropenem. 
 
Inhibition kinetics 
 Inhibiting BlaC by forming stable AIs results in decreased β-lactam hydrolysis 
and inactivation. β-lactams that are poor substrates for β-lactamase behave as classical 
competitive inhibitors
99
. Inhibition of BlaC by faropenem, biapenem, and tebipenem was 
measured by monitoring the linear initial velocities of nitrocefin hydrolysis in presence 
of varying concentrations of the β-lactams. Inhibition curves and chemical structures are  
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Figure 2.2. Time course of BlaC reactions analyzed with Fourier transform ion cyclotron resonance mass 
spectrometry. The population of regenerated enzyme for BlaC reactions with tebipenem (green), biapenem 
(red), and faropenem (blue) are plotted as a function of time (s). 
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displayed for each β-lactam (Figure 2.3). Faropenem (Ki = 14.2 ± 2.5 µM) inhibits BlaC 
with an affinity that is 5-fold less than tebipenem (Ki = 3.0 ± 0.2 µM) and 4 fold less 
affinity than biapenem (Ki = 3.7 ± 0.3 µM).  
 
BlaC-β-lactam acyl-intermediate crystal structures 
 BlaC AI complex crystal structures were solved to examine the structural 
features that influence the affinity for the BlaC active site and stability AI complexes. 
Crystallographic data collection and refinement statistics are reported in Appendix Table 
A1. Catalytically incompetent BlaC Glu166Ala mutant crystals were used to trap 
amoxicillin, cefotaxime, cefoperazone, and faropenem AIs in the BlaC active site. Each 
structure had four crystallographically independent molecules in the asymmetric unit, 
two of which had adequate solvent accessibility to allow ligand binding.  
 Each lactam was covalently linked to BlaC by the catalytic Ser70, which 
positioned the carbonyl oxygen in the acyl-linkages to hydrogen bond with the backbone 
amide nitrogen of Thr237 (Figure 2.4). The amoxicillin AI (Figure 2.4 a) 2’-carboxylate 
hydrogen bonded to side chain hydroxyls of Ser130 (2.8 Å), and Thr235 (2.8 Å). The 
Thr237 backbone carbonyl oxygen hydrogen bonded to amoxicillin’s side chain amide 
nitrogen (3.0 Å). The side chain carbonyl oxygen of Asn170 of the substrate specificity 
loop formed a 2.2 Å hydrogen bond with the amino group of amoxicillin in chain B, 
with a distance of 3.5 Å in chain C of the asymmetric unit. The difference underscores 
the flexibility of the loop and weak electron density in this region. 
 Cephalosporins, cefotaxime and cefoperazone, were designed with bulky R2 
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Figure 2.3. Inhibition of BlaC by β-lactams. Faropenem (a), Biapenem (b), and Tebipenem (c). 
 
c 
b 
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Figure 2.4. Active site details of BlaC acyl-intermediate crystal structures. (Left) Ligand binding pocket 
surface colored by binding property. white = neutral surface, green = hydrophobic surface, red = hydrogen 
bonding acceptor potential, and blue = hydrogen bond donor potential. (Middle) FO-FC omit map electron 
density surrounding acyl-intermediates contoured at 2σ (green) and hydrogen bonds as displayed as black 
lines. (Right) Active site interactions of BlaC acyl-intermediates represented as black lines. (a) 
amoxicillin, (b) cefoperazone, (c) cefotaxime. 
 
a 
a 
b 
c 
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groups that confer stability to β-lactamase mediated hydrolysis138,139. The structures 
showed that the BlaC active site was large enough to contain cefoperazone and 
cefotaxime AIs. Stabilizing salt bridges between Asp172 - Arg178 and Asp176 - Arg178 
present in the BlaC apo structure
97
 were broken to increase the flexibility of the loop for 
Michaelis complex and AI formation. 
 The BlaC cefoperazone AI structure is the first crystal structure of cefoperazone 
in complex with  β-lactamase (Figure 2.4 b). The structure depicts conserved hydrogen 
bonds between the side chain hydroxyl of Ser130 and the lactam amide nitrogen (2.9 Å), 
the 2’- carboxylate oxygen atoms and the side chain hydroxyls of Thr235 (2.4 Å) and 
Thr237 (3.1 Å), and the backbone amide nitrogen (2.9 Å) and carbonyl oxygen atoms 
(3.0 Å) of Thr237 with cefoperazone. Displacement of the substrate specificity loop 
(residues 164 - 172) enlarged the BlaC active site to accommodate the cefoperazone AI. 
 The BlaC cefotaxime AI (Figure 2.4 c) formed the same hydrogen bonds with 
Ser130 (3.1 Å), Thr235 (2.9 Å), and Thr237 (2.8 Å) side chain hydroxyls and to the 
backbone amide nitrogen (3.2 Å) and carbonyl oxygen atoms of Thr237 (3.1 Å). In both 
liganded molecules of the asymmetric unit, freedom of rotation of cefotaxime’s 2-
amino-4-thiazolyl prevents precise placement of atomic coordinates. The cefotaxime AI 
was bound in the same orientation as other class A β-lactamase structures in complex 
with cefotaxime, with the aminothiazole in proximity of the side chain carboxylate of 
Asp240
140,141
. The Asp240Gly mutation in class A β-lactamase CTX-M-27 reduced 
cefotaxime turnover, demonstrating the importance of this residue in cefotaxime 
binding
142
. Sparse electron density for the substrate specificity loop prevented the 
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Figure 2.4 continued. Active site details for BlaC acyl-intermediates (d) biapenem, (e) tebipenem, and (f) 
faropenem.  
 
 
 
 
 
f 
e 
d 
 35 
 
placement of the side chains and backbone atoms for residues 164-169. 
 AI crystal structures of BlaC with biapenem, tebipenem, and faropenem showed 
conserved hydrogen bonds with the substrate recognition residues (Ser130, Thr235, 
Thr237) and delicate variations in the interactions with the substrate specificity loop and 
Ile105 that influence binding and stability (Figure 2.4 d-f). The BlaC biapenem AI 
hydroxyethyl group is positioned to share hydrogen bonds with the side chain 
carboxylate oxygen of Glu166 (3.2 Å) and the neighboring side chain oxygen of Asn170 
(3.2 Å) of the substrate specificity loop, similar to the pre-isomerized ertapenem and 
doripenem AIs with BlaC
100
. In contrast, the BlaC tebipenem AI tautomerized to the Δ1-
pyrroline isomeric state, evidenced by the sp3 hybridized C3 atom. Instead, the 
tebipenem hydroxyethyl formed a 2.4 Å hydrogen bond with Glu166 side chain 
carboxylate oxygen atoms and a 3.2 Å hydrogen bond with Lys73 side chain amino 
nitrogen. This conformation is consistent with the post-isomerized ertapenem, 
doripenem, and meropenem BlaC AI complexes
98,100
. The R2 methyl group of biapenem 
and tebipenem faced the hydrophobic side chain of Ile105 side chain that encloses the 
BlaC active site. The BlaC faropenem AI did not tautomerize to the Δ1-pyrolline isomer. 
The absence of stabilizing interactions between faropenem’s hydroxyethyl group, 
Glu166, Asn170, and Lys73 were attributed to the Glu166Ala mutation.  Since 
faropenem lacks the R2 methyl group that is present in biapenem and tebipenem, no 
hydrophobic interaction occurred between the side chain of Ile105 and faropenem. 
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Therapeutic efficacy of faropenem against M. tuberculosis infected mouse model 
 The lack of innate resistance of Mtb to faropenem in whole cell assays prompted 
us to examine if faropenem has activity on Mtb in vivo. Balb/CJ mice were infected with 
50-100 cfus/lung Mtb Erdmann strain by aerosol inhalation. The experiment included a 
not treated control, isoniazid treated control, and faropenem treated groups (n=5).  After 
6 days of once daily treatment, faropenem reduced the bacterial burden in the lung by 
0.7 log cfu relative to the no treatment control group (Figure 2.5). Isoniazid decreased 
the bacterial burden by 2.3 log cfu. The preliminary data demonstrated faropenem’s 
activity in vivo and potential utility as a therapeutic in combination with other 
antibiotics. 
 
DISCUSSION 
 
 Since the unveiling of the Mtb H37Rv genomic sequence
143
, numerous 
investigators have made significant contributions to understanding the TB pathogen, and 
develop new cost effective therapeutic regimens. These advancements realize the 
possibility of eradication of one of the most infamous global diseases. There are many 
drug targets and lead molecules in development that have potential to become 
therapeutics. β-lactams have endured the test of time and remain a safe, highly effective, 
and untapped resource for tuberculosis chemotherapy. Historically, innate resistance of 
Mtb to β-lactams has prevented clinical implementation. 
 A plausible approach to circumvent innate resistance of Mtb to β-lactams  
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Figure 2.5: Effect of faropenem treatment on Mtb infected BALB/CJ mice. Lung colony forming units 
(cfu/mL) are displayed for faropenem treated and not treated control groups. Error bars represent the 
standard deviation for each group (n=5). 
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includes combining a β-lactamase inhibitor with a β-lactam. Meropenem-clavulanate 
combination has proven to be effective against Mtb in vitro
98
, and even has activity in  
vivo
101
. An alternative approach involves treating Mtb with a “magic bullet” β-lactam 
that does not require an inhibitor of β-lactamase to prevent innate resistance. To identify 
β-lactams that are less susceptible to BlaC mediated innate resistance in Mtb, we 
compared the MIC of β-lactams alone and in combination with the BlaC inhibitor 
clavulanate. BlaC AI crystal structures were solved to understand the intermolecular 
interactions that explain the differential innate resistance of Mtb to these β-lactams by 
BlaC. We also compared the difference in stability of the BlaC-AI complexes and ability 
to inhibit BlaC. The structure activity relationship depicted structural features of 
amoxicillin, cefoperazone, cefotaxime, biapenem, tebipenem, and faropenem AIs that 
distinguish their susceptibility to inactivation by BlaC and whole cell activities against 
Mtb. 
 Each class of β-lactam antibiotics has a characteristic structure that determines 
susceptibility to β-lactamase enzymes (Figure 2.1). The BlaC amoxicillin AI structure 
finally depicted amoxicillin’s size, shape, and electrostatic complementarity to the active 
site that facilitates rapid turnover of penams
69
.  Penams, like amoxicillin (MIC >10 
µgmL-1), are more effective against Mtb when combined with clavulanate (
a
MIC = 1.3 
µgmL-1) because they are specific class A β-lactamase substrates that don’t form stable 
AI complexes or behave as inhibitors
53
 
 Cephalosporin AI crystal structures showed that the bulky cephalosporin R2 
groups sterically hinder binding to BlaC by forcing displacement of the substrate 
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specificity loop. This observation is consistent with the reported Km of cefotaxime (5570 
± 1360 µM)
69
. Cefotaxime (MIC = 1.3 µg mL
-1
), or newer fourth generation 
cephalosporins that evade innate resistance by resisting binding and turnover by BlaC 
may be useful scaffolds for rational design of target selective β-lactam for Mtb.
 Carbapenems and penems possess a characteristic R1 hydroxethyl group that 
interrupts the completion of the class A β-lactamase reaction by binding to and 
stabilizing the enzyme in a catalytically incompetent conformation
98,136,137,144
. We 
measured the stability of faropenem, biapenem, and tebipenem BlaC-AIs with mass 
spectrometry. The spectra showed that tebipenem formed a more stable AI complex with 
BlaC than faropenem or biapenem, evidenced by the duration of detectable AI and the 
time required to regenerate the free BlaC enzyme. These results suggest that tebipenem 
should be less susceptible to BlaC mediated resistance by inhibiting further turnover.
 Faropenem, biapenem, and tebipenem differ primarily by the structure of their 
R3 side chains, but the crystal structures did not show any specific interactions between 
the R3 side chains and the active site, indicating that the differences in the stability of 
their AI complexes and susceptibility to inactivation by BlaC are due to other 
interactions (Figure 2.4 d-f). The tebipenem AI isomerized within the BlaC active site 
and formed hydrogen bonds with Glu166 (2.4 Å) and Lys73 (3.2 Å), where the less 
stable biapenem AI formed interactions with Glu166 (3.2 Å) and Asn170 (3.2 Å). 
Previous characterization of ertapenem and doripenem AIs with BlaC revealed that these 
conformations and interactions were time dependent, and suggested that the isomerized 
conformation was the most thermodynamically preferred orientation
144
. It is plausible 
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that biapenem and faropenem could also isomerize and adopt a more stable AI 
conformation, but no evidence suggests that isomerization is necessary for reaction 
completion. The structures showed that the stability of the faropenem, biapenem, and 
tebipenem AI complexes are partly dependent on subtle differences in the orientation of 
the R1 hydroxyethyl group relative to residues in the BlaC active site. 
 Certainly, the affinity of BlaC for the β-lactams has an effect on the level of 
innate resistance observed. If the β-lactams do not bind to the β-lactamase enzyme, they 
will not be turned over. Inhibition constants determined for tebipenem (Ki = 3.0 ± 0.2 
µM) and biapenem (Ki = 3.7 ± 0.3 µM) were similar to the previously determined 
inhibition constant for meropenem (Ki = 1.1 ± 0.8 μM). The previously reported steady 
state Michaelis constant for faropenem (Km =55 ± 11 μM) was approximately 4 times 
greater than the inhibition constant determined for faropenem (Ki = 14.2 ± 2.5 µM) in 
this study. Whether assayed as an inhibitor or a substrate, faropenem does not bind as 
tightly to BlaC as carbapenems. 
 The main feature that reduces the affinity of BlaC for faropenem relative 
carbapenems is the likely the lack of the R2 methyl group on faropenem (Figure 2.2). 
The active site of BlaC is partially bordered by a loop containing Ile105, which forms a 
hydrophobic environment that encloses substrates. BlaC AI with biapenem and 
tebipenem both have an R2 methyl group that can form hydrophobic interactions with 
the side chain of Ile105 upon binding to the active site (Figure 2.4 d-e). This interaction 
likely contributes to the affinity of BlaC for biapenem and tebipenem. Faropenem lacks 
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the R2 methyl group and hydrophobic interaction with Ile105, which is consistent with 
the decreased affinity of faropenem for BlaC relative to biapenem and tebipenem. 
 Despite their structural similarity, the results showed that Mtb is more resistant to 
biapenem and tebipenem than faropenem; when clavulanate was added, biapenem’s MIC 
decreased from 2.5 µg mL
-1
 to 0.6 µg mL
-1, tebipenem’s MIC decreased from 0.6 µg 
mL-1 to < 0.3 µg mL
-1, and faropenem’s MIC remained at 0.6 µg mL-1. However, 
tebipenem binds more tightly to BlaC than biapenem and faropenem, and forms the most 
stable AI complex, suggesting that tebipenem would be less susceptible to inactivation. 
Therefore, it seems that binding is the limiting factor to evading inactivation by BlaC 
because the formed AI is committed to hydrolysis. For example, tebipenem (Ki = 3.0 ± 
0.2 µM) binds 4 fold tighter to BlaC than faropenem (Ki  = 14.2 ± 2.5 µM), which results 
in increased inactivation of tebipenem relative to faropenem at their MIC (0.6 µg mL
-1
 
or 1.9 µM). 
 A recent study involving chronically Mtb-infected mice reported a modest 
reduction in lung cfu’s after 6 days of meropenem-clavulanate treatment, demonstrating 
the efficacy of carbapenems in murine tuberculosis models
101
.  Faropenem by itself 
seems to have as much activity in vivo as the combination of meropenem-clavulanate. 
Further experiments will be required to determine optimal dosing as well as investigate 
the in vivo efficacy of faropenem in combination with frontline and second-line drugs. 
While the activity of β-lactams is only modest against Mtb, experience in other 
organisms suggests that β-lactams synergize with a broad range of other antimicrobials, 
possibly by increasing the permeability of the cell wall and allowing other drugs to 
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penetrate better aminoglycosides
24,56
. Thus, this class of compounds could prove to be 
useful clinically in combination even if they are not highly potent themselves. 
 Faropenem is already on the market in Japan
145
, and has demonstrated clinical 
efficacy against acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and 
community acquired pneumonia from phase III clinical trials in the US, demonstrating 
faropenem’s bioavailability in the respiratory tract145. Faropenem and tebipenem are 
intravenously, as well as orally, available in prodrug form as faropenem medoxomil
146
 
and tebipenem pivoxil
147
, which potentially extends the treatment radius to locations 
without available intravenous therapy. 
 The structure activity relationship explains the molecular basis for differential 
innate resistance of Mtb to faropenem, biapenem, and tebipenem by showing the specific 
interactions between BlaC and the lactams that govern AI complex stability and affinity 
for the BlaC active site. These results are important for the rational design and dual 
optimization of β-lactams, like faropenem, that circumvent innate resistance by reduced 
binding to BlaC as well as transient inhibition of the enzyme once bound. With structural 
and mechanistic information available for the Mtb persistent state targets of β-lactams148-
150
, selectivity of β-lactams that bind more tightly to essential PBP targets than BlaC can 
be rationally designed. 
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MATERIALS AND METHODS 
 
Cloning, expression, and purification  
 Wild-type BlaC was cloned from M. tuberculosis H37Rv genomic DNA as 
described
97
. The deacylation deficient Glu166Ala mutant was generated using the 
Quickchange
TM
 site directed mutagenesis kit (Stratagene no. 200519). Mutant and wild-
type protein expression and purification were performed as described
97
. 
 
Crystallization 
 Crystals of wild-type and Glu166Ala BlaC were grown using the hanging drop 
vapor diffusion method
151
. BlaC was concentrated to 10 mg/ml and equilibrated 
overnight at 4º C with mother liquor (2.0 M NH4H2PO4, .1M Tris pH 8.0) at a 1:1 ratio 
(protein-:-mother liquor). The solution was centrifuged for 10 min at 13 krpm to remove 
insoluble precipitate. Hanging drops were set up and equilibrated against 1ml of mother 
liquor. Microseeding with horsehair was sufficient to produce larger diffraction quality 
crystals. Crystals were transferred to a stabilization solution containing 30% glycerol in 
mother liquor and were subsequently soaked with β-lactam antibiotics for 2-4 hours. The 
concentration of substrate was slowly increased by transferring the crystals to successive 
drops to prevent cracking. Derivatized crystals were flash frozen in liquid nitrogen. Data 
Collection and Processing. X-ray diffraction data was collected on beamlines 19ID and 
23ID at The Advanced Photon Source, Argonne National Laboratory, Argonne, IL. Data 
sets were reduced using HKL3000
152
. Data was collected at a temperature of 120 K.  
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Structure determination 
 Initial phases were obtained by molecular replacement using Phaser 
Crystallographic Software
153
 in the CCP4 suite
154
 and 2GDN as a search model
97
. Each 
data set was refined against the resulting model, and iterative cycles of model building 
and refinement were performed with Coot 0.6.1
155
 and PHENIX
156. PDB ID’s are as 
follows for the following BlaC-acyl intermediates: amoxicillin (4EBN), cefoperazone 
(4EBO), cefotaxime (4EBP), faropenem (4EBL), biapenem (4EBM), and tebipenem 
(4EBI). 
 
Inhibition kinetics 
 Apparent inhibition constants (Ki) for BlaC were determined by monitoring the 
linear burst of reporter substrate, nitrocefin (60 µM), hydrolysis as a function of β-
lactam concentration as described
99. The resulting IC50’s were used to calculate 
apparent inhibition constants (Ki)
157
.  Error bars represent the standard deviation of at 
least 6 data sets. 
Ki = ( IC50 ) / ( 1 + ( [S] / Km )) 
 
Fourier transform ion cyclotron resonance mass spectrometry 
 Purified BlaC (100 µM) in 10 mM ammonium acetate was saturated with 1 mM 
β-lactam substrates to achieve 100% conversion to the acyl intermediate. The reactions 
were aliquoted and flash frozen in liquid nitrogen to trap the reaction at different time 
points. Quenched reactions were diluted to 2 µM as the working concentration with an 
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electrospray ionization (ESI) solution of 50% acetonitrile containing 0.1% formic acid. 
All MS experiments were performed on a SolariX 9.4 T: hybrid quadrupole-FTICR mass 
spectrometer (Burker Daltonik GmbH, Bremen, Germany) equipped with a nano-ESI 
source and acquired in positive ion mode (m/z 300-3000) using electrospray voltage of 
+1800 V. All MS spectra were obtained by quadrupole mass selection of m/z 950 to 
1050 and accumulation of 50 spectra. The mass accuracy and resolution were 
approximately 5 ppm and 85,000, respectively, for m/z 1018.8, the 30+ charge state of 
BlaC. The molecular weight of each protein sample was calculated based on the mass-
to-charge (m/z) ratio of the +30 charge state of each reaction species using the equation 
of m = (m/z x 30) – 30 on the centroid of the isotopic cluster. Reaction species including 
AIs and regenerated BlaC were detected by monitoring the change in relative abundance 
of representative peaks over time. The raw data was displayed as a function of time. 
Relative abundances of the AI and regenerated enzyme species were plotted as a percent 
of the BlaC population as a function of time. Data for the regenerated enzyme were fit to 
a four parameter non-linear regression. 
F(x) = ((A-D)/(1+((x/C)^B))) + D 
 
Whole-cell assays 
 Cultures of M. tuberculosis Mc
2
7000 were grown as previously described
158
. 
Cultures were grown with serial dilutions of β-lactams in the presence and absence of 
2.5 μg ml-1 clavulanate. MIC was determined as described159. 
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Animal experiments 
 BALB/CJ mice, 6-8 weeks old, were obtained from Jackson laboratory, Maine, 
USA. The mice were infected with M. tuberculosis Erdmann strain. 50-100 cfus/lung 
were deposited via an aerosol infection method. 6 days post infection (PI), the bacterial 
colony forming units (cfu) in lung for 5 mice was determined. The mice were treated 
with drugs starting Day 7 PI. The drugs faropenem (160mg/kg body weight) and 
Isoniazid (25mg/kg body weight) were administered (intraperitoneally) every day for six 
days. A no drug control group received buffered saline. The efficacy of the drugs was 
assessed after three and six doses. The homogenates of lungs and spleens from 5 mice 
(from each drug group) were collected, plated on Middlebrook 7H10 agar plates and 
incubated at 37°C. The bacterial colonies were counted three weeks later and cfu 
determined. All protocols, animal purchases, and personnel were approved by the 
Institutional Animal Care and Use Committee (IACUC). 
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CHAPTER III  
 
STRUCTURAL BASIS FOR POTENTIATION OF BETA-LACTAM ANTIBIOTIC 
ACTIVITY ON Mycobacterium tuberculosis BY BENZOXABOROLES: INHIBITION 
OF BlaC 
 
OVERVIEW 
 
 Multidrug resistant strains of Mycobacterium tuberculosis (Mtb) are on the rise 
which increases the need for alternative antibiotic therapeutic strategies for treatment of 
infection. β-lactams are an unexploited class of antibiotics for tuberculosis (TB) 
treatment because of the innate resistance of Mtb to β-lactams conferred by the β-
lactamase BlaC. Potentiation of β-lactam antibiotic activity by inhibiting BlaC activity is 
a strategy to resensitize Mtb to this class of drugs. To develop new BlaC inhibitors, a 
boronic acid inhibitor library was enzymatically screened with BlaC which revealed 
benzoxaborole as a potential inhibitor scaffold. Biochemical characterization of several 
benzoxaborole inhibitor derivatives with BlaC revealed chemical moieties that increased 
potency of BlaC inhibition. Co-crystal structures of the inhibitors with BlaC reveal 
structural insights into the binding and inhibition of BlaC by benzoxaboroles. Lead 
molecule AN4715 competitively inhibited BlaC (Ki = 0.79 ± 0.02 µM) and potentiated 
the antibiotic activity of amoxicillin against Mtb.  
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INTRODUCTION 
 
 The World Health Organization (WHO) estimated that tuberculosis claimed 1.4 
million lives in 2011 
94
. The Mtb genome has been acquiring mutations over the last 
several decades that confer resistance to the classical chemotherapy cocktail of 
Isoniazid, Rifampicin, Ethambutol, Pyrazinamide and other second-line drugs
95
. 
Multidrug resistant tuberculosis (MDR-TB) strains are additionally resistant to a 
fluoroquinolone and an aminoglycoside limiting treatment options
59,160-162
. The need for 
new anti-tubercular drugs is paramount. 
 The blaC gene in Mtb encodes a broad spectrum class A β-lactamase (BlaC) that 
is responsible for the innate resistant of Mtb to β-lactam antibiotics96. Effective 
inhibition of BlaC restores sensitivity of Mtb to β-lactams98. FDA approved β-lactamase 
inhibitors like clavulanic acid, tazobactam, and sulbactam
61
 mimic β-lactam antibiotic 
substrates and inhibit BlaC by forming transient covalent acyl-intermediate complexes 
with a catalytic serine residue. Once the inhibitor acyl-intermediate becomes hydrolyzed 
by the enzyme, the inhibitor is no longer active. These inhibitors are actually poor BlaC 
substrates because they are turned over and eventually enzymatic activity is restored 
within minutes for sulbactam and tazobactam, and hours for clavulanic acid
69,70
. 
NXL104 is a  mechanism-based β-lactamase inhibitor, which also forms a covalent 
linkage with the catalytic serine residue of serine β-lactamase. It was recently 
characterized with BlaC and found to form incredibly more stable adducts with the 
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enzyme than clavulanic acid. However, the authors described modest affinity of BlaC for 
NXL104 prevents practical application
70
. 
 Boronic acids have long been studied as serine protease inhibitors because their 
electron deficient boron atom acts as an electrophile by forming covalent bonds with the 
deprotonated active site serines
71-75
. They have also been extensively characterized as 
inhibitors of serine β-lactamases because they share a similar mechanism. Boronic acid 
based-inhibitors of class C β-lactamase AmpC have been optimized for the last decade 
and have reached subnanomolar binding constants and activity in vivo
81-84
. 
 Benzoxaborole are derivatives of phenylboronic acids that have received recent 
attention for their biological activity as antifungals, anti-inflammatory, and sugar sensing 
molecules
163
. Benzoxaboroles were also recently reported to inhibit both class A  and 
class C β-lactamases with low micromolar to nanomolar affinities85.  To develop tight-
binding BlaC inhibitors, we enzymatically screened a library of boronic acids and 
confirmed that the benzoxaborole scaffold also inhibited BlaC. Several derivatives were 
enzymatically characterized to generate a structure activity relationship. The most potent 
benzoxaborole, AN4715, competitively inhibited purified BlaC enzyme as well as 
potentiated the activity of β-lactams against whole cells of Mtb. The co-crystal structures 
of BlaC with three benzoxaboroles were solved to reveal structural insights into the 
binding and the mechanism of inhibition of BlaC. The results suggest additional 
modifications to the benzoxaborole scaffold that may increase potency for BlaC, and 
support the belief that tight binding benzoxaboroles can be used to restore sensitivity of 
Mtb to β-lactam antibiotics by competitively inhibiting BlaC.  
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RESULTS 
 
Inhibition of BlaC by benzoxaboroles 
 Screening of a boronic acid based library led to the identification of the lead 
benzoxaborole molecule AN4715 (Appendix Figure A2). The mode of inhibition of 
AN4715 was determined to be competitive by inspection of the Lineweaver-Burke plot 
(Figure 3.1 b). Fitting the data to a competitive inhibition model with a global non-linear 
regression revealed the inhibition constant (Ki = 0.79 ± 0.02 µM). 
 To investigate the functional groups on the benzoxaborole scaffold that 
contribute to the inhibitory activity against the BlaC enzyme, IC50’s were determined for 
benzoxaboroles with different modifications at the 3’, 4’, and 6’ positions. The results 
are summarized in Table 3.1. Inhibitory activity of the benzoxaborole scaffold 
diminished when the 3’ carboxymethyl was substituted with sulfonyl methyl, 
phosphonomethyl, or ethyl ester groups, confirming the importance of the 3’ 
carboxymethyl in BlaC binding and inhibition. The 4’position tolerated a variety of 
hydrophobic substitutions without drastically effecting the IC50’s (4.1 ± 0.2 - 6.6 ± 0.4 
µM). When more hydrophilic substitutions were made, the IC50 increased up to 3-fold 
(19.6 ± 0.7 µM), suggesting that the 4’ position contributes to binding and inhibition 
through hydrophobic interaction with BlaC. Heterocyclic substitutions made at the 6’ 
position increased the IC50 by > 100-fold (122 ± 15 µM). Compounds with one aryl 
group were more potent than the bulkier compounds with heterocycles, indicating that 
the 6’ position is subject to steric constraints in the BlaC active site (Table 3.1). 
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Figure 3.1. Competitive inhibition of BlaC by benzoxaborole AN4715. (a) Nitrocefin hydrolysis by BlaC 
in presence of varying concentrations of AN4715. (b) Double reciprocal plot of BlaC reaction with 
nitrocefin in presence of varying concentrations of AN4715. 
 
b 
a 
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ID 3’R IC50 (µM)  ID 4’R IC50 (µM)  ID 6’R IC50 (µM) 
AN3447 
     
29 ± 3  AN4845 
 
 
 
4.1 ± 0.2  AN4715 
       
0.99 ± 0.05 
AN3668 
 
76 ± 11  AN4482 
 
4.2 ± 0.1  AN4967 
 
3.3 ± 0.5 
AN3737 
 
> 250  AN4449 
 
4.4 ± 0.2  AN3740 
 
8.0 ± 1 
 
AN3446 
 
 
> 250  AN4497 
 
6.6 ± 0.4  AN5620 
           
19.6 ± 0.7 
    AN3973 
    
5.4 ± 0.2  AN3915 
     
25.7 ± 0.5 
    AN4474 
        
6.1 ± 0.2  AN3893 
   
122 ± 15 
    AN4496 
 
15.8 ± 0.3     
    AN4892      19.6 ± 0.7     
 
Table 3.1. Structure activity relationship of BlaC inhibition by benzoxaboroles. Modifications were made 
at the 3’R group (left), 4’R group (middle), and 6’R group (right) derivatives. IC50s (µM) are listed for 
each compound. 
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Co-crystal structures of BlaC-benzoxaborole complexes 
 To further understand the structure activity relationship between benzoxaboroles 
and inhibition of the BlaC enzyme, co-crystal structures of 3 benzoxaborole inhibitors 
were solved in complex with BlaC, each bearing at least one different R group from the 
others. The data collection and refinement statistics are summarized Appendix Table A2. 
Two of the four BlaC molecules in the asymmetric unit had adequate solvent 
accessibility to the active site to allow inhibitor binding, and the other two active sites 
were relatively buried. 
 The benzoxaborole inhibitors shared many of the same interactions with the BlaC 
active site, many of which mimic substrate binding. Each inhibitor made contacts with 
substrate recognition resides Ser70, Ser130, Thr235 and Thr237 (Figure 3.2 a-c). The 
benzoxaboroles formed covalent bonds between the boron atom of the oxaborole ring 
and the side chain oxygen of the catalytic Ser70 of BlaC. Adjacent to the boron atom, 
the 1’ hydroxyl group hydrogen bonded to the backbone carbonyl oxygen of Thr237 (2.7 
- 3.1 Å), similar to how β-lactam acyl-intermediates are stabilized. Also, the 2’ oxygen 
accepted hydrogen bonds from the side chain hydroxyl of either Ser130 or the backbone 
amide nitrogen of Thr237. The negatively charged 3’ carboxymethyl of the 
benzoxaborole was electrostatically attracted to the positively charged pocket of the 
BlaC active site adjacent to the oxyanion hole.  The carboxylate fit directly between the 
side chain hydroxyl groups of Thr235 and Thr237 forming stabilizing hydrogen bonds 
(2.2 - 3.1 Å) with the enzyme in a manner analogous to how the conserved carboxylate 
group of β-lactams binds to BlaC. 
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Figure 3.2. Active site details of BlaC-benzoxaborole inhibitor complexes. AN4715 (a), AN4845 (b), 
AN4967 (c). FO-FC omit map electron density surrounding benzoxaboroles contoured at 1.5σ (top). Ligand 
binding pocket surface colored by electrostatic potential red = negative, blue = positive (middle). Active 
site hydrogen bonds between BlaC and benzoxaboroles represented as black dotted lines (bottom).  
 
 
 
 
b c a 
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 The 4’ position of the benzoxaborole was occupied by either a methyl group 
(Figure 3.2 a,c) or a bulky methoxyphenyl group (Figure 3.2 b). The methyl groups 
formed long range hydrophobic interactions with the aliphatic side chain of Ile105 at 
distances ranging from 4.4 - 4.5 Å similar to how the methyl group of biapenem and 
tebipenem (Chapter 2) interacts with Ile105. The larger flexible methoxyphenyl group 
reached out of the active site and into open solvent; its freedom of rotation and the lack 
of specific interaction with the enzyme surface resulted in decreased electron density for 
the 4’ methoxyphenyl group (Figure 3.2 b, top). Therefore, it is assumed that the 
methoxyphenyl group adopts multiple conformations that are capable of forming 
transient hydrophobic interactions with the side chain of Ile105 once bound to the 
enzyme. 
 Each of the inhibitors selected for co-crystal structure determination with BlaC 
differed primarily by the substitutions at the 6’ position because the inhibition profile at 
this position resulted in a wide range of BlaC inhibition (0.99 ± 0.05 - 122 ± 15 µM). 
Each 6’ substitution of the benzoxaborole formed hydrogen bonds with the backbone 
amide nitrogen of Ile105. Interestingly, two of the inhibitors, AN4715 and AN4976 
(Figure 3.2 a, c, bottom), formed this interaction indirectly through a bridging water 
molecule and the 6’ oxygen atom linking the cyclic substituent. The 6’ pyrazine of 
AN4845 (Figure 3.2 b, bottom) directly hydrogen bonded to the backbone amide 
nitrogen of Ile105 at 2.46 Å.  
 In contrast to AN4845, both, AN4715 and AN4967 6’ substitutions rotated 
approximately 90 ° about the oxygen linker toward the roof of the BlaC active site 
 56 
 
(Figure 3.2 a - c).  The propyl amine of AN4967 reached up into the acidic pocket at the 
top of the active site, and donated a hydrogen bond to the side chain carboxylate oxygen 
atom of Asp240 (3.37 Å) in molecule C of the asymmetric unit.  However, this did not 
happen in molecule B, which underscores the flexibility of the propylamine group.  The 
unbiased Fo-Fc electron density for the 6’ phenol ring of AN4715, was consistent with 
two possible orientations, where one had less occupancy than the other.  In the dominant 
orientation (Figure 3.2 a), the hydroxyl group of AN4715 donates a hydrogen bond to 
the side chain carboxylate oxygen atom Asp240 at 3.18 and 3.27 Å in molecules C and 
B, respectively.  If rotated approximately 180°, the phenol hydroxyl group of AN4715 is 
poised to form a cation-pi interaction with the guanidinium of Arg171. Once bound to 
the enzyme, the small size of the 6’ substitution of AN4715 relative to AN4967 affords 
rotation within the active site, and facilitates an additional interaction with Arg171. 
 
AN4715 potentiates β-lactam activity against Mycobacterium tuberculosis 
 The BlaC enzyme is constitutively expressed by Mtb
164,165
, and is the major 
determinant for resistance to β-lactam antibiotics 96. A common strategy for overcoming 
resistance due to β-lactamase is combining a β-lactam with a β-lactamase inhibitor. The 
most potent benzoxaborole inhibitor of BlaC in this investigation, AN4715, was selected 
to test for potentiation of β-lactam activity against Mtb. Amoxicillin was chosen as a 
model β-lactam because of its specificity for BlaC. Cultures of Mtb were treated with 
amoxicillin in presence and absence of 10 µM AN4715, and cell viability was assayed as 
described
159
. The cell viability averaged from 4 experiments was plotted as a logarithmic 
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function of amoxicillin concentration, and the dose response curves were fit to a four 
parameter non-linear regression (Figure 3.3). Combining AN4715 with amoxicillin 
potentiates the activity of β-lactam antibiotics against whole cells of Mtb, decreasing the 
MIC by approximately two-fold. 
 
DISCUSSION 
 
 The prevalence of drug-resistant Mycobacterium tuberculosis infections 
drastically reduces treatment options and extends already exhaustive treatment regimens. 
Development of new TB diagnostics and drugs, as wells as repurposing existing drugs as 
TB therapeutics, are effective strategies for reducing disease transmission and decreasing 
morbidity rates. 
 β-lactam antibiotics are attractive candidates for TB chemotherapy because they 
effectively bind to and inhibit target penicillin-binding proteins (PBP) hypothesized to 
remodel the Mtb cell wall during the persistent state of infection
28,166
. The chromosome-
encoded β-lactamase enzyme BlaC is the primary mechanism of resistance to these 
antibiotics
96. The combination of β-lactam antibiotics with mechanism-based β-
lactamase inhibitors has proven to be effective against Mtb in vitro
98
, and has modest 
activity against murine tuberculosis models
101. Increasing the effectiveness of β-lactams 
against Mtb can be achieved by improving bioavailability, increasing the affinity of β-
lactams for their target PBPs, and importantly decreasing BlaC-mediated resistance with 
β-lactamase inhibitors. 
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Figure 3.3. AN4715 potentiates activity of amoxicillin against Mtb. 
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 Inhibition of class A β-lactamases by clavulanic acid proceeds through formation 
of a covalent acyl adduct with the enzyme’s catalytic serine residue61. For BlaC, 
enzymatic activity is restored within a matter of hours due to hydrolysis of the enzyme-
inhibitor complex, which leaves the inhibitor inactive and unable to rebind
70
. This 
suggests that it would have to be administered continuously for maximum effectiveness 
use as a therapeutic in combination with effective β-lactams like meropenem. The slow 
decarbamylation reaction of NXL-104 with BlaC holds promise for future potent and 
stable derivatives as useful BlaC inhibitors
70
. 
 Benzoxaboroles have demonstrated inhibitory activity against class A and C 
serine β-lactamase CMY-10, TEM-1, CTX-M, and AMP-C, suggesting that they would 
also inhibit BlaC
85
. To develop potent inhibitors that can potentially be used in 
combination with β-lactam antibiotics, we enzymatically screened BlaC against a 
boronic acid library and identified the benzoxaborole inhibitor AN4715 (Ki = 0.79 ± 
0.02 µM).   Kinetic characterization confirmed the competitive mode of inhibition of 
BlaC by benzoxaboroles (Figure 3.1 a, b). A structure activity relationship was 
constructed by substitution of the benzoxaborole 3’, 4’, and 6’ positions and subsequent 
IC50 determination with BlaC (Table 3.1), which led to identification of modifications 
that increased the potency of the inhibitors for BlaC. Crystal structures of BlaC in 
complex with the inhibitors demonstrated that benzoxaboroles are β-lactam substrate 
mimics that form many of the same interactions observed the BlaC acyl-intermediate 
structures (Chapter 2). 
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 The 4’ position seemed to tolerate the most diverse modifications with the least 
consequential loss of BlaC enzymatic inhibitory activity with IC50 values ranging from 
4.1 ± 0.2 to 19.6 ± 0.7 µM. This is likely because the 4’ groups mostly face away from 
the BlaC active site cavity and into open solvent, but still within proximity of the Ile105. 
Crystal structures elucidated that even distant hydrophobic interactions (4.2 - 4.5 Å) 
between the 4’ substituents and the side chain of Ile105 played a role in binding and 
inhibition of BlaC, as these hydrophobic substitutions were the most potent 4’ 
modifications. This observation is supported by the ~4-fold increase in IC50 (5.4 ± 0.2 - 
19.6 ± 0.7) resulting from exchanging a methyl with a hydroxyl at position 4’. 
 The acidic groups at the benzoxaborole 3’ position were indispensable for BlaC 
inhibition. Substitution with sulfonyl methyl was sufficient to maintain binding and 
inhibition, but resulted in a 3-fold decrease in potency relative to carboxymethyl. 
Phosphonomethyl substitution at this position abolished inhibitory activity. Despite 
similar structure and the electronegative character of the 3’ modifications, their 
inhibitory activities deviated drastically. The inhibitor co-crystal structures with BlaC 
illustrated the delicate fit of the carboxymethyl group required for maintaining optimal 
potency and hydrogen bonding geometry with side chains of substrate recognition 
residues Thr235 and Thr237 (Figure 3.2 a - c). The sulfonate group of NXL-104 
mediates similar hydrogen bonds with Thr235 and Thr237
70
, suggesting that substitution 
of the sulfonate with a carboxylate group may improve binding affinity of NXL-104 for 
BlaC. 
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 The 6’ position of the benzoxaborole seems to offer the most opportunity for 
improvement of the affinity for BlaC. Initial development and optimization of the 
benzoxaborole as β-lactamase inhibitor scaffold revealed that a bridging oxygen atom is 
the best linker for aryl modifications at the 6’ position85. The crystal structures of BlaC 
with such benzoxaboroles demonstrate the involvement of the bridging oxygen atom in 
hydrogen bonding to the backbone amide nitrogen of Ile105 indirectly through ordered 
solvent mediated contacts. The distal region of the BlaC active site is wide and can 
expand through movement of the substrate specificity loop (residues 160-180). Smaller 
monoaryl 6’ substituents fit within this pocket without requiring active site expansion, 
and can potentially form hydrogen bonds with any of the surrounding residues including 
Asn170, Glu166, Arg171, and Asp240. The inhibitors characterized in this investigation 
show that a single hydrogen bond formed between the 6’ hydroxyl group on AN4715 
and the side chain carboxylate of Asp240 increases the potency 8 fold relative to the 
same compound without the hydroxyl group (AN3740). Since the inhibition constant of 
AN4715 is sub-micromolar, it is easy to envisage designing a sub-nanomolar BlaC 
inhibitor by picking up a few more hydrogen bonds in this region, which is a feat that 
has recently been surmounted using fragment based design to optimize boronic acids for 
AmpC inhibition
84. The 5’ and 7’ positions of the benzoxaborole scaffold have yet to be 
explored in chemical space, which offer two additional places for modifications that may 
enhance specificity and potency for BlaC. Furthermore, the dual conformations and 
interactions of the 6’ phenol of AN4715 with BlaC suggest that additional hydrogen 
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bond donor or acceptor modifications to the phenol ring will improve potency by 
hydrogen bonding with backbone or side chain atoms in the substrate specificity loop. 
 The results of this investigation reveal the molecular basis for inhibition of class 
A β-lactamases by benzoxaboroles, and provided structural and functional insights into 
the binding and inhibition of BlaC by benzoxaboroles. The structure activity relationship 
presents a useful framework to enable future optimization and structure based design of 
benzoxaboroles with increased potency and specificity for BlaC. Moreover, the 
prospective utility of these inhibitor molecules as potentiators of β-lactam antibiotic 
activity against Mtb has been demonstrated.  Combination of an appropriately selected β-
lactam antibiotic that either evades BlaC inactivation by reduced binding or slow 
turnover with a potent benzoxaborole could prove to be clinically useful to resensitize 
the TB pathogen to the most widely used antibiotic class in history. 
 
MATERIALS AND METHODS 
 
Cloning, expression, and purification  
 Wild-type BlaC was cloned from M. tuberculosis H37Rv genomic DNA as 
described
97
. The deacylation deficient Glu166Ala mutant was generated using the 
Quickchange
TM
 site directed mutagenesis kit (Stratagene no. 200519). Protein expression 
and purification were performed as described
97
. 
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Inhibition kinetics 
 Inhibition of BlaC by benzoxaboroles was measured by monitoring the initial 
velocities of reporter substrate hydrolysis (CENTA, λ = 404 nm) in presence of varying 
concentrations of inhibitors (.122 - 250 µM). Reactions were performed in 50 mM 
potassium phosphate buffer (pH = 7.0) with 0.1 % Triton-X 100 and 10 nM enzyme. 
Percent inhibition of BlaC activity was plotted versus inhibitor concentration and the 
concentration of inhibitors required to decrease the reaction velocity by 50% (IC50) were 
determined by fitting the mean values from 3 data sets to a nonlinear regression model in 
Prism 6.0. BlaC inhibition constant (Ki) of AN4715 was measured by monitoring the 
initial velocities of reporter substrate hydrolysis (nitrocefin, λ = 486 nm, ε =20,500) in 
presence of 0.0, 0.3, 1.0, and 3.0 µM of AN4715. Reactions were performed in 50 mM 
potassium phosphate buffer (pH = 7.0) with 0.1 % Triton-X 100 and 1 nM enzyme. The 
mean values from 3 data sets data were fit to a global nonlinear regression model of 
competitive inhibition using Prism 6.0. 
 
Crystallization 
 Crystals of wild-type and Glu166Ala BlaC were grown using the hanging drop 
vapor diffusion method
151
. BlaC was concentrated to 10 mg/ml and equilibrated 
overnight at 4º C with mother liquor (2.0 M NH4H2PO4, .1M Tris pH 8.0) at a 1:1 ratio 
(protein-:-mother liquor). The solution was centrifuged for 10 min at 13 Krpm to remove 
insoluble precipitate. Hanging drops were set up and equilibrated against 1ml of mother 
liquor. Microseeding with horsehair was sufficient to produce larger diffraction quality 
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crystals. Crystals were transferred to a stabilization solution containing 30% glycerol in 
mother liquor and were subsequently soaked with β-lactam antibiotics for 2-4 hours. The 
concentration of inhibitor was slowly increased by transferring the crystals to successive 
drops to prevent cracking. Derivatized crystals were flash frozen in liquid nitrogen.  
 
Data collection and processing 
  X-ray diffraction data was collected on beamlines 19ID and 23ID at The 
Advanced Photon Source, Argonne National Laboratory, Argonne, IL. Data sets were 
reduced using HKL3000
152
. Data was collected at a temperature of 120 K. For data 
quality, crystallographic, and refinement statistics, see Table 2. 
 
Structure determination 
 Initial phases were obtained by molecular replacement using Phaser 
Crystallographic Software
153
 in the CCP4 suite
154
 and 2GDN as a search model
97
. Each 
data set was refined against the resulting model, and iterative cycles of model building 
and refinement were performed with Coot 0.6.1
155
 and PHENIX
156
. 
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CHAPTER IV  
 
RAPID POINT-OF-CARE DETECTION OF THE TUBERCULOSIS PATHOGEN 
USING A BlaC-SPECIFIC FLUOROGENIC PROBE* 
 
OVERVIEW 
 
Early diagnosis of tuberculosis can dramatically reduce both its transmission and 
the associated death rate. The extremely slow growth rate of the causative pathogen, 
Mycobacterium tuberculosis (Mtb), however, makes this challenging at the point of care, 
particularly in resource-limited settings. Here we report the use of BlaC (an enzyme 
naturally expressed/secreted by tubercle bacilli) as a marker and the design of BlaC-
specific fluorogenic substrates as probes for Mtb detection. These probes showed an 
enhancement by 100–200 times in fluorescence emission on BlaC activation and a 
greater than 1,000-fold selectivity for BlaC over TEM-1 β-lactamase, an important factor 
in reducing false-positive diagnoses. Insight into the BlaC specificity was revealed by 
successful co-crystallization of the probe/enzyme mutant complex. A refined green 
fluorescent probe (CDG-OMe) enabled the successful detection of live pathogen in less 
than ten minutes, even in unprocessed human sputum. 
1
 
                                                 
*Reprinted with permission from Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-
specific fluorogenic probe. Xie, H., Mire, J., Kong, Y., Chang, M., Hassounah, H., Thornton, C. N., 
Sacchettini, J. C., Cirillo, J. D., and Rao, J., (2012). Nature Chemistry, 4, 802-809, Copyright 2012 by 
Nature Publishing Group.  
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This system offers the opportunity for the rapid, accurate detection of very low numbers 
of Mtb for the clinical diagnosis of tuberculosis in sputum and other specimens. 
 
INTRODUCTION 
  
 Tuberculosis is one of the most deadly diseases that kills over one million people 
each year and infects one-third of the world’s population167. The disease is spread by 
infection with Mycobacterium tuberculosis (Mtb). Owing to its airborne transmission, 
early diagnosis is critical to the prevention and control of TB. Standard diagnostic 
methods, acid-fast smear from sputum, often do not become positive until after 
transmission occurs, which allows the spread of the disease. Culture-based techniques 
are more sensitive, but take weeks to obtain results because of the extremely slow 
growth rate of Mtb. Recently, nucleic acid-based diagnostic strategies were shown to 
have a higher sensitivity than that of sputum smear microscopy
168-170
. With a semi-
automated DNA amplification system (Cepheid GeneXpert), it is thought that TB can be 
diagnosed with 98% reliability
171
. However, its high cost
172
 and requirement for a high 
technical competence to carry out the test prevent it from being widely available in 
resource-limited settings. In addition, the sensitivity of this test has not reached that of 
the gold standard culture, and it cannot evaluate bacterial viability, a critical aspect of 
evaluating therapeutic outcome. TB eradication efforts would be facilitated greatly by 
methods that can detect tubercle bacilli in a sensitive, rapid, specific and quantitative 
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manner in vitro at a low cost, particularly in resource limited settings where TB is the 
most prevalent.  
 Tubercle bacilli naturally express BlaC, an enzyme that belongs to the class A β-
lactamase family
96,98
. Extended spectrum class A β-lactamase are capable of hydrolyzing 
all classes of β-lactam substrates, including cephalosporins. The mechanism of 
cephalosporin hydrolysis by β-lactamase yields hydrolyzed β-lactam and, more 
importantly, may be concomitant with the loss of a 3′ leaving group139,173-175. Based on 
this mechanism, a number of fluorogenic and bioluminogenic probes were developed for 
the detection of β-lactamase activity in vitro, in living cells and even in whole 
animals
176-180
. We developed cephalosphorin-based fluorogenic substrates that enable the 
sensitive detection of Mtb and bacillus Calmette– Guérin (BCG) in vitro and in living 
mice
181
. Previous probes lack specificity for BlaC in Mtb; the common TEM-1 β-
lactamase (TEM-1 Bla) in gram-negative bacteria can also generate fluorescence, which 
reduces its utility for TB diagnosis. Earlier probes are generally large and display slow 
hydrolytic kinetics for BlaC. Here we report a rational design of a series of fluorescent 
probes based on chemically modified cephalosporins by taking advantage of the unique 
flexibility of the BlaC substrate-specificity loop. Enzymatic kinetic, structural analyses 
and whole-cell assays confirmed their high specificity and sensitivity for BlaC over its 
close class A homologue TEM-1 Bla as well as over β-lactamase produced by 
Pseudomonas, Staphylococcus and the environmental Mycobacterium smegmatis. 
Successful detection and imaging of BCG directly in unprocessed patient sputum at 
levels of less than 100 bacilli are demonstrated, even with a simple, inexpensive imaging 
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system of a cellular phone. This new BlaC-specific probe has potential for the clinical 
diagnosis of Mtb in patient sputum and other diagnostic specimens. Structural insights 
obtained from the BlaC acyl intermediates in this work should facilitate the development 
of more BlaC-specific probes for Mtb detection and imaging, and of BlaC-specific 
inhibitors to be used in anti-Mtb therapeutic regimens. 
 
RESULTS 
 
Design of BlaC-specific fluorogenic probes 
 The substrate specificity of class A β-lactamase is conferred by Ambler residues 
(163–178) that comprise the omega loop, or substrate-specificity loop, and is partially 
dependent on the ability of the catalytic base, E166, to assume the optimal conformation 
for hydrolytic water coordination and deacylation
182,183
. To design a cephalosporin 
substrate specific for BlaC to achieve the specific detection of Mtb, we exploited the 
unique flexibility of the BlaC substrate-specificity loop by introducing bulky 
substitutions on the lactam. Such a cephalosporin may be accommodated by the BlaC 
substrate-specificity loop with the coordination of E166 still optimal for efficient 
deacylation.  
  We designed a series of fluorescent probes with substitutions on the side chain 
(R1) of the 7-amino group or the 7-position of the lactam ring (R2) (Figure 4.1). Each 
probe contains the alkylated umbelliferone at the 3′-position and initially fluoresces little 
when excited at 400 nm. We hypothesized that these substituted substrates could be 
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Figure 4.1. General structures of blue fluorescent probes and their hydrolysis by BlaC. Hydrolysis triggers 
the release of umbelliferone and turns on fluorescence. 
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hydrolyzed readily by BlaC and release free fluorophore to turn on the fluorescence, but 
their hydrolysis by other β-lactamase, such as TEM-1 Bla, would proceed with much 
slower kinetics. These blue fluorescent probes were synthesized
184,185
 and 
unambiguously characterized. 
 
Enzymatic kinetics for BlaC and TEM-1 Bla 
 We first recorded the fluorescent spectra of CDC-1, CDC-3, CDC-OMe and 
CDC-OEt before and after BlaC treatment to examine their responses to BlaC. With 
excitation at 400 nm, all the probes exhibited over a 100-fold increase in the 
fluorescence intensity at 455 nm after incubation with BlaC (Figure 4.2 a), but their 
reaction rates varied significantly (Figure 4.2 b). Under the same conditions, the 
hydrolytic rate by BlaC decreased in the order CDC-1.CDC-OMe.CDC-OEt, which 
appears to correlate with the size of the R2 group. CDC-OMe showed more than a 30-
fold enhancement of fluorescence intensity in less than 30 minutes. The larger 
substitution (ethoxy versus methoxy) provided CDC-OEt with only a slight fluorescence 
enhancement within 30 minutes. In comparison, the same concentration of TEM-1 Bla 
(50 nM) gave no change in the fluorescence intensity within 30 minutes with CDC- 
OMe, but produced rapid fluorescence with CDC-1 and CDC-3. These results 
demonstrate that CDC-OMe can preferentially detect BlaC over TEM-1 Bla. 
 We next examined the response of CDC-OMe to varying concentrations of BlaC 
and TEM-1 Bla (in the range 1 pM to 100 nM) to investigate its specificity (Figure 4.2 
c). BlaC (1 nM,100 ml) induced a 130% increase in the fluorescence intensity within 
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Figure 4.2. Kinetic comparison of CDC probes with β-lactamase. (a) Fluorescent emission spectrum of 
CDC-OMe (1 mM in PBS) before and after treatment with BlaC (1 mM) (excitation, 400 nm). (b) Time 
courses of fluorescent activation of CDC-1 and CDC-OMe with BlaC (filled circles) or TEM-1 Bla (open 
squares). (c,d) Enhanced fluorescent intensity of CDC-OMe (c) and CDC-1 (d) (5mM in PBS) by BlaC or 
TEM-1 Bla at the indicated concentrations for one hour. F/F0 represents the turn-on ratio of fluorescence 
intensity by β-lactamase. Error bars are ± standard deviation (s.d.). a.u.= arbitrary units. 
  
 
 
  
a b 
c d 
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one hour (F/F0 = 2.3), but a 100-fold higher TEM-1 Bla concentration (100 nM) 
produced only a 30% fluorescence enhancement (F/F0 = 1.3). In contrast, TEM-1 Bla 
generated a stronger signal with CDC-1 than with BlaC (Figure 4.2 d). 
 The kinetic parameters of fluorescent probes for both BlaC and TEM-1 Bla, 
including the catalytic constant kcat and the Michaelis constant Km, were obtained from 
Lineweaver–Burk plots and are summarized in Table 4.1. Consistent with the above 
observations, the kinetic efficiency (kcat/Km) of CDC-OMe for BlaC is 2.1 × 10
4
 s
-1
 M
-1
, 
over 1,000 times higher than that for TEM-1 Bla (16 s
-1
 M
-1
). When an ethoxy group is 
introduced at the 7-position (CDC-OEt), no hydrolysis by TEM-1 Bla was detected, and 
the value of kcat/Km by BlaC decreased substantially to 1.9 × 10
2
 s
-1
 M
-1
. 
 Additional structural modifications were explored for their effects on the 
enzymatic kinetics of BlaC and TEM-1 Bla. Probes with a large substitution group on 
the 7-amine position (R
1
), such as CDC-3, displayed less catalytic efficiency for BlaC 
(8.7 ×10
4
 s
-1
 M
-1
) than for TEM-1 Bla (1.3 × 10
6
 s
-1
 M
-1
). However, substitution by 
phenylacetyl or acetyl groups (for example, CDC-1 and CDC-4) at this position resulted 
in only a slight difference in the catalytic efficiency between BlaC and TEM-1 Bla 
(CDC-1, 2.1 × 10
5
 versus 3.6 × 10
5
 s
-1
 M
-1
; CDC-4, 6.8 ×10
4
 versus 7.5 × 10
4 
s
-1
 M
-1
, 
respectively). Oxidation of the sulfur into sulfoxide (CDC-2) caused a decrease in the 
kinetic efficiency for both BlaC and TEM-1 Bla. These kinetic analyses confirm CDC-
OMe as a BlaC-specific fluorogenic probe with more than a 1,000-fold higher catalytic 
efficiency for BlaC than for TEM-1 Bla. 
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Table 4.1.  Kinetic parameters of fluorescent probes for BlaC and TEM-1 Bla. Kinetic data were measured 
in PBS buffer (×1, pH = 7.4) at room temperature (22 °C) unless otherwise noted. All data indicate 
averages of three replicate experiments. *Data in parentheses were measured in MES buffer (0.1 M, pH 
6.6) at 22 8C. ND = not determined due to extremely slow kinetics. 
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Analysis of the crystal structure 
 X-ray crystallographic structures of the acyl intermediate complex structures of 
CDC-OMe and CDC-1 with BlaC were obtained to probe the structural origin of the 
observed specificity of CDC-OMe for BlaC (Table 4.1). The substrate-specificity loops 
of TEM-1 Bla and BlaC share a 67% sequence identity over 20 residues (160–180). 
Conserved saltbridges in both enzymes formed by D172–R178 (E171–R178 in TEM-1 
Bla) and D176–R178 stabilize the loop conformers of the unoccupied active sites 
(Figure 4.3 a)
97,186
. 
 The largest phenotypic difference between the two enzymes results from residue 
164, which is an arginine in TEM-1 Bla and an alanine in BlaC. R164 plays a central 
role in the molecular dynamics of the substrate-specificity loop in TEM-1 Bla. The R164 
guanidinium side-chain nitrogens (Nε, NH and NH2) stabilize a triad of carboxylates 
from the D176, D179 and E171 side chains with electrostatic interaction distances of 
3.99 Å, 2.75Å and 2.87 Å, respectively
186
, by forming three additional salt bridges 
(Figure 4.3 b)
97,186
. 
 A164 mutation results in the loss of these stabilizing salt bridges in BlaC, which 
ultimately increases the flexibility of the BlaC substrate-specificity loop relative to that 
of TEM-1 Bla. The increased flexibility is underscored by B-factors for residues 
that surround E166 (164–168), which are 108% of the mean B-factor in BlaC and 87% 
of the mean B-factor in TEM-1 Bla
97,186
. The structural plasticity of these residues 
allows the catalytic base E166 to sample multiple conformations and increases the 
capability of BlaC to hydrolyze substrates in the acyl-intermediate state. The acyl- 
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Figure 4.3. Comparison of BlaC and TEM-1 Bla active sites and substrate-specificity loops. a, Conserved 
salt bridges in both enzymes formed by D172–R178 and D176–R178 stabilize the loop conformers of the 
unoccupied active sites. b, TEM-1 Bla (1M40, white) R164 forms salt bridges with E171 (2.87 Å), D176 
(3.99 Å) and D179 (2.75 Å). BlaC (2GDN, purple) A164 prevents these stabilizing interactions, which 
results in an increased flexibility of the loop and catalytic base E166. c, Superimposition of unoccupied 
TEM-1 Bla and BlaC active sites. d, Superimposition of unoccupied TEM-1 Bla (white) and the BlaC–
CDC-OMe acyl intermediate complex (purple). The arrow indicates the expansion of the substrate loop in 
BlaC on binding CDC-OMe. 
  
 
 
a b 
c d 
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intermediate complex structures of BlaC–CDC-1 and BlaC–CDC-OMe exist in similar 
orientations, and share conserved electrostatic interactions with substrate-recognition 
residues T235, T237, S130 and S70 (Figure 4.4). The phenyl groups in both 
CDC-1 and CDC-OMe are disordered as a result of the lack of active-site contacts 
and facing open to the solvent. In contrast, CDC-1 makes a unique hydrogen bond (2.76 
Å) with the backbone carbonyl oxygen of T237. The methoxy group of CDC-OMe 
forms an electrostatic interaction with the side-chain amino group of K73 (3.29 Å). The 
orientation of the CDC-OMe 7′-phenylacetylamino substituent is rotated approximately 
90° relative to the CDC-1 acyl intermediate (Figure 4.4 c). The CDC-OMe–K73 
interaction positions the methoxy group directly in the path between the acyl bond and 
catalytic residue E166, which may interfere with the hydrolytic water coordination for 
deacylation and lead to a decreased turnover number for CDC-OMe (Table 4.1). 
Replacement of the methoxy group with a bulkier ethoxy group (CDC-OEt) causes a 
more serious occlusion, which leads to a further 40-fold reduction in turnover number 
(Table 4.1). However, these unique interactions in the CDC-OMe acyl intermediate 
accommodated by the BlaC flexible substrate-specificity loop confer the specificity of 
CDC-OMe for BlaC (Figure 4.3 c,d). 
 
Detection and imaging of live mycobacteria 
 We first sought to evaluate the feasibility of CDC-OMe for the detection of BlaC 
expressed by Escherichia coli. CDC-OMe was incubated with the same number of E. 
coli that expressed no β-lactamase, TEM-1 Bla or BlaC for two hours and a strong  
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Figure 4.4. Active-site details of the BlaC-CDC-OMe (top) and BlaC–CDC-1 (bottom) acyl intermediate 
complexes. (a,b) Electrostatic surface potential (a) and cartoon diagrams (b) of acyl intermediates with FO 
- FC electron-density maps displayed in grey for CDC-OMe (2.0s) and CDC-1 (1.5s) prior to fitting each 
ligand for refinement protocols. Active-site residues are displayed as sticks. (c) Ligplot analysis of active-
site interactions. 
 
 
 
 
 
 
 
a b c 
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fluorescence was observed only with E. coli that expressed BlaC. As a control, the 
fluorescence for CDC-1 was present in E. coli that expressed either TEM-1 Bla or BlaC. 
This result demonstrates that CDC-OMe can detect BlaC specifically in intact E. coli. 
However, the sensitivity for detecting BlaC expressed by the Mtb var. bovis strain BCG 
is low because of the high background of BCG at the excitation and emission 
wavelengths of umbelliferone. Therefore, we replaced umbelliferone with the green 
fluorescent dye Tokyo Green (Figure 4.5 a). Tokyo Green allows a stable single-site 
attachment at its phenolic position
187
, but the direct coupling product with cephalosporin 
at the 3′-position, similar to that in CDC probes, displayed a 21-fold less stability (with a 
spontaneous hydrolysis rate of 7 × 10
-6
 s
-1
 in PBS) than that of CDC-OMe. A benzyl 
ether linker was thus introduced between the 3′-position of the lactam and Tokyo Green 
to increase its stability (Figure 4.5 a).  
 On treatment with BlaC, the fluorescence emission of CDG-OMe at 520 nm 
increased by up to 218-fold (Figure 4.5 b). In addition to the gain in the stability of the 
probe obtained from the additional linker, the specificity of CDG-OMe for BlaC 
improved, with an 11-fold increase in kcat/Km to 2.3 × 10
5
 s
-1
 M
-1
 in PBS (Table 4.1). 
Even at a more than 1,000-fold higher concentration, the fluorescence signal of CDG-
OMe generated by TEM-1 Bla (400 nM) was just 30% of that generated by BlaC (400 
pM) in 300 minutes, which confirms its high selectivity for BlaC (Figure 4.5 c). Less 
than 1 fmol of BlaC was readily detectable with CDG-OMe after eight hours of 
incubation (Figure 4.5 d). When TEM-1 Bla- and BlaC-expressing E. coli were  
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Figure 4.5. β-lactamase selectivity of fluorescent probes CDG-1 and CDG-OMe. a, BlaC hydrolyses green 
probes and turns on the fluorescence signal. b, Fluorescent emission spectrum of CDG-OMe (20 nM in 
MES) before and after treatment of BlaC (0.2 µM) (excitation, 490 nm). c, Time courses of fluorescence 
enhancement with CDG-OMe (8 µM in MES buffer) and various concentrations of β-lactamase. d, 
Enhanced fluorescence intensity of CDG-OMe (8 µM in MES, front) and CDG-1 (8 µM in MES, back) by 
serially diluted solutions of BlaC or TEM-1 Bla for eight hours. Data were collected in 384-well plates 
with a total volume of 25 µl in each well. e, Magnified view of the rectangular region in (d). ΔF represents 
the difference in fluorescence intensity with and without β-lactamase incubation. Data in (d) and (e) are 
the average of three replicate experiments. Error bars are ± s.d. 
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incubated with CDG-1 and CDG- OMe, CG-1 displayed no selectivity, but CDG-OMe 
showed excellent selectivity for BlaC over TEM-1 Bla.  
 We further tested the sensitivity and specificity of CDG-OMe for detecting 
bacteria present in raw unprocessed sputum samples obtained from cystic fibrosis 
patients. BCG or other bacteria that expressed β-lactamase, including E. coli, 
methicillin-resistant S. aureus (MRSA), P. aeruginosa strain PA01 and M. smegmatis 
were incubated with CDG-OMe in human sputum. We could detect Mtb readily in 
sputum down to ten colony-forming units (c.f.u.) (P < 0.05), which demonstrates the 
high sensitivity of this system for evaluating clinical samples (Figure 4.6 a). 
Fluorescence emission generated by 10 c.f.u. of BCG in sputum is significantly (P < 
0.05) higher than fluorescence from the negative control and 10
5
 c.f.u. of E. coli, MRSA, 
PA01 and M. smegmatis (Figure 4.6 b).  
 To investigate the applicability of this system in low-resource settings, we built a 
handmade box equipped with a simple LED light source, excitation filter and emission 
filter, and took a picture with a cell phone through a hole in the box. As shown in Figure 
4.6 c, 10 c.f.u. of BCG in 200 µl of human sputum was detected readily within ten 
minutes of incubation with the probe, and the use of luminance mapping allowed facile 
optimization of image visualization. In summary, CDG-OMe demonstrates excellent 
sensitivity and specificity for detecting Mtb var. bovis strain BCG in clinical specimens, 
even using low-cost detection systems. 
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Figure 4.6.  Sensitivity and specificity of CDG-OMe in unprocessed human sputum. a, Detection of BCG 
in sputum with CDG-OMe. b, Specificity of CDG-OMe for detecting BCG in sputum. 10 c.f.u. of BCG or 
10
5
 c.f.u. of the indicated β-lactamase-expressing bacteria were added to human sputum samples obtained 
from cystic fibrosis patients and incubated with CDG-OMe (2.5 µM) at room temperature for 160 minutes. 
Fluorescence was measured with excitation at 490 nm and emission at 535 nm. *P < 0.05 as compared to 
10 c.f.u. of BCG. c, Imaging of BCG in sputum with CDG-OMe using a cellular phone. BCG-spiked 
sputum samples were incubated with CDG-OMe (5 µM) at room temperature for ten minutes before they 
were imaged in a simple handmade light box: light from an off-the-shelf LED assembly (<US$10.00) 
passed through a 490 nm excitation filter (bandpass 20 nm) was reflected through a 530 nm emission filter 
(bandpass 43 nm) and photographed with an iPhone 4S. The photograph was analyzed with iPhotoLux v. 
1.0. Error bars are ± s.d. 
 
a b 
c 
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DISCUSSION 
 
 One of the critical needs for improving the diagnosis of TB is to identify accurate 
biomarkers for active Mtb
188
. Recently, the trehalose mycolyltransferase enzymes were 
utilized to incorporate unnatural trehalose analogues into Mtb for TB detection
189
. As it 
requires cell culturing for the probe incorporation, the process can take a long time 
because of the slow growth rate of Mtb. BlaC has the potential to serve here and has 
many advantages as a diagnostic marker. All TB complex bacteria examined displayed a 
strong signal dependent on β-lactamase, including BCG, TB laboratory strains and TB 
clinical isolates, with a total of more than 20 different strains. In addition, complete 
genome sequencing of more than 54 Mtb strains from numerous geographical regions, 
multidrug resistant and extensively drug-resistant strains demonstrates that BlaC is 
highly conserved in all Mtb clinical isolates, with only two non-synonymous single-
nucleotide changes, but they still produce an active enzyme
95
. These observations are 
consistent with reports in the literature that indicate 100% (18 examined for Mtb, nine 
for M. bovis, five for M. africanum) of the strains within the TB complex and M. 
kansasii (17 examined) produce β-lactamase and are positive for enzymatic activity190. 
As BlaC is an enzyme, its activity promises great sensitivity for the detection of tubercle 
bacilli, as we have shown with fluorogenic substrates. However, previously available 
probes lack specificity for BlaC
181
, which allows activation by other β-lactamase, such 
as TEM-1 Bla, commonly found in gram-negative bacteria
54,191
, which reduces their 
accuracy for TB diagnosis. 
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 Extensive research is devoted to β-lactamase because of their role in rendering 
bacteria resistant to lactam antibiotics. However, most previous studies focused on 
designing molecules that are poor β-lactamase substrates69,100, in contrast to the goal of 
this study, to design substrate probes that have rapid kinetics and are selective for BlaC. 
We took advantage of the unique substrate specificity loop of BlaC and explored its 
chemistry to design BlaC-specific fluorogenic substrates. The replacement of R164 in 
TEM-1 Bla by Ala results in the loss of stabilizing salt bridges in BlaC and thus an 
increase in the flexibility of the BlaC substrate specificity loop. Therefore, it is more 
probable that the active site of BlaC accommodates chemical modifications on the 
lactam structure. Based on this structural insight, we explored substitutions at the 7-C 
position of the lactam ring. The introduced methoxy group is accommodated well in the 
pocket of BlaC, as revealed by the acyl intermediate structural complex. In this study, 
we examined the effect of modifications only on the 7-C position of the lactam ring, and 
it remains possible that other positions on the lactam structure may be modified to 
generate specificity for BlaC. 
 CDC-OMe showed excellent selectivity for BlaC over TEM-1 Bla, but low 
catalytic efficiency for BlaC (kcat/Km = 2.1 ×10
4
 s
-1
 M
-1
), which requires long co-
incubation times for a positive result. CDG-OMe has a much improved kinetic efficiency 
(an 11-fold increase of kcat/Km, 2.3 × 10
5
 s
-1
 M
-1
) and still maintains high stability and 
selectivity for BlaC over TEM-1 Bla. The use of green fluorophore further enhanced its 
sensitivity for detecting live mycobacteria in solution. 
 84 
 
 Using a simple handmade device and a cell phone, we detected as low as 10 c.f.u. 
of BCG in human sputum, which not only demonstrates excellent sensitivity, but also 
suggests high specificity, because the cystic fibrosis patients from whom these samples 
were obtained commonly have chronic infection of S. aureus, Haemophilus influenza 
and P. aeruginosa
192
, which can express β-lactamase activity. Indeed, we found high 
levels of ampicillin resistant bacteria in our sputum samples but their presence did not 
impact selectivity or sensitivity. 
 In summary, we have developed a series of fluorogenic probes specific for Mtb 
by taking advantage of the uniquely flexible substrate-specificity loop of the BlaC 
enzyme expressed by tubercle bacilli. These probes are chemically modified 
cephalosporin lactams with a 7a-methoxy substitution. The acyl intermediate complexes 
of the E166A BlaC mutant and the probes were co-crystallized successfully for X-ray 
structure determination to reveal structural insights into the observed specificity of the 
probes for BlaC. A green fluorescent probe, CDG-OMe, enabled the successful detection 
and imaging, with high specificity, of live pathogen present at very low levels in patient 
sputum. With such a good sensitivity and specificity, it is highly promising that CDG-
OMe could be developed easily into a rapid, low-cost TB diagnostic tool to meet the 
needs of people who live in remote, resource-limited areas. The success of this strategy 
may greatly contribute to decreasing Mtb-associated death rates and transmission. 
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MATERIALS AND METHODS 
 
Cloning, expression, and purification of BlaC 
 Wild-type BlaC was cloned from Mtb H37Rv genomic DNA as described 
previously
97
. The deacylation deficient E166A mutant was generated using the 
Quickchange site-directed mutagenesis kit (Stratagene no. 200519). Mutant and wild-
type protein expression and purification were performed as described previously
97
. 
 
Enzymatic kinetics 
 To a series of different concentrations of the probe (20, 40, 60, 80, 100, 120 and 
150 µM) in 1× PBS (pH 7.4) in a 96-well plate (black and flat bottomed) was added 
TEM-1 Bla or BlaC. PBS was added to adjust the total volume to 100 µl. The 
fluorescence intensity at 454 nm was measured immediately in a microplate reader 
(excitation wavelength of 400 nm) over a period of 20-minutes at 22 °C. The values of 
the kinetic parameters (Km and kcat) were determined from the double reciprocal plot of 
the hydrolysis rate versus the substrate concentration (Lineweaver–Burk plot). To 
determine the spontaneous hydrolysis rate of the probes, the fluorescence intensity was 
monitored over five days without the addition of enzyme. The rate was calculated from 
the plot of ln([S]0/([S]0 – [P])) versus time. Fluorescence spectra were collected on a 
Fluoromax-3 spectrafluorometer (Jobin Yvon). Kinetic experiments were conducted in a 
M1000 microplate reader (TECAN, Research Triangle Park, North Carolina). 
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Crystallization 
 Crystals of wild-type and E166A BlaC were grown using the hanging-drop 
vapour-diffusion method
151
. BlaC was concentrated to 10 mg ml
-1
 and equilibrated 
overnight at 4° C with the mother liquor (2.0 M NH4H2PO4, 0.1 M Tris buffer, pH 8.0) 
in a 1:1 ratio (protein:mother liquor). The solution was centrifuged for ten minutes at 
13,000 revolutions per minute to remove insoluble precipitate. Hanging drops were set 
up and equilibrated against 1 ml of mother liquor. Microseeding with horsehair was 
sufficient to produce large diffraction-quality crystals. Crystals were transferred to a 
stabilization solution that contained 30% glycerol in the mother liquor and subsequently 
soaked with substrates for 2–4 hours. The concentration of substrate was increased 
slowly by transferring the crystals to successive drops to prevent cracking. Derivatized 
crystals were flash frozen in liquid nitrogen. 
 
Data collection and processing 
 X-ray diffraction data were collected on beam lines 19ID and 23ID at the 
Advanced Photon Source, Argonne National Laboratory, Argonne, Illinois. Data sets 
were reduced using HKL3000
193
. Data were collected at a wavelength of 0.97 Å and a 
temperature of 120K. Data collection and refinement statistics reported in Appendix 
Table A3. 
 
Structure determination 
 Initial phases were obtained by molecular replacement
153
 using the CCP4 suite
154
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and 2GDN as a search model
97
. Each data set was refined against the resulting model, 
and iterative cycles of model building and refinement were performed with Coot 0.6.1
155
 
and PHENIX
156
. Protein Data Bank codes for BlaC–CDC-1 and BlaC–CDC-OMe acyl 
intermediate crystal structures are 3VFH and 3VFF, respectively. 
 
Detection of mycobacteria in sputum 
 Mtb var. bovis strain BCG was cultured in 7H9 medium with a 10% oleic acid 
albumin dextrose complex (OADC) and 0.25% Tween-80 until it reached the log phase 
(optical density at 600 nm (OD600) of 0.5–1). E. coli, MRSA, P. aeruginosa strain 
PA01 and M. smegmatis were cultured in Luria–Bertani medium until OD600 = 0.5–1. 
After measuring the bacterial OD600, 10
7
 c.f.u. of each bacterial strain was added into 
Eppendorf tubes. Bacteria were centrifuged, the supernatant removed and resuspended 
into the same medium (7H9 medium with 10% OADC) to normalize the 
autofluorescence from different media. A series of tenfold dilutions of BCG were made. 
Bacteria were then incubated at 37 °C to allow β-lactamase production for 0.3–0.5 
bacterial generations, using a 20 hour calculated generation time for BCG, a two hour 
calculated generation time for M. smegmatis and a 20 minute calculated generation time 
for Pseudomonas, Staphylococcus and E. coli. Then 10 µl of bacteria, 40 µl of sputum 
and 50 µl of CDG-OMe (5 µM) were mixed in a 96-well plate, incubated at room 
temperature for 160 minutes and the fluorescence read with a spectrometer (Mithras LB 
940, Berthold Technologies, Oakridge, Tennessee) at 490 nm excitation and 535 nm 
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emission. For cellular phone imaging, the handmade imaging box consisted of a light-
tight box, true cyan color light-emitting diode (LED) with a peak emission at 505– 
510 nm, an excitation filter (490 ± 10 nm) between the LED and sample, and an 
emission filter (530 nm, bandpass 43 nm) between the sample and an imaging hole in the 
box. BCG (10 µl), sputum (90 µl) and CDG-OMe (10 µM, 100 µl) were mixed, and after 
ten minutes samples were photographed with an Apple iPhone 4S through a hole in the 
box. The photograph was then analyzed for luminance (cd m
-2
) using iPhotoLux v.1.0 
(Maxime Bombrun, ISIMA, France), a free iPhone application. 
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CHAPTER V 
  
STRUCTURE OF APO AND MONOMETALATED FORMS OF NDM-1, A HIGHLY 
POTENT CARBAPENEM-HYDROLYZING METALLO-BETA-LACTAMASE* 
 
OVERVIEW 
 
 The New Delhi Metallo-β-lactamase (NDM-1) gene makes multiple pathogenic 
microorganisms resistant to all known β-lactam antibiotics. The rapid emergence of 
NDM-1 has been linked to mobile plasmids that move between different strains resulting 
in world-wide dissemination. Biochemical studies revealed that NDM-1 is capable of 
efficiently hydrolyzing a wide range of β-lactams, including many carbapenems 
considered as ‘‘last resort’’ antibiotics. The crystal structures of metal-free apo- and 
monozinc forms of NDM-1 presented here revealed an enlarged and flexible active site 
of class B1 metallo-β-lactamase. This site is capable of accommodating many β-lactam  
substrates by having many of the catalytic residues on flexible loops, which explains the 
observed extended spectrum activity of this zinc dependent β-lactamase. Indeed, five 
loops contribute residues in the active site including side chains involved in metal 
binding. Loop 1 in particular, shows conformational flexibility, apparently related to the
2
  
                                                 
*Reprinted with permission from Structure of Apo- and Monometalated Forms of NDM-1—A Highly 
Potent Carbapenem-Hydrolyzing Metallo-β-Lactamase. Kim, Y., Tesar, C., Mire, J., Jedrzejczak, R., 
Binkowski, A., Sacchettini, J., Joachimiak, A., (2011). PLoS ONE, 6, e24621, Copyright 2011 by the 
Public Library of Science. 
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acceptance and positioning of substrates for cleavage by a zinc-activated water  
molecule.  
 
INTRODUCTION 
 
 The imminent threat posed by the recent discovery and dissemination of the 
plasmid encoded New Delhi Metallo-β-lactamase (NDM-1) gene (blaNDM-1) harbored 
by multiple pathogenic microorganisms has prompted the formation of a global 
scientific corps d’armée194. Biochemical and structural elucidation of NDM-1 facilitates 
the thorough mechanistic understanding required for a rational design of small molecule 
inhibitors specific to NDM-1 for co-administration with β-lactam antibiotics. The crystal 
structures of NDM-1 presented here reveal an open, enlarged and flexible active site that 
explains the observed extended spectrum activity of this zinc dependent β-lactamase. 
 One of the last lines of defense against multiple and extensively drug resistant 
infections is the carbapenem class of β-lactam antibiotics, which was developed to evade 
β-lactamase mediated resistance posed by aerobic as well as anaerobic pathogens. 
Unfortunately, the integrity of the ‘‘big guns’’ (meropenem, imipenem, doripenem, 
ertapenem) has become compromised by a number of β-lactamase with extended 
spectrum activity, that is, the ability to inactivate all classes of β-lactam antibiotics, 
including carbapenems
195
.  
 β-lactams are the most broadly used antibacterials world-wide due to their 
effectiveness at irreversibly inhibiting cell wall biosynthetic enzymes required for 
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peptidoglycan recycling, and minimal toxicity in humans
61,196
. The first β-lactam 
discovered, penicillin, inhibits the function of the D-Ala-D-Ala transpeptidase that links 
the peptidoglycan molecules in bacteria
1,8,13,14,22,61
. Simultaneously, cell wall hydrolases 
and autolysins continue to break down peptidoglycan crosslinks, resulting in cellular 
lysis and death. Since the discovery of penicillin, several classes of naturally occurring 
and semi-synthetic β-lactams have entered the clinic. Concomitantly, broad use of β-
lactams as antibacterials applies a selective pressure that increases the reproductive 
success of pathogenic strains carrying evolved β-lactamase genes capable of combating 
our arsenal of β-lactam antibiotics. 
 The vast structural diversity designed into the semi-synthetic β-lactams 
evades β-lactamase mediated resistance by either preventing initial Michaelis complex 
formation, or by stabilizing transient intermediates that inhibit further β-lactam turnover. 
Carbapenems have proven to be the most effective broad-spectrum β-lactams, and their 
utility is generally reserved as a last line of defense against the toughest drug-resistant 
infections including MRSA
197
, XDR-TB
198
, and bacterial meningitis
199
.  
 However, it appears that the ‘‘target’’ met the challenge. In the past several 
years, new pathogenic strains carrying carbapenemase genes have been documented in 
patients from India, Pakistan, Bangladesh and other countries
200-206
. Carbapenemases are 
members of class A (KPC, IMI/NMC, SME), class B (IMP, VIM, SPM) and D (OXA) 
β-lactamase, for review see references57,126,207. Class B β-lactamase depend on divalent 
cation metal cofactors for their activity, and are described as metallo-β-lactamase 
(MBLs)
126,207-209
 Unlike serine β-lactamases, MBLs are not inhibited by the classic 
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irreversible β-lactamase inhibitors such as clavulanic acid, sulbactam and tazobactam, 
but instead are inhibited by metal chelators such as EDTA and o-phenanthroline
57,126,209
. 
Thiol compounds such as 2-omega-phenylalkyl-3-mercaptopropionic acid
210
  and N-(2-
mercaptoethyl)-2-phenylacetamide
211
are also competitive inhibitors. However, thus far 
the therapeutic potential of these inhibitors has not been demonstrated.  
 MBLs have been found in widely distributed bacteria such as Escherichia coli, 
Klebsiella pneumoniae and Acinetobacter baumannii
206,212,213
. VIM and IMP are the 
most frequently acquired subclasses of B enzymes
57
. MBLs show significant diversity of 
the active site, catalytic properties, and metal ion requirements and have been divided 
into three subclasses: B1, B2, and B3
57,126,195
. Subclass B1 includes several 
chromosomally encoded enzymes BcII, Bacillus cereus 
214
, CcrA, Bacteroides 
fragilis
215
,BlaB, Chryseobacterium meningosepticum
216
, and transferable VIM, IMP, 
SPM, and GIM type enzymes
126,217,218
. Subclass B2 includes CphA
219
 and ImiS
220
 
lactamases from the Aeromonas species and Sfh-I from Serratia fonticola
221
. Subclass 
B3 is represented by L1 from Stenotrophomonas maltophilia
222,223
, FEZ-1 from 
Fluoribacter gormanii
216,224
, GOB from E. meningoseptica
225,226
, CAU-1 from 
Caulobacter crescentus
227
, and THIN-B from Janthinobacterium lividum
228
. 
 A new mobile subgroup B of MBLs was recently discovered and named New 
Delhi Metallo-β-lactamase (blaNDM-1). This multidrug resistance gene was 
characterized initially in an isolate from Sweden that originated from New Delhi, India. 
Since then, Enterobacteriaceae isolates harboring the NDM-1 gene have been found in 
multiple areas of India, Pakistan, Bangladesh but also in the USA, Canada, China, Japan, 
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and United Kingdom
200-206
. The emergence of blaNDM-1 in India and China has been 
linked to its spread on the IncL/M incompatibility plasmid group types
229
. A current 
survey of the New Delhi vicinity identified NDM-1 carrying isolates from drinking 
water and seepage
212
. NDM-1 has been reported to be a highly potent carbapenem-
hydrolyzing, zinc-dependent MBL. When expressed in bacteria, it makes these bacteria 
resistant to a broad range of β-lactams. Currently, no inhibitor of NDM-1 approved for 
medical treatment is available. NDM-1 positive bacterial infections can only be treated 
with a few antibacterials, including colistin, tigecycline, fluoroquinolones, D-captopril, 
and polymyxin B
109
. In view of the emerging multidrug-resistant strains carrying NDM-
1, the discovery of effective inhibitors is critical and urgent. Here we report hydrolytic 
activity of NDM-1 against selected β-lactams and carbapenems, the three high-resolution 
crystal structures of apo- and the first structure of monometalated form of NDM-1 
derived from K. pneumoniae. Our results show that NDM-1 is unique among other 
MBLs due to its enlarged and flexible active site, and explain the observed extended 
spectrum β-lactamase activity. 
 
RESULTS AND DISCUSSION 
 
Expression, purification and structure determination of NDM-1 
 The NCBI database lists a number of identical sequences to NDM-1 from K. 
pneumoniae [CAZ39946)] from a number of other organisms [BAJ76899 
[Stenotrophomonas maltophilia], ADY00041 and ADP20459 [E. coli], AEA41876 
 94 
 
[Acinetobacter baumannii], ADU02194 [A. junii], and ADP37377 [Enterococcus 
faecium]]. Identical sequence entries are found in other records where the N-terminal 
region is missing. The N-terminal region of the NDM-1 protein contains a signal peptide 
[1–28] according to the Phobius transmembrane topology and signal peptide prediction 
server
230
 consistent with the possible cleavage site after residue 28. Several other MBLs 
(VIM-1-Ec, VIM-2-Pa, IMP-1-Ab and IMP-4-Kp) contain signal peptides. In contrast, 
the PSORTb subcellular localization tool predicts no signal peptide and no predictive 
localization of the enzyme
231
. The sequence alignment of several selected MBLs 
reinforces the presence of a signal with possible localization to the periplasm. 
 We expressed in E. coli full-length recombinant K. pneumoniae NDM-1 β-
lactamase, but because it expressed poorly and showed low solubility, we designed 
several constructs. These constructs were based on the NDM-1 homology models 
obtained using tools developed as part of the Protein Structure Initiative
232
 and low 
sequence similarity MBLs with structures available in Protein Data Bank (PDB) IMP-1, 
PDB id 1DD6 
233
, VIM-2, PDB id 2YZ3
234
 and VIM-4, PDB id 2WHG
235
. Three 
recombinant NDM-1 β-lactamase: full-length NDM-1, and two constructs NDM-1 
Δ38 and NDM-1 Δ36NY, which showed improved solubility, were expressed and 
purified to homogeneity. Purified enzymes exhibited a single band on SDS-PAGE, 
indicating Mr= 28.5 and 24.5 and 24.8 kDa for NDM-1, NDM-1 Δ38, and NDM-1 
Δ36NY, respectively.  
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NDM-1 structure 
 The three apoNDM-1 structures include two pairs of monomers A and B and one 
monomer A, and the structure of monometalated NDM-1 (mZnNDM-1 Δ36NY) 
includes four monomers (A, B, C, D), respectively in the asymmetric unit, providing 
nine crystallographically independent views of the molecule for NDM-1 Δ38, NDM-1 
Δ36NY (monoclinic), NDM-1 Δ36NY (orthorhombic), mZn-NDM-1 Δ36NY 
(tetragonal) (Appendix Table A4). Full length NDM-1 and NDM-1 Δ36NY are 
monomers in solution as shown by size exclusion chromatography. The model for 
NDM-1 Δ38 contains 226 residues (45–270) out of a possible 232 residues and 131 
water molecules. The electron density maps obtained for the NDM-1 Δ38 structure 
allowed modeling of 226 residues of both A and B chains, except the 10 N-terminal 
residues including the three residues Ser-Asn-Ala left over from cloning, which are 
disordered and not included in the final model. The NDM-1 Δ38 models were refined 
against 2.0 Å data with a final Rwork of 19.5% and Rfree of 24.3% (Appendix Table 
A4). The structure of NDM-1 Δ36NY, which includes two chains each containing 
residues of 45–270 (A) and 44–270 (B), is very similar to that of NDM-1 Δ38 (rmsd 
between C  atoms of comparing 452 residues of both chains is 0.21 Å), except for a few 
loop regions and an acetate molecule found in the active site in chain A. The two 
structures of NDM-1 Δ36NY obtained under different crystallization conditions and in 
different crystal packing are virtually identical (rmsd between C  atoms of comparing 
436 residues of both chains is 0.45 Å). Our NDM-1 Δ38 and two NDM-1 Δ36NY 
structures are also very similar to the recently published high-resolution structure of 
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dizinc NDM-1 Δ29236, except for the N-terminal region (missing or disordered in our 
structures and some loop regions). The structure of mZnNDM-1 Δ36NY was obtained in 
the presence of 10 mM zinc chloride. The structure contains one zinc atom bound in the 
active site to the metal site 1 (Zn1). The metal bound structure is very similar to apo 
structures (for example, rmsd between C  atoms of apoNDM-1 Δ38 comparing 218 
residues of chain B of mZnNDM-1 Δ36NY is 0.46 Å). 
 NDM-1 resembles the common β-lactamase fold, although it shows low 
sequence similarity to β-lactamase deposited in PDB (20–33% sequence identity). The 
protein is made up of four layers /β/β/  and forms a sandwich. The core of NDM-1 
consists of two β-sheets, one (N-terminal) is composed of seven antiparallel strands (β1–
β7) and the other (C-terminal) is composed of five antiparallel strands (β8–β12). The N-
terminal β-sheet is highly twisted (>100 degrees). The interaction between β-sheets is 
mainly hydrophobic. The seven connecting helices are located below ( 1– 4 and 310 
helix 5) and above ( 6– 7) the plane of the β-sandwich (Figure 5.1 a). The interactions 
between helices and β-sheets are hydrophobic but also involve several hydrogen bonds 
(Q96 with carbonyl of Y64, T98 with carbonyl of A92, Y229 with carbonyl of Leu209 
and S232 with carbonyl of P187). Strands and helices are connected through flexible 
loops with the most prominent loop (residues 206–228) located above an >600 Å3 active 
site cavity containing a sulfate ion in monomer A and two sulfate ions in monomer B. 
The two β-sheets and four associated helices show a previously reported two-fold 
symmetry of the ‘‘ββββ β β’’ topological motif214. The symmetry is not ideal with one 
unit showing a ‘‘βββ β β’’ motif and the second unit ‘‘ββββ β β β’’ is enlarged. The 
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Figure 5.1. NDM-1 structure and comparisons with selected carbapenemases. a. Aerial view of active site 
(represented by two phosphate ions), the protein is made up of four layers, /β/β/ , and forms a sandwich. 
Secondary structure elements and N- and C-termini are labeled. b. Comparison of K. pneumoniae NDM-1 
(PDB id 3RKJ – magenta, N and C-termini are labeled) with three MBLs with carbapenemase activity P. 
aeruginosa VIM-2 (PDB id 2YZ3 - wheat), P. aeruginosa IMP-1 (PDB id 1DD6 - light blue) and P. 
aeruginosa VIM-4 (PDB id 2WHG - pale green). Loops contributing to the active site are labeled ASL1–
5. Zn1 and Zn2 (blue spheres) are from the structure of VIM-2. 
 
 
 
 
 
 
 
 
 
a b 
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NDM-1 secondary structure is shown in Figure 5.1 a. 
 The search for structural homologs of NDM-1 using the DALI server
237
 
identified a number of closely related homologs. More than 400 entries were identified 
with a Z-score higher than 4. The closest structural homologs are MBLs (class B), 
followed by class A, C, and D β-lactamase. Over 1,200 β-lactamase superfamily 
members were also identified in 340 species showing highly diverse sequences. The top 
250 structural homologs (Z-score>10) were clustered using CD-HIT
238
 with a 90% 
sequence identity cut-off value resulting in 40 structure classes. Similar clustering was 
observed using 80% and 70% cut-off values. Representative structures from the 40 
structure clusters were aligned based on the secondary structure. The alignment reveals 
that the NDM-1 structure (and its MBL homologs) displays expansions in some loop 
regions, for example ASL1, ASL4. The proteins belonging to the 40 structure clusters 
show several different catalytic activities (lactamase, oxidoreductase, 
hydroxyacylglutathione hydrolase, glyoxalase, nitric oxide reductase, parathion 
hydrolase, teichoic acid phosphorylcholine esterase). These enzymes utilize a broad 
range of substrates (β-lactams, hydroxyacylglutathione, nitric oxide, parathion, 
phosphorylcholine) suggesting that the lactamase fold seems highly adaptable and 
has evolved to support multiple functions and accept a wide range of substrates
126
. 
 
Active site expansion in NDM-1 and implications for ligand binding 
 Active site template searches using ProFunc
239
 identified the B. fragilis MBL 
(PDB id 1BMI)
240
 as an active site match with a similarity score of 422.6 and E-value of 
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1.09x10
-10
. Seven active site residues in the B. fragilis MBL structure (His82, His84, 
Asp86, His145, Cys164, Asn176, His206) matched the corresponding residues in NDM-
1 (His120, His122, Asp124, His189, Cys208, Asn220, His250) with an rmsd of 1.87 Å 
(over 13 atoms). Overall, the template identified 19 identical residues and 8 similar 
residues in the NDM-1/B. fragilis MBL active sites with local sequence identity of 
52.8%. These residues form a solvent accessible surface that extends along the middle of 
the molecule between two β-sheets (Figures 5.1, 5.2). This well-defined hydrophobic 
and partly positively charged cavity is shaped by five active site loops (ASL1–5). From 
the bottom (as viewed in Figures 5.1 a, 5.2 and 5.3), two loops between strands β2 and 
β3 (residues 65–73, ASL1) and β5 and 2 (residues 118–124, ASL2) are contributing to 
form the base of the active site. At the top of the pocket, loops between β8 and β9 
(residues 184–194, ASL3), β10 and 5 (residues 206–228, ASL4), and β11 and β12 
(residues 248–255, ASL5) form the roof and walls of the active site (Figure 5.1). In 
MBLs, these loops provide key conserved side chains for coordinating metal ions as well 
as proposed catalytic general acid/base. As evident from the NDM-1structures, these 
residues appear to have well-defined conformations in the absence and presence of metal 
ions and this part of the active site is structurally well conserved (Figure 5.2). Additional 
residues from these loops, in particular ASL1, seem to also participate in the positioning 
of ligands in the active site in an orientation suitable for hydrolysis of the β-lactam ring. 
This is evident from several crystal structures of MBLs obtained with ligands
216,233,241-
244
. MBLs, including NDM-1, show the longest ASL1 as compared with other β-
lactamase superfamily members. The alignment of the NDM-1 structure with the closest 
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Figure 5.2. Active site comparisons of K. pneumoniae NDM-1 metalated states. Apo (PDB id 3RKJ) 
(aqua) vs monozinc NDM-1 (PDB id 3SFP) (violet) vs dizinc NDM-1 PDB id 3Q6X (wheat). Zn1’ and 
Zn2’ (wheat) are from the structure of di-zinc NDM-1 and Zn1” is from the structure of monozinc NDM-
1. Conformations of residues coordinating Zn1 (His120, His122 and His189) and Zn2 (Asp124, Cys208 
and His250) are shown for all three structures. 
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MBL structural homologs, di-zinc VIM-4 (PDB id 2WHG, Z-score 31.9, rmsd 1.9 Å), 
VIM-2 (PDB id 2YZ3, Z-score 11.2, rmsd 1.45 Å, between chain A of 3RKJ and chain 
A of 2YZ3), and IMP-1 (PDB id 1DD6, Z-score 11.7, rmsd 1.52 Å , between chain A of 
3RKJ and chain A of 1DD6) reveals several unique features of the NDM-1 structure 
(Figure 5.1). Region 162–176 shows a very different conformation with a short 310 helix 
( 4) formed in the middle of the loop region (Figure 5.1 b). This region forms a β-strand 
in VIM-2, VIM-4 and IMP-1. NDM-1 and IMP-1 show the longest ASL1 loop (Figure 
5.1) but NDM-1 has a Phe insertion instead of Trp in this loop. This smaller side chain 
may provide more flexibility to accommodate bulky substrates. In NDM-1, ASL4 shows 
a more open conformation and the C-terminal helix is quite shifted in comparison to 
VIM-2, VIN-4 and IMP-1. However, the most important difference between these MBLs 
structures is a significantly larger active site cavity. This region in NDM-1 provides the 
opportunity to accommodate large substrates. In VIM-2, VIM-4 and IMP-1, side chains 
from the ASL1 and ASL4 loops bridge over the active site, dividing it into sub-
cavities
233-235,240
. In contrast, the NDM-1 ASL1 and ASL4 loops are shifted outward 
considerably (Figures. 5.1 b and 5.3) and do not close over the active site but instead 
leave the site much more open and accessible to potential ligands (Figures 5.1 b and 
5.3).  
 There is a reduction in the volume of residues contributing to the active site 
(Ala121 in NDM-1, typically Phe or Trp in other MBLs; Tyr229 in NDM-1, typically 
Trp in other MBLs; sequence Ala72Val73 in NDM-1 in ASL1, which is typically Val or 
Phe in other MBLs; Phe70 in NDM-1 in ASL1 which is Trp in IMP-1 and related 
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MBLs). There is also a reduction in the volume of residues contributing to the 
hydrophobic core. One indication of this volume reduction is an increase (15.2%) in 
alanine occurrence in NDM-1, which is nearly double the average alanine occurrence 
typically found in other proteins. These changes can contribute to the opening of the 
groove to solvent and can also increase the flexibility of structural elements. A larger 
active site would be more accessible to a broader range of antibiotics (or inhibitors) and 
thus provide an evolutionary advantage to bacteria. This can explain the observed 
enzyme promiscuity in accepting and hydrolyzing a broad range of β-lactams and 
carbapenems. A more open active site would allow for many substrates to bind in an 
extended conformation along the elongated-shaped groove with the β-lactam ring 
positioned over the active site metal ions while the rest of the substrate could be further 
stabilized by the interaction with side chains projecting from flexible loops ASL3, 
ASL4, and ASL5 (Figures 5.3, 5.4). 
 To investigate the structural implications of residue substitutions near the active 
site cavity, we performed a surface analysis on IMP-1 (PDB id 1DD6), VIM-2 (PDB id 
2YZ3), VIM-4 (PDB id2WHG), and NDM-1. For each protein, solvent accessible 
cavities were identified
245
. NDM-1 has the largest cavity (surface area = 412.4 Å
 2
; 
volume = 591.3 Å
 3
) followed by IMP-1 (surface area = 339.5 Å
 2
; volume = 303.1 Å
 3
), 
VIM-2 (surface area = 223.9 Å
 2
; volume = 140.1 Å
 3
), and VIM-4 (surface area = 112.4 
Å
 2
; volume = 45.3 Å
 3
). The active site cavity for each protein is shown in Figure 5.4 
(green). It should be noted that the VIM-2 structure has a bound ligand in the cavity, 
which may affect the apo cavity structure and volume. However, even in a bound state 
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Figure 5.3. Flexibility of the NDM-1 active site loops. a. Structures of six NDM-1 molecules (identified 
using PDB ids) were aligned (PDB id 3RKJ (this work) molecule A - blue, PDB id 3RKJ (this work) 
molecule B - light blue, PDB id 3SBL (this work) molecule A - green, PDB id 3RKK (this work) molecule 
B – red, PDB id 3SFP (this work) molecule B – violet and PDB id 3Q6X236 molecule B – wheat), hAmp is 
a hydrolyzed ampicillin and Zn1’ and Zn2’ are zinc atoms from the structure of NDM-1 (PDB id 3Q6X 
molecule B) and Zn1” is from the structure of monozinc NDM-1. b. The structural variability at each 
residue position in the ASL1 loop is evaluated across six structurally unique loops shown in A. After a 
structural alignment of the entire molecules, the Euclidean distance between the residues’ center-of-mass 
was measured between all pair combinations at each position. The results are summarized as a boxplot 
showing the median, quartiles, maximum and minimum distances for each residue. The aligned loops are 
shown in cartoon putty representation, with the loop radius proportional to residue B-factors (view facing 
active site, left; top-down view, right). 
 
 
 
 
 
 
 
 
 
 
a b 
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the volume is considerably less than the NDM-1 cavity. To highlight the differences 
between the cavities, the molecules were superimposed onto the NDM-1 molecule. It is 
VIM-2 (surface area = 223.9 Å
 2
; volume = 140.1 Å
 3
), and VIM-4 (surface area = 112.4 
Å
 2
; volume = 45.3 Å
 3
). The active site cavity for each protein is shown in Figure 5.4 
(green). It should be noted that the VIM-2 structure has a bound ligand in the cavity, 
which may affect the apo cavity structure and volume. However, even in a bound state 
the volume is considerably less than the NDM-1 cavity. To highlight the differences 
between the cavities, the molecules were superimposed onto the NDM-1 molecule. It is 
evident that the expanded cavity volume in NDM-1 is due to residue substitutions 
occurring in the surrounding loops. Figure 5.4 shows the protruding residues in both 
stick and surface rendered forms.  
 In our three apo and one monozinc structures, there are nine independent 
representations of NDM-1 molecules with different crystallization conditions and 
packing environments. In these structures, most active site loops show very small 
conformational changes with the exception of ASL1 (Figures 5.1 b and 5.3) and to some 
extent ASL4. These are key loops contributing to the expansion of active site 
accessibility. Zhang and Hao, based on the comparison of their NDM-1 structure with 
other MBLs, hypothesized that the ASL1 loop may be flexible
236
. Our data clearly 
demonstrate that this is indeed true. As shown in Figure 5.3 b, ASL1 shows the ability of 
assuming several alternative conformations that may be important for binding ligands.  
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Figure 5.4. Active site expansion of NDM-1. The active site cavity comparisons of K. pneumoniae NDM-
1 (gray) and three MBLs: IMP-1 (light brown), VIM-2 (orange) and VIM-4 (magenta). Superposition of 
the IMP-1, VIM-2 and VIM-4 molecules with NDM-1 reveal highly conserved structural arrangements. 
The most prominent variations occur between the catalytic sites (shown as surface representations), in 
which the side chains of IMP-1, VIM-2 and VIM-4 restrict the access to the active site by decreasing the 
volume of the cavity. (a) depicts NDM-1 and its active site surface (green) in secondary structure cartoon 
(left) and surface representation (right). (b-d) NDM-1 structural alignments with IMP-1, VIM-2 and VIM-
4. Each highlights the IMP-1, VIM-2 and VIM-4 molecules’ respective active sites, shown as colored 
surfaces. To highlight the greater accessibility to the NDM-1 active site, the aligned NDM-1 molecule is 
shown in surface representation (right). The obstructing interactions between ASLs restricting access to 
active site in IMP-1, VIM-2 and VIM-4 are observed as colored protrusions through the NDM-1 molecule 
and are highlighted for IMP-1, VIM-2 and VIM-4 with black circles. 
 
 
 
 
 
 
 
 
 
a b 
c 
d 
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Metal binding 
 NDM-1 has both β-lactamase and carbapenemase activities that are zinc-
dependent
212,236,246,247
, this work. Three of our apoNDM-1 structures are zinc-free and 
are the first structures of a wild-type apo-enzyme in subclass B1. Interestingly, the 
second crystal form (PDB id 3RKK) was obtained in the presence of 5 mM zinc acetate. 
No zinc is found in the structure and only an acetate ion can be modeled in the active site 
interacting with His250. Because of the location, the architecture and sequence 
conservation of the active site in NDM-1 are very similar to the metal binding sites of 
other β-lactamase. The active site similarity (presence of principal zinc-binding motif 
(HaHqD)) allows us to unambiguously identify all residues involved in zinc 
coordination. The active site template search identified all residues that are involved in 
metal binding in other MBLs of B1 subclass. It is predicted that NDM-1 would bind two 
zinc ions. Zinc 1 would be coordinated by His120, His122 and His189 and zinc 2 by 
Asp124, Cys208 and His250. Indeed, zinc was found bound to the Zn1 site in the crystal 
structure of NDM-1 obtained in the presence of zinc chloride. All four monomers in the 
asymmetric unit contain zinc atoms bound to the Zn1 site (His120, His122 and His189), 
therefore confirming NDM-1 as a member of subclass B1 of MBLs
236,247
 and showing 
that Zn1 is a higher affinity site, as predicted for other MBLs
248,249
. This zinc atom is 
shifted approximately 0.8 Å compared with the di-zinc NDM-1 structure and shows 
somewhat longer Zn-His distances (Figure 5.2)
236
. The zinc coordinating residues are 
provided by ASL2, ASL3, ASL4, and ASL5. ASL2 contributes residues coordinating 
both zinc ions. In apoNDM-1 structure conformations of some of these residues are very 
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similar to zinc-bound states (His120, Asp124, and His250), while others show somewhat 
different side chain orientations (His122, His189, and Cys208) (Figure 5.2). Cys208 
exists in two orientations in apo-state, one is similar to the zinc bound state and the other 
is rotated about 45 and 90 degrees in chain A and B, respectively. It has been noticed 
that MBLs are sensitive to metal chelators and it was suggested that they could bind zinc 
with lower affinity
57,126,219,248,250
. The range of affinities for zinc reported for MBLs vary 
from micromolar to millimolar. 
 The NDM-1 active site is located on its surface and is fully accessible to solvent. 
In the apoNDM-1 structure, two water molecules are coordinated by zinc-binding side 
chains, including Asp124, His122, and His250. In MBLs, the metal ions may have a dual 
role in catalysis. One zinc ion activates a metal-bound water molecule to perform a 
nucleophilic attack on the β-lactam carbonyl. The second zinc ion binds and polarizes 
this carbonyl group. A negatively charged carboxyl group of a zinc-bound Asp residue is 
involved in the activation of the water molecule. During the reaction, a tetrahedral 
intermediate is formed, followed by the delivery of a proton from a general acid/base 
residue (possibly Asp or another water molecule) to the lactam nitrogen and the cleavage 
of the lactam bond. All required residues are present in NDM-1 and therefore this 
enzyme should follow the general MBL catalytic mechanism involving a hydrolytic 
water molecule activated by a metal ion. In the mZnNDM-1 Δ36NY structures, there are 
several water molecules near the zinc atom. Monomer C contains tightly coordinated 
water (H-bond distance 2.8 Å) that may correspond to the position of the catalytic water 
molecule involved in β-lactam hydrolysis. Conserved Asp223 was proposed to function 
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as the general acid/base during catalysis suggesting that conserved Thr190 (or Ser), 
which is centrally positioned on the loop overhanging the active site, may play an 
important role in substrate recognition and transition-state stabilization
249,251
. It is easy to 
envision this loop undergoing movements upon substrate binding. The structure of zinc-
free NDM-1, along with the previously reported structures, provides important insight 
into the conformational changes associated with the metal binding properties of NDM-1. 
 
Steady state kinetics 
 NDM-1 kinetic parameters obtained using NDM-1 Δ38 are summarized in Table 
5.1. NDM-1 is an extended spectrum zinc dependent β-lactamase capable of hydrolyzing 
nearly all classes of β-lactams, impairing the ability to treat life-threatening infections 
with intravenously and orally available carbapenems. Carbapenem substrates appear to 
be the most specific class of β-lactams for NDM-1. However, the specificity constants 
for cephamycin and penem substrates deviate by less than an order of magnitude, 
indicating that the evolved promiscuity is related to the relaxed the substrate specificity 
of NDM-1. The observed lack of well-defined substrate specificity has previously been 
observed for the MBL NDM-1 homolog GIM-1
218,252
. The carbapenems; imipenem, 
biapenem and tebipenem have very similar kinetic constants likely due to their structural 
similarity. Tebipenem, although turned over less quickly (kcat = 0.39 s
-1
), has relatively 
high specificity, with a nearly two fold tighter Michaelis complex (Km=69 mM) relative 
to other carbapenems. The majority of the Michaelis constants falls between 50 µM and 
150 µM, and includes penem, carbapenem and cephamycin classes of β-lactams.  
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Table 5.1. Steady state kinetic parameters of NDM-1 Δ38 with a selected set of β-lactam antibiotics. 
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 Substrates that are most efficiently (kcat/Km) turned over in general have 
extended hydrophobic characteristics that complement the linear and hydrophobic nature 
of the NDM-1 active site cavity. The primary hydrophobic arrangement is contributed by 
residues Leu65, Met67, Pro68, Val73, Gly69, Phe70, and Val73 of ASL1, which contour 
the flexible roof of the active site (Figures 5.3, 5.4). In addition, alkyl moieties of 
Leu209, Ile210, Lys211, Asp212, Lys214, Ala215, Lys216, and Asn220 side chains of 
ASL4 give the distal region and base of the active site a partially hydrophobic surface 
area, while simultaneously maintaining hydrogen bond capability. The degrees of 
freedom of the aforementioned residues serve to increase the flexibility of the active site, 
thereby increasing promiscuity, but may do so at the expense of Michaelis complex 
formation for most substrates.  
 In accordance with previous kinetic characterizations of metallo-β-lactamases 
GIM-1
218,252
, IMP-1
253
, VIM-2
254
, and NDM-1
109
, kinetic constants could not be 
calculated for the suicide inhibitor clavulanic acid or the monobactam aztreonam. 
Although not yet implemented, this observation signifies the potential of treating NDM-
1 harboring pathogenic bacteria with aztreonam or other structurally similar 
monobactams in combination with a new NDM-1 inhibitor. 
 
Mechanistic and drug discovery implications 
 It is likely that NDM-1 has evolved to have a more open and flexible active site, 
to be able to inactivate the highly decorated β-lactam antibiotics that have progressed 
over the years from relatively simple (penicillin) to larger and more complex compounds 
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with new added substituents. It has been suggested that evolution of MBLs has enabled 
these enzymes to hydrolyze many compounds that interfere with key bacterial pathways, 
and is linked to increased flexibility and improved catalysis
249,251,255
.  
 The X-ray structures of NDM-1 presented herein provide a structural foundation 
for the corroboration of the proposed reaction mechanism of NDM-1 and drug design. It 
seems that there are three distinct states of the NDM-1: metal free, singly metalated and 
doubly metalated. All these states could be targeted for structure-based inhibitor design. 
Analysis of structures and previously reported kinetic and spectroscopic studies on MBL 
enzymes allows us to propose a refined mechanism of catalysis for this antibiotic 
resistant lactamase. NDM-1 would bind a zinc atom to the Zn1 site and a second zinc to 
the Zn2 site. The binding of the second zinc could be cooperative as proposed for some 
MBLs. This would organize the residue in the active site for productive catalysis. The 
key step in catalysis for NDM-1 is likely recognition of the ligand by side chains in the 
cavity adjacent to the Zn1 site. Only ligands conforming to the NDM-1 site would bind. 
Next, the β-lactam ring of the ligand coordinates to Zn1, expanding its coordination 
number from four to five and activating it for a nucleophilic attack. It is clear that the 
ASL1 plays a key role in positioning the β-lactam ring over the dimetalated site. 
Deprotonation of the metal-bound water molecule by Asp124 to form a nucleophilic 
hydroxide moiety is consistent with the postulated pKa of the zinc-bound water 
molecule. Once the zinc-bound hydroxide is formed, it can attack the activated carbonyl 
carbon of the substrate, forming a transition-state complex
249,251,256,257
. In the dimetalated 
site, the second metal ion likely coordinates the β-lactam oxygen in a bridging fashion of 
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the substrate. Asp124 may provide a proton to the penultimate amino nitrogen, similar to 
that observed for DapE
258
, returning it to its ionized state thus facilitating product 
release. Here again the flexibility of ASL1 is important to release the product. Once the 
products are released, a water molecule bridging the two metal ions is replaced. Recent 
mechanistic studies of MBL showed that Zn2 is the only metal ion capable of stabilizing 
an anionic intermediate that accumulates during β-lactam hydrolysis, in which the C–N 
bond has already been cleaved. Conserved Asp124 would provide a proton to complete 
product release. 
 Kinetic studies with NDM-1 show that the Km for biapenem and imipenem were 
130 µM and 134 µM, respectively (Table 5.1), which are significantly above the 
minimum inhibitory concentrations (MICs) against most pathogenic microorganisms (< 
2 µg/mL or 6 µM) including Klebsiella spp. and E. coli , and Pseudomonas 
aeruginosa
259,260
, each of which has been found to harbor the NDM-1 gene
261
. 
Pharmacokinetic analysis demonstrates that human serum levels of biapenem were 
maintained at above the aforementioned MICs in young and elderly adults in a dose 
dependent manner
262
. Unlike other carbapenems, biapenem is stable to human renal 
dihydropeptidase-1 (DHP-1), eliminating the need to co-administer the DHP-1 inhibitor 
cilistatin
263
. These studies suggest that the orally available carbapenem, biapenem, could 
be of potential use to treat patients with NDM-11 linked bacterial infections because the 
MICs and human serum concentrations are far below the Km of biapenem for NDM-1. 
Therefore, next generation β-lactams used to fight NDM-1 linked bacterial infection may 
be derivatives of carbapenems like biapenem. However, given the broad specificity and 
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likelihood of compensatory mutations, novel metallo-β-lactamase inhibitors will be 
required. 
 
MATERIALS AND METHODS 
 
Protein cloning, expression, and purification 
 The ORF NDM-1 gene from Klebsiella pneumoniae subsp. pneumoniae MGH 
78578 was synthesized chemically and initially cloned into vector pUC57. The full 
length NDM-1 and several Nterminal deletion constructs were subsequently amplified 
with KOD DNA polymerase using conditions and reagents provided by Novagen, 
Madison, WI and cloned into the pMCSG7 according to the ligation-independent 
procedure
264,265
  and transformed into the E. coli  BL21(DE3)-Gold strain (Stratagene), 
which harbors an extra plasmid (pMgk) encoding one rare tRNA (corresponding to rare 
Arg codons, AGG and AGA). These constructs provided a system to produce a fusion 
protein containing an N-terminal His6-tag followed by a TEV protease cleavage site and 
a target protein (pMCSG7). To produce the protein, the bacterial culture was grown at 
37°C, 200 rpm in enriched M9 medium
266
 until it reached OD600 = 1.0. After air-
cooling it down at 4uC for 60 min, NDM-1 expression was induced by 0.5 mM 
isopropyl-b-Dthiogalactoside (IPTG). The cells were incubated overnight at 18uC, 
harvested and resuspended in lysis buffer (500 mM NaCl, 5% (v/v) glycerol, 50 mM 
HEPES pH 8.0, 20 mM imidazole, and 10 mM β-mercaptoethanol). Cells were disrupted 
by lysozyme treatment (1 mg/ml) and sonication, and the insoluble cellular material was 
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removed by centrifugation. The native NDM-1 protein was purified from other 
contaminating proteins using Ni-NTA affinity chromatography and the AKTAxpress 
system (GE Health Systems) with the addition of 10 mM β-mercaptoethanol in all 
buffers as described previously. This was followed by the cleavage of the His6-tag using 
recombinant His6-tagged TEV protease and an additional step of Ni-NTA affinity 
chromatography was performed to remove the protease, uncut protein, and affinity tag. 
The pure protein was concentrated using Centricon (Millipore, Bedford, MA, USA) in 
20 mM HEPES pH 8.0 buffer, 250 mM NaCl, and 2 mM dithiothreitol (DTT). Protein 
concentrations were determined from the absorbance at 280 nm using a molar absorption 
coefficient (28,500 M
-1
 cm
-1
). The concentration of NDM-1 Δ38 and NDM-1 Δ36NY 
samples used for crystallization was ~40 mg/mL. Individual aliquots of purified NDM-1 
Δ38 and NDM-1 Δ36NY were stored in -80°C until needed. The full-length protein 
expressed rather poorly at ~ 2 mg/L of culture and it could only be concentrated to 8 
mg/mL. Truncation of the first 38 residues of NDM-1 yielded a much more stable 
protein construct (NDM-1 Δ38) with the expression yield of soluble protein ~100 mg/L 
culture that can be concentrated up to 150 mg/mL. Protein crystallization Native NDM-1 
as well as several mutants, including NDM-1 Δ38 (the first 38 N-terminal residues 
deleted) and NDM-1 Δ36NY (the first 36 N-terminal residues deleted followed by Q36N 
and Q37Y mutations), were screened for crystallization conditions with the help of the 
Mosquito liquid dispenser (TTP Labtech, Cambridge, MA, USA) using the sitting-drop 
vapor-diffusion technique in 96-well CrystalQuick plates (Greiner Bio-one, Monroe, 
NC, USA). For each condition, 0.4 mL of protein (40 mg/mL) and 0.4 mL of 
 115 
 
crystallization formulation were mixed; the mixture was equilibrated against 135 mL of 
the reservoir in the well. Some protein was prepared in the presence of 5 mM zinc 
acetate or 5 mM zinc acetate and 20 mM citrate. Several commercially available 
crystallization screens were used including: MCSG-1–4 (Microlytic Inc. MA, USA) and 
Index (Hampton Research, Aliso Viejo, CA, USA) at 16uC and 4uC. Microcrystals were 
obtained under several conditions. Crystals of the zinc-free form of NDM-1 Δ38 and 
NDM-1 Δ36NY in the presence of 5 mM zinc acetate were grown at 16°C by vapor 
diffusion in sitting drops containing 0.4 mL of precipitant solution and 0.4 mL of 40 
mg/mL of NDM-1 Δ38 or NDM-1 Δ36NY with 5 mM zinc acetate. The crystals grew 
within five days and reached sizes of approximately 0.100 mm x 0.020 mm x 0.010 
mm
3
. The best crystals appeared at 16°C under the condition of 0.17 M ammonium 
sulfate, 25.5% (w/v) PEG4000 and 15% glycerol, which corresponds to condition G6 
from the MCSG-3 screen. These crystals had dimensions of 100 x 25 x 10 microns
3
 and 
diffracted to 1.9 Å using the 19-ID minibeam
267
. The crystals of NDM-1 Δ38 belonged 
to the primitive space group P21 with unit cell parameters a= 59.71 A °, b= 51.11 Å, c = 
70.6 Å, β =106.96°. The NDM-1 Δ36NY crystals were also P21 with a similar unit cell 
dimension of a= 59.76 Å, b= 50.86 Å , c = 70.72 Å , b = 106.98°. The asymmetric unit 
contains two molecules with a Vm value of 2.1 Å 
3
/dalton (solvent content 41.5%). Data 
collection was carried out on the 19-ID beamline of the Structural Biology Center at the 
Advanced Photon Source according to the procedure described previously
268
. Data for 
the NDM-1 Δ38 and the NDM-1 Δ36NY crystals were collected to 2.0 Å and 2.35 Å at a 
wavelength of 0.9792 Å from the single crystals using a 20 micron mini-beam and were 
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processed using HKL3000
269
. The third crystal was obtained from NDM-1 Δ36NY co-
crystallizing with 10 mM aztreonam in the condition containing 1.8 M ammonium 
citrate dibasic, and 0.1 M sodium acetate trihydrate pH 4.6. The I-centered orthorhombic 
crystal (I222) of approximately 0.2x0.1x0.07 mm, a broken piece from a big multiple 
congregate, diffracted beyond 2.0 Å, though they are multiple with cell dimensions of a 
=66.05 Å, b =83.27 Å, c = 105.4 Å. The data were collected using ~75 micron beam. 
Crystals of mZnNDM-1 Δ36NY were obtained in the presence of 10 mM ZnCl2 in the 
presence of 0.17 M ammonium sulfate, 25.5% (w/v) PEG 4000, 15% (v/v) glycerol and 
20 mM citrate and belong to tetragonal space group P43212, with unit cell dimensions of 
a= 97.94 Å, b =97.94 Å, c =187.55 Å. These crystals diffracted X-rays to 2.2 Å.  
 
Size exclusion chromatography 
 The molecular weight of native NDM-1 protein in solution was determined by 
size-exclusion chromatography using a Superdex 200 GE Healthcare 16/60 column. The 
column was calibrated with aprotinin (6.5 kDa), carbonic anhydrase (29 kDa), 
conalbumin (75 kDa), catalase (232 kDa), and thyroglobulin (669 kDa).The separation 
was carried out at 22°C at a flow rate of 2.0 mL/min. The calibration curve of Kav 
versus log molecular weight was prepared using the equation Kav= (Ve-Vo/)/(Vt-Vo,), 
where Ve = elution volume for the protein, Vo = column void volume, and Vt = total 
bed volume. Size exclusion chromatography indicates a protein monomer. 
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Data collection 
 An X-ray diffraction data set extending to 2.0 Å resolution was collected at the 
Structural Biology Center 19-ID beamline with the 20 x 20 µm mini-beam at the 
Advanced Photon Source, Argonne National Laboratory using the program SBCcollect. 
The crystal was pre-cooled in liquid nitrogen and exposed for 3 sec. per 1.0° rotation of 
omega with the crystal to a detector distance of 280 mm at 100 K using 0.9792 Å X-
rays. The complete data were recorded on an ADSC 315r CCD detector scanning 185° 
on omega until the crystal was severely decayed. The second crystal form of NDM-1 
Δ36NY was prepared in the presence of 5 mM zinc acetate and diffracted beyond 2.35 Å 
and a data set was collected similarly at the same beamline. The third crystal form 
produced by co-crystallization with aztreonam diffracted beyond 2.0 Å, however, the 
data were good only to 2.30 Å, because the crystal was multiple and decaying during the 
data collection. The data were collected by the similar procedures. For the mZnNDM-1 
Δ36NY crystal, the energy was set to 1.2825 Å to exploit anomalous signal from zinc 
atoms. All of the diffraction data were integrated and scaled with the HKL3000 suite
269
. 
The processing statistics are given in Appendix Table A4. 
 
Structure solution and refinement 
 The structure of NDM-1 Δ38 was determined by molecular replacement with the 
native data using MOLREP
270
 within the HKL3000 software suite and BALBES
271
 (R-
factor of 42.2%, correlation coefficient score of 0.634), as described previously. 
Coordinates of MBL (PDB id 2YZ3) from P. aeruginosa, which exhibits ~33% identity 
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with NDM-1 from K. pneumoniae, were used as a search model. Further extensive 
model building was performed manually in COOT
272
, while crystallographic maximum 
likelihood refinement with TLS groups
273
 for two protein chains were refined by 
PHENIX.refine 
156
. The structure of the two protein chains each containing residues 45–
270 was refined to final R and Rfree factors of 0.19 and 0.24, respectively. The final 
model is characterized by a 0.007 Å rmsd from ideal bond lengths. 97.8% of the residues 
occupy the most favored areas of the Ramachandran plot according to the 
MOLPROBITY validation results
274
. The 2.35 Å structure from the second crystal with 
zinc acetate was determined by molecular replacement using the first structure as a 
search model on HKL3000 and refined using COOT and PHENIX.refine. The final 
refined model of the two protein chains (residues of 44–270 and 45–270) converged to 
the R and Rfree values of 0.21 and 0.28, respectively. The two protein structures are 
very close in details (rmsd of 0.21 Å with 452 Ca atoms) except that the second structure 
contains an acetate molecule in the active site. The structure was refined to a 
final model after several rounds of COOT and PHENIX.refine steps. Similarly, the third 
structure obtained from the co-crystallization with aztreonam was also determined to 
2.31 Å by molecular replacement using the same search model (3RKJ). The final refined 
structure includes one chain with residues 41–269 and has an Rwork of 20.6% and Rfree 
of 27.0% with a good stereochemistry. Although the antibiotic molecule was not present 
in the structure, there were subtle changes found in the structure. For the NDM-1 
Δ36NY crystal obtained in the presence of zinc chloride (mZnNDM-1 Δ36NY), the data 
were collected near the zinc absorption peak energy (1.2825 Å). However, zinc 
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anomalous diffraction signal was weak and structure could not be solved. Instead, 
molecular replacement with the structure of chain A of 3Q6X as a search model yielded 
the structure using HKL3000. The structure contained a single zinc bound NDM-1 
Δ36NY in all four monomers in the asymmetric unit. The subsequent number of 
cycles of refinement by PHENIX.refine and COOT finalized the structure with Rwork of 
18.1% and Rfree of 23.6% with a good stereochemistry. The final refinement statistics 
for all three structures are presented in Appendix Table A4. 
 
Steady state kinetics 
 Steady state kinetic parameters were calculated for NDM-1 Δ38 β-lactamase 
substrates by directly monitoring initial velocities as the appearance or disappearance of 
the respective β-lactam antibiotic chromophore over time; Nitrocefin (λ =486 nm, 
e=20,500 M
-1
 cm
-1
), Imipenem (λ =298 nm, Δε=9,035 M-1 cm-1), Tebipenem (λ=300 nm, 
Δε =6,850 M-1 cm-1), Biapenem (λ=295 nm, Δε=7,020 M-1 cm-1), Cefoxitin (l=262 nm, 
Δε =5,382 M-1 cm-1), Faropenem (λ =306 nm, Δε =2,662 M-1 cm-1). All experiments 
were performed in 10 mM HEPES pH=6.75, 250 mM NaCl, 100 mM ZnCl2. The final 
concentration of NDM-1 was 10 nM. Reactions were performed in UV transparent 
Costar 96 well plates and monitored with the Thermo Scientific Multiskan Go plate 
reader. Initial velocities were fit to the Michaelis-Menten Equation using KaleidaGraph 
4.0. 
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CHAPTER VI  
 
NDM-1, THE ULTIMATE PROMISCUOUS ENZYME: SUBSTRATE 
RECOGNITION AND CATALYTIC MECHANISM*
3
 
 
OVERVIEW  
 
 The specter of a return to an era in which infectious disease looms as a 
significant threat to human health is not just hyperbole; there are serious concerns about 
the widespread overuse and misuse of antibiotics contributing to increased antibiotic 
resistance in pathogens. The recent discovery of a new enzyme, first identified in 
Klebsiella pneumoniae from a patient from New Delhi and denoted as NDM-1, 
represents an example of extreme promiscuity: It hydrolyzes and inactivates nearly all 
known β-lactam-based antibiotics with startling efficiency. NDM-1 can utilize different 
metal cofactors and seems to exploit an alternative mechanism based on the reaction 
conditions. Here we report the results of a combined experimental and theoretical study 
that examines the substrate, metal binding, and catalytic mechanism of the enzyme. We 
utilize structures obtained through X-ray crystallography, biochemical assays, and 
numerical simulation to construct a model of the enzyme catalytic pathway. The NDM-1 
 
 
                                                 
*Reprinted with permission from NDM-1, the ultimate promiscuous enzyme: substrate recognition and 
catalytic mechanism. Kim, Y., Cunningham, M. A., Mire, J., Tesar, C., Sacchettini, J., and Joachimiak, A., 
(2013). The FASEB Journal, 27, 1917, Copyright 2013 by the Federation of American Societies for 
Experimental Biology. 
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enzyme interacts with the substrate solely through zinc, or other metals, bound in the 
active site, explaining the observed lack of specificity against abroad range of β-lactam 
antibiotic agents. The zinc ions also serve to activate a water molecule that hydrolyzes 
the β-lactam ring through a proton shuttle. 
 
INTRODUCTION 
 
 Bacterial resistance to antibiotic agents is now recognized as an ancient 
evolutionary adaptation and not solely provoked by modern therapeutic practice 
275
. Nevertheless, the spread of pathogenic strains resistant to multiple drugs is a serious 
issue, and human activities strongly contribute to it, although the situation is not quite as 
desperate as depicted in the popular press
133
. Microorganisms must continuously cope 
with microbial warfare and have developed a wide range of mechanisms to achieve 
antibiotic resistance
276
. One of the most effective mechanisms employed by pathogens is 
the expression of enzymes known as β-lactamases that can hydrolyze the 4-membered  
β-lactam ring found in commonly used antibiotics like penams, cephalosporins, and 
carbapenems. These antimicrobials target bacterial cell wall synthesis. The β-lactamase 
enzymes are divided into 4 main classes (classes A–D) based on sequence homology53. 
Class B enzymes utilize 1 or 2 zinc ions to catalyze the hydrolysis; the other 3 classes 
rely on an active-site serine residue
53
.  
 A recent addition to the list of class B enzymes is the New Delhi metallo-β-
lactamase (NDM-1) from Klebsiella pneumoniae that has demonstrated an ability to 
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proficiently hydrolyze nearly all β-lactam antibiotics107,277-279. A number of X-ray crystal 
structures of the apo enzyme and the enzyme in complex with a variety of substrates and 
with varying occupation of the zinc binding sites have been reported
46-50
. In addition, 
mechanistic studies have been conducted in an attempt to understand how the enzyme 
achieves its catalytic capacity
51
. A general framework for the activity of metallo-β-
lactamases has been laid out previously
127
. Briefly, it is presumed that the carbonyl 
carbon atom of the β-lactam ring is attacked by a hydroxide ion, forming an intermediate 
state that is stabilized by the zinc ions
280
. Ring cleavage requires subsequent protonation 
of the nitrogen atom. However, at issue are the specifics of mechanistic and energetic 
details defining how precisely the enzyme environment facilitates the reaction.  
 Theoretical calculations have been carried out for the monozinc enzyme, CphA, 
with results that generally agree with the experimental data for that system
45,129,281
. 
Recent calculations in the dinuclear zinc L1 enzyme from Stenotrophomonas 
maltophilia have also been reported and offer insights into the catalytic mechanism, but 
these calculations do not provide evidence for protonation of the nitrogen in the final 
state of the reaction and presume that an active site aspartic acid plays the key role of a 
general base in the reaction
128
. This is contrary to mutational studies of the CphA 
enzyme in which an aspartic acid to asparagine mutation resulted in a 100-fold reduction 
in catalytic efficiency but did not stop the reaction entirely, suggesting that the aspartic 
acid is important for zinc binding but does not serve as a general base
127,129
.  
 Here, we report the results of a combined experimental/theoretical examination 
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of the NDM-1 enzyme designed to address a number of outstanding issues regarding 
substrate recognition and the hydrolytic pathway. The experimental data suggest a 
multistep process
51
, but the available crystal structures represent either the initial step of 
the reaction, prior to substrate binding or the (relaxed) product state subsequent to the 
catalytic reaction. As a result, definition of the Michaelis complex and the reaction 
pathway remain contentious subjects. In addition, different distances between zinc ions 
observed in several crystal structures and solution measurements suggest a possibility for 
alternative mechanisms
46-51
. To resolve these issues, we have determined the crystal 
structure of NDM-1 with 2 zinc ions and hydrolyzed ampicillin at atomic resolution 
(1.05 Å, the highest resolution of an NDM-1 structure to date); the crystal structure with 
2 manganese ions and hydrolyzed ampicillin at 1.50 Å resolution; the crystal structure 
with 2 cadmium ions and a mixture of hydrolyzed and unhydrolyzed ampicillin at 1.50 Å 
resolution; and the lower-resolution crystal structure with 2 cadmium ions and 
faropenem. The structure with ampicillin and cadmium corresponds to the Michaelis 
complex. We have utilized these structures as starting points for our numerical studies 
and employed molecular dynamics calculations to assess structural aspects of substrate 
binding. Subsequent hybrid quantum mechanics/molecular mechanics (QM/MM) 
calculations were performed to determine the energy surfaces along the putative reaction 
pathways. We have also determined the pH dependence and metal requirements of the 
NDM-1 catalyzed reaction.  
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RESULTS 
 
Active site organization 
 The NDM-1 active site contains 2 zinc-binding sites. One notable discrepancy 
among the experimental crystal structures is the observed distance between the zinc 
ions, which ranges on average from 3.5 to 4.6 Å
46-51
. It was shown earlier that the zinc 
ion (Zn1 site) coordinated by 3 histidine residues is occupied before the second zinc ion 
(Zn2 site) coordinated by Asp124, Cys208, and His250. It appears that both zinc ions 
have the flexibility to move considerably within the active site
48
. All of the structures 
confirm electron density between the zinc ions that is interpreted variously as a water 
molecule or hydroxide ion. We have conducted a number of molecular dynamics 
simulations with and without substrates for typical times of 10–15 ns duration. In the 
simulations, the site between the zinc ions was populated with alternatively, a water 
molecule, a hydroxide ion, or a chloride ion. For the cases where the site was occupied 
by water, we observed the Zn-Zn distance to be 5.6 Å; for Cl, the distance is 4.6 Å; and 
for OH, the distance is 3.6 Å. Averaged over several nanoseconds of simulation time, the 
standard deviaions are in the range of 0.10–0.15 Å and are largely independent of the 
presence or absence of the substrate (imipenem). The shortened distances observed in 
our simulations with ions present between the two zinc ions reflect the strong 
electrostatic interactions between the positively charged zinc ions and the negatively 
charged hydroxide or chloride ion. In our atomic resolution 1.05-Å structure of the 
NDM-1 protein, depicted in Figure 6.1 (similar but higher resolution structure to PDB 
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3Q6X
46
), in which a hydrolyzed ampicillin substrate is present, the observed Zn-Zn 
distance is 4.6 Å, suggesting that the active site is partially occupied by a water molecule 
and partially by a hydroxide ion (electron density is consistent with both). In one of the 
NDM-1 structures published recently (PDB 3SPU), Zn-Zn distances are substantially 
shorter (3.8 Å) and consistent with the presence of a bridging hydroxide ion
47
. These 
crystals were obtained at a high pH. Interestingly, our atomic resolution structure with 
ampicillin was crystallized at a pH of 6.5, and the crystals leading to the 3SPU structure 
were obtained at a pH of 7.5. Similarly, EXAFS solution scattering data
51
, suggesting a 
3.38-Å spacing between the zinc ions, were obtained at a higher pH (pH 7.6). We 
suggest that the different experimentally observed zinc distances reflect the pH 
conditions of crystallization: occupation by a water molecule at low pH and a hydroxide 
ion at higher pH.  
 K. pneumoniae is a gram-negative bacterium, and it belongs to the 
Enterobacteriaceae family that can grow in a variety of environments in a pH range of 5 
to 8. Its intracellular pH has not been measured, but we can expect it to be similar to 
other bacteria in this family. Intracellular pH for Escherichia coli is very well established 
using several methods, and its value (7.6 ± 0.1) is quite independent of the external 
medium pH
282,283
. The pH of the periplasm, where NDM-1 resides, is more variable, 
more closely reflecting the pH of the extracellular environment. Assuming a similar 
intracellular pH for K. pneumoniae, we anticipate that the active site of NDM-1 is 
populated partly by a water molecule and partly by a hydroxide ion. This finding is 
 126 
 
consistent with the observation that the distance between zinc ions at a pH range of 6.5 
to 7.5 varies between 3.9 and 3.6 Å, respectively. 
 
Promiscuity of substrate recognition 
 The active site in NDM-1 is a narrow slot defined by the two mobile loops, 
ASL1 and ASL4
46
. At the bottom of the slot, 2 zinc ions are each coordinated by 3 
protein side chains: His120, His122, and His189 for Zn1, and Asp124, Cys208, and 
His250 for Zn2, as depicted in Figure 6.1. The zinc ions held by the protein side chains 
appear to provide the essential capability to recognize β-lactam substrates and define 
what we term the catalytic core of the active site. The β-lactam substrates that are 
hydrolyzed by NDM-1 all possess carboxyl and carbonyl groups that are spaced by their 
similar, roughly planar core geometries. Oxygen atoms from these groups coordinate 
with the zinc ions to form the principal substrate-recognition unit of the enzyme. The 
distance between zinc atoms (4.1 Å; an average from available crystal structures) 
matches well with the distance range of the β-lactam carbonyl and carboxyl (3.45– 4.42 
Å) oxygen atoms. Other potential substrates with a nonplanar core are selected against 
by the action of the slot narrowing. The various substitutions to the R1 and R2 moieties 
extend into larger, open, and solvent-filled spaces on the protein surface
46
. Crystal 
structures with ligands and modeling show that R1 and R2 generally do not interact with 
the protein directly, thus explaining the enzyme’s capacity for hydrolyzing a broad range 
of substrates, all containing supported by the crystal structure of NDM-1 with ampicillin 
and 2 manganese ions (Δ30-amp-Mn). 
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Figure 6.1. NDM-1 in complex with hydrolyzed ampicillin. Stereoview of the active site, with carbon 
atoms in the protein shown in cyan; those in the substrate are pink. Nitrogen atoms are blue, oxygen atoms 
are red, sulfur atoms are yellow, and zinc ions are magenta. An oriented water molecule (W) is gray. The 
Fo-Fc electron density around the substrate is contoured at 3σ. Dashed lines indicate key interactions 
between the protein and zinc ions. 
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This structure obtained at pH 7.5 shows a metal distance of 4.5 Å and a completely 
hydrolyzed ampicillin. Similarly, structures with ampicillin, faropenem, and 2 cadmium 
ions show partly disordered ligands with exception of the β-lactam core. Our data clearly 
suggests that NDM-1can substitute zinc with manganese, or cadmium, as was reported 
earlier
284
, and bind substrates using different metals in the catalytic core.  
 In our molecular dynamics simulations with imipenem and ampicillin bound to 
NDM-1, we found persistent interactions only between the β-lactam carbonyl and 
carboxyl oxygen atoms of the substrate and the zinc ions (Figure 6.2). The binding cleft 
in NDM-1 is lined with nominally hydrophobic residues, so no specific hydrogen-
bonding interactions occurred between the β-lactam core and the protein. The R1 and R2 
substituents of imipenem and ampicillin extend into larger cavities and are primarily 
solvated by water. For imipenem, we observed a hydrogen bond formed between 
Asp124 and the hydroxyethyl group (R2) that can persist for hundreds of picoseconds, 
but no long-lived bonds were observed between the protein and the R1 moiety. No such 
interactions were observed in simulations with ampicillin, where the R2 moiety made 
sporadic interactions with the protein. R1 and R2 substituents are partly disordered in the 
crystal structures with unhydrolyzed β-lactams.  
 What we have also observed in our simulations, as illustrated in Figure 6.2 b, is 
that the cavity can widen due to the relative motion of the mobile ASL1 and ASL4. 
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Figure 6.2. NDM-1 simulation active site. The protein is depicted as a surface and the (imipenem) 
substrate is colored as in Fig. 1, except for carbon atoms, which are cyan here. (a) Substrate recognition is 
provided by interactions between the zinc ions and the carboxyl and carbonyl oxygen atoms of the 
substrate (dashed yellow lines) and nonspecific, generally hydrophobic interactions with the protein. The 
oriented water molecule occupies a pocket between the zinc ions. (b) When the mobile loops move, a thin 
film of water surrounds the substrate, including 2 water molecules that serve as the nucleophile and as the 
source of the final proton required for cleavage (dashed green lines). 
 
 
 
 
 
 
 
 
 
 
 
 
a b 
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When this happens, although this does not necessarily always occur in the time scales 
accessible in our simulations, a monolayer of water molecules can intrude between the 
substrate and the protein. The hydrogen bonding network of the bulk water is disrupted 
within the monolayer, with hydrogen bonds forming preferentially with the ligand and 
not the (hydrophobic) protein residues. We believe that the motion of the active site 
loops provides a mechanical filter of sorts that selects substrates with a core geometry 
that is nearly planar. 
 
Reaction pathways 
 Previous discussions of the enzyme mechanism have focused on the oriented 
water molecule (hydroxide ion) identified between the two zinc ions, where it is 
presumed that this molecule will serve as the nucleophile that initiates the hydrolytic 
reaction. We have investigated several possible reaction pathways by identifying 
conformations from the molecular dynamics simulations where molecules were aligned 
appropriately for an attack of the C7 carbon atom of the substrate to be productive. That 
is, we initiated the attacks from what would be described as near-attack 
conformations
285
. The QM/MM calculations were conducted by computing optimized 
structures along a putative reaction pathway, defined by placing constraints on key 
distances like that between the C7 carbon atom of the substrate and the Ow oxygen atom 
of the attacking water (hydroxide) and changing the constraints in a stepwise fashion. 
This initial guess for the reaction pathway was then optimized using a nudged elastic 
band method
286
, in which no atoms were constrained, producing an estimate of the 
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potential energy surface along the path. Subsequent dynamics calculations on the MM 
partition allowed us to estimate the free energy along the pathway; given the 
computational requirements for such calculations, free energy calculations were only 
performed for the most favorable pathways. In our methodology, the estimate of the free 
energy is dominated by the quantum component, with the MM component providing 
corrections typically of the order of 20–30 kJ/mol. In our experience, the MM 
component will not lower a 200 kJ/mol barrier to a 100 kJ/mol barrier.  
 On analyzing all of the different reaction pathways, the subset of pathways 
studied in which the oriented water or hydroxide ion served as the nucleophile was 
energetically unfavorable. For the attack of a hydroxide ion, we observed a potential 
energy surface that rises monotonically to 170 kJ/mol at the intermediate state. Such a 
state would not be stable, so we have also considered attacks using an initial oriented 
water molecule and a pathway that utilized Asp124 as a general base; a concerted attack 
in which the N4 nitrogen atom was directly protonated by the attacking water molecule; 
and a pathway in which a bulk water molecule served as a base. In each of these 
scenarios, we found barriers of 200 kJ/mol or more, suggesting that the oriented water 
molecule is not the nucleophile. Previous experimental results in the CphA system, 
which is a class B2 β-lactamase, have excluded Asp124 as a base. It is possible that the 
mechanisms in the two enzymes differ, but we believe the experimental findings lend 
credence to our computational modeling results, at least in terms of excluding Asp124 as 
the general base.  
 We have identified conformations from the molecular dynamics simulations in 
 132 
 
   
 
          
Figure 6.3. NDM-1 reaction mechanism. (a) The oriented hydroxide ion serves as a general base 
to accept a proton from a bulk water molecule. (b) A proton from the intermediate state is 
transferred to another bulk water molecule. (c) The proton is then shuttled to the N4 nitrogen of the 
substrate. (d) The nitrogen (N4)-carbon (C7) bond is cleaved in the final state. Energy values are estimates 
of the free energy from the QM/MM calculations. (e) Comparison of the pathway energetics with a bulk 
water as the nucleophile (red, blue) or the oriented water acting as the nucleophile (green). Reaction 
coordinates correspond to steps shown in panels (a–d). 
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which the substrate was solvated by bulk water. We have also examined pathways 
in which the oriented water or hydroxide ion served as a general base and the 
nucleophilic water originated from the bulk solvent. In Figure 6.3 a-d, we depict the 
proposed mechanism of action for a pathway in which a bulk water molecule transfers a 
proton to the oriented hydroxide ion and then attacks the carbonyl group of the substrate.  
Formation of the intermediate is the rate-limiting step of the reaction; subsequent proton 
translocations involving a second bulk water molecule result in protonation of the N4 
nitrogen atom of the substrate and ring cleavage. Subsequent steps along the pathway are 
energetically downhill.  
 Finally, we have also studied the pathway possibility where a water molecule 
occupies the site between the zinc ions. In this case, the initial proton transfer to the 
oriented water results in protonation of the carboxyl group of the substrate. Subsequent 
proton translocations also result in cleavage of the N4-C7 bond. The observed barrier is 
~80 kJ/mol. By comparison, in Figure 6.3 e, we compare the relative energetics along 
the pathways involving bulk water serving as the nucleophile and one of the cases in 
which the oriented water served as the nucleophile. We observed a relatively large 
barrier for the latter pathway, typical of all the pathways in which the oriented water or 
hydroxide ion served as the nucleophile. These results suggest that the most probable 
reaction mechanism involves a bulk water molecule serving as the nucleophile, and 
either the oriented water molecule or hydroxide ion, serving as the general base. Our 
proposed mechanism is consistent with an increased volume of the active site, high 
flexibility of NDM-1 and its chemical environment. 
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pH and metal dependence of NDM-1 activity 
 To gain further structural insights into the mechanism of binding and hydrolysis 
of β-lactam substrates by NDM-1, we sought to trap the Michaelis complex of NDM-1 
with various β-lactam substrates. Several attempts were made by co-crystallization, as 
well as crystal soaking, but structures revealed only product bound in the active site 
when NDM-1 was liganded with zinc or manganese. To facilitate trapping of the 
Michaelis complex of NDM-1 with β-lactam substrates, we sought to identify conditions 
that would decrease the turnover number of NDM-1. We approached this from the 
perspective of pH and selection of divalent metal cation.  
 We have determined the turnover number of NDM-1 as a function of pH, and in 
the presence of varying concentrations of divalent cations zinc and cadmium. The results 
reveal a direct dependence of turnover number kcat on pH (Figure 6.4). As the pH is 
increased from 5.5 to 8.5, kcat increased 4-fold from 26 ± 2 to 101 ± 5 s
-1
, respectively. 
The results are consistent with an increasing frequency of zinc-liganded hydroxide ion as 
the pH increased.  
 The dependence of kcat on divalent cation concentration showed that in the 
presence of 1–200 M zinc, the turnover number increased from 23 ± 3 to 110 ± 4 s -1, 
with a plateau between 100 and 200 µM zinc. In the presence of 1–200 µM cadmium, 
kcat decreased from 6 ±1 to 1 ± 1 s 
-1
, with a plateau between 100 and 200 µM. 
 Although the activity of NDM-1 was severely attenuated when liganded with 
cadmium, a basal level of hydrolysis was maintained, which is consistent with partially 
hydrolyzed faropenem and ampicillin molecules in the active site of cadmium liganded 
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Figure 6.4. Dependence of NDM-1 turnover number on divalent cation concentration. The kinetic 
parameter (kcat)  was determined for NDM-1 using ampicillin as a substrate and increasing concentrations 
of Zn
2+
 (blue circles) or Cd
2+
 (red circles). Error bars are depicted in black. 
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NDM-1 (Figure 6.5). 
 
Structure of the Michaelis complex 
 As shown in Figure 6.4, cadmium ion is a very poor substituent for zinc, 
consistent with earlier reports that substituting cadmium for zinc inhibits enzyme 
activity
40
. We have obtained 2 crystal structures of the enzyme with cadmium: a high-
resolution structure in complex with ampicillin (Δ30-amp-Cd) and a lower resolution 
structure in complex with faropenem (Δ30-far-Cd). Unlike the  Δ30-amp-Zn structure 
that shows well-defined electron density for hydrolyzed ampicillin bound to the active 
site containing 2 Zn ions, only partial electron density (2Fo-Fc) for the ligand was 
observed in the presence of cadmium ions. In the case of the high-resolution Δ30-amp-
Cd structure (Figure 6.6), Cd in the primary metal site (Cd1)
48
 is split into 2 positions in 
both protein chains in the asymmetric unit, Cd1a and Cd1b, that are 1.01–1.18 Å apart 
and have 64–65 and 35–36% occupancies, respectively. Both metal ions are coordinated 
by the same set of interactions with active site residues. The second metal site (Cd2) 
maintains its usual position and shows two different distances between the two metal 
sites, 3.53–3.72 and 4.29–4.30 Å, respectively. The electron density for the ligand is 
somewhat different from both hydrolyzed ampicillin and unhydrolyzed ampicillin; while 
the 5-membered ring in the lactam moiety and its carboxyl group are well-defined, the 4- 
membered ring (unhydrolyzed) or carboxyl group (hydrolyzed) are partly disordered, 
and the phenyl peptide assumes a distinct conformation from that of a hydrolyzed 
ampicillin, albeit not well-defined (Figure 6.6 c). This electron density was interpreted as 
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Figure 6.5. pH dependence of NDM-1 turnover number. The kinetic parameter, (kcat) was determined for 
NDM-1 using CENTA as a substrate. Error bars are depicted in black. 
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Figure 6.6. Structure of NDM-1 in complex with two cadmium ions and ampicillin. (a) The intermediate 
(int-amp) is superposed with the modeled unhydrolyzed ampicillin (yellow). (b) The hydrolyzed 
ampicillin (gray) from Δ30-amp-Zn is compared with the int-amp. Notice that the hydrolyzed ampicillin is 
rotated a few degrees (ccw) from the intamp. (c) The partially hydrolyzed ampicillin (green; intermediate) 
is fitted in the Fo-Fc electron density contoured at 2σ level. The split Cd2+ is also indicated. 
 
 
 
 
 
a b 
c 
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being partially occupied by unhydrolyzed and hydrolyzed ampicillin. This crystal 
structure indicates that on hydrolysis, one part of the ligand is very well ordered, and the 
other part undergoes conformational changes. The 5-membered ring of the β-lactam and 
the R1 moiety of the phenyl peptide show an ensemble of unhydrolyzed and hydrolyzed  
intermediates and appear as disordered regions in the ligand. We also noted that the 
position of the ligand in the Δ30-amp-Cd structure is slightly different from that of the 
hydrolyzed ampicillin in the Δ30-amp-Zn structure (Figure 6.6 a,b). Perhaps the action 
of active site narrowing and widening by ASL1 and ASL4 as the catalytic reaction 
progresses forces the ligand (substrate, intermediate, or product) to move about, rotation 
of a few degrees counterclockwise in this case, for a higher catalytic efficiency.  
 In the lower-resolution Δ30-far-Cd structure, the density for the ligand is not as 
well defined as that of other structures of NDM1-hydrolized ampicillin complexes 
(3Q6X, 4H0D, 4HL2) and is only visible for the β-lactam moiety. Faropenem is smaller 
than ampicillin, but the electron density is different from what was predicted for 
hydrolyzed faropenem. We modeled the electron density as a mixture of hydrolyzed and 
unhydrolyzed faropenem; however, only a portion corresponding to the β-lactam moiety 
refined well, and it is difficult to resolve the two conformations. The metal-metal 
distance is significantly shortened (3.46 –3.48 Å); no well-ordered oriented water 
molecule is present between the cadmium ions, and the Asp124 carboxyl group 
coordinates both cadmium ions (2.80 –2.83 and 3.44 –3.82 Å). With this rearrangement, 
the active site appears to be in a conformation that is not quite optimal for binding β-
lactam antibiotics (faropenem) and hydrolyzing it. We also note that the furyl group (R1) 
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of the substrate is poorly resolved in the structure, consistent with our observations that 
the R1 and R2 moieties of ampicillin were only partially ordered in the other NDM1-
hydrolyzed ampicillin structures.  
 Using the cadmium-bound structures observed experimentally as a starting model 
we have conducted a number of molecular dynamics simulations. From these 
simulations, we have obtained a structure in which the active site is organized in a 
conformation like the proton shuttle-starting configuration that was described for our 
zinc containing structures. The potential energy along a proposed proton shuttle pathway 
computed through QM/MM yields a high barrier of 200 kJ/mol. The high-energy barrier 
is consistent with experimental observations that the enzyme efficiency is greatly 
reduced when zinc is substituted by cadmium. In the structure depicted in Figure 6.6, we 
interpret the density to indicate that the ampicillin is only partially hydrolyzed, 
suggesting that cadmium replacement does not completely disable the enzymatic activity 
of the protein and this is confirmed experimentally (Figure 6.4). These results show that 
the dimetal ion core is essential for ligand binding and that very specific framework of 
that core is needed for efficient substrate hydrolysis.  
 
DISCUSSION 
 
 Metallo-β-lactamases represent a family of enzymes capable of evolving multiple 
catalytic activities and accepting a wide range of substrates
276
. Therefore, it is not very 
surprising that the NDM-1 represents an evolutionary step that can bind and hydrolyze a 
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broad range of β-lactam-based antibiotics. The enzyme shows a high flexibility of loops 
forming the active site and, with exception of the β-lactam moiety, does not seem to 
make extensive interactions with the substrates, which is a characteristic of promiscuous 
enzymes
287-289
. Recognition of the substrate is provided almost entirely by what we can 
call the catalytic core of the active site; the two zinc ions interact with the carboxyl and 
carbonyl oxygen atoms of the β-lactam. The presence of divalent metal cations seems to 
be essential for binding. The zinc ions can be replaced with other metals (Mn
2+
,Cd
2+
) 
that provide an equivalent β-lactam binding framework, but not necessarily the same 
catalytic potential as Zn
2+
. Modest substrate specificity is provided by the mechanical 
action of the mobile loops, ASL1 and ASL4, which select planar core ligand structures. 
 When the mostly hydrophobic trench widens, a single layer of water molecules is 
admitted into the space between the substrate and protein, and it is these water molecules 
that are apparently recruited to hydrolyze the β-lactam ring. As the protein surface is 
predominantly hydrophobic, the water molecules preferentially coordinate with the 
substrate and catalytic core. The dinuclear zinc catalytic core is coordinated by 6 side 
chains that form 2 catalytic triads. Interestingly, the distance between the metal ions can 
vary considerably (3.1– 4.6 Å) and this distance seems pH dependent. In addition, dizinc 
coordinates water or a hydroxide ion between the metal ions that we propose serves as 
the general base in the catalytic reaction. The presence of the zinc ions provides a 
pathway for shuttling protons among the water molecules that would not be present in 
bulk water, explaining the relative stability of the substrates in solution.  
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 Our structures and calculations are consistent with two pathways; one, at lower 
pH, involves a zinc-coordinated water molecule, and the second, at higher pH, involves a 
zinc-coordinated hydroxide ion. In both of these mechanisms, a bulk water molecule 
serves as the nucleophile, and the zinc-coordinated molecule serves as the general base. 
Ring cleavage is achieved through a proton translocation process that utilizes another 
bulk water molecule. The suggested mechanism (Figure 6.3) is in some sense similar to 
that we have previously observed in the human aldose reductase system
290
, where proton 
translocation was shown to be essential for catalysis. Our proposed mechanism is also in 
agreement with EXAFS data
51
 that suggest a multistep reaction. The NDM-1 enzyme 
can be considered the ultimate example of enzyme promiscuity. It shows lack of 
specificity for substrate recognition, with exception of the β-lactam moiety, and can use 
multiple metal cofactors and switch catalytic mechanisms based on pH.  
 We believe that the cadmium structures represent the Michaelis complex for the 
reaction. A significant reorganization of the active site is observed in Figure 6.6, and the 
shorter Cd-Cd distance does not admit an oriented water molecule as was observed in 
the zinc liganded structures. We find the near-attack conformations from our simulations 
correspond closely with the observed crystal structures with cadmium. We believe that 
this lends credibility to the Michaelis complexes that we identified from our simulations 
in the zinc bound systems, where no crystal structures are available. Moreover, our 
simulations indicate that a proton shuttle pathway would encounter a high barrier when 
NDM-1 is liganded with Cd
2+
, in agreement with our observation of partially hydrolyzed 
 143 
 
ampicillin in the crystal structure, and the known much lower enzyme activities. From 
these results we would predict a significant isotopic effect for the reaction.  
 Development of inhibitors for the NDM-1 enzyme has proven challenging. A 
structure of NDM-1 in complex with L-captopril (IUPAC (2S)-1-[(2S)-2-methyl-3-
sulfanylpropanoyl] pyrrolidine-2-carboxylic acid) has been reported recently
50
. In this 
structure, the sulfur atom binds between the two zinc ions, with the remainder of the 
molecule extending beyond the catalytic core of the active site. Our results suggest that 
other planar scaffolds that contain oxygen atoms to coordinate the zinc ions should also 
prove to be successful inhibitors.  
 
MATERIALS AND METHODS 
 
Protein cloning, expression, and purification 
 The Δ30 construct of the NDM-1 gene from K. pneumoniae subsp. pneumoniae 
MGH 78578 was cloned into the pMCSG7 vector using a modified LIC protocol as 
described by Kim et al
291
. This process generated an expression clone producing a fusion 
protein with an N-terminal His6 tag and a tobacco etch virus (TEV) protease recognition 
site. The expressed protein was purified using standard procedures on an ÄKTAxpress 
automated purification system (GE Healthcare Life Sciences, Piscataway, NY, USA) as 
described previously
292
. The concentration of the purified protein was determined 
utilizing an ND-1000 spectrophotometer system (NanoDrop Technologies, Wilmington, 
DE, USA). The fusion tag was then removed by adding recombinant TEV protease at a 
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ratio of ~1:75 (mg) and incubated for 48 h at 4°C. The cleaved protein was then 
separated using Ni-NTA affinity chromatography and the ÄKTAxpress system. The 
purified protein solution was dialyzed in a crystallization buffer [20 mM HEPES, pH 
8.0; 250 mM NaCl; and 2 mM dithiothreitol (DTT)] and concentrated using an Amicon 
Ultra centrifugal filter device with a nominal molecular weight limit of 3000 (Millipore, 
Bedford, MA, USA).  
 
Protein crystallization  
 The protein was crystallized using sitting-drop vapor diffusion at 16 and 4°C in 
96-well CrystalQuick plates (Greiner Bio-One North America, Inc., Monroe, NC, USA). 
A 400-nl droplet of protein (40–80 mg/ml) was mixed with a 400-nl droplet of 
crystallization reagent and allowed to equilibrate over 135 µl of crystallization reagent. 
Nanopipetting was performed using the Mosquito nanoliter liquid handling system (TTP 
LabTech, Cambridge, MA, USA). Several commercially available crystallization screens 
were used, including MCSG-1–4 (Microlytic Inc. Burlington, MA, USA) and Index 
(Hampton Research, Aliso Viejo, CA, USA). The plates were then incubated at 16 and 
4°C in a RoboIncubator automated plate storage system (Rigaku, The Woodlands, TX, 
USA). Automated crystal visualization was utilized in locating several crystals 
(CrystalTrak; Rigaku). The best crystals of the 30 construct protein preincubated with 80 
mg/ml of ampicillin (Δ30-amp-Zn) appeared at 16°C under the conditions of 0.2 
M ammonium sulfate, 0.1 M Bis-Tris (pH 5.5), and 25% PEG3350, which corresponds 
to condition A6 from the MCSG-1 screen. The 30 protein preincubated with 80 
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mg/ml of faropenem and mixed with 10 mM cadmium chloride (Δ30-far-Cd) was 
crystallized in the same conditions, except for an additional 5 mM CdCl2. The 30, 
ampicillin, manganese (Δ30-amp-Mn) crystals were produced from the MCSG-1 screen 
condition H11, containing 0.2 M sodium chloride, 0.1 M HEPES (pH 7.5), and 25% 
(w/v) PEG3350, plus 5 mM MnCl2. The co-crystals of Δ30, ampicillin, and cadmium 
(Δ30-amp-Cd) were obtained from the MCSG-1screen condition B11, containing 0.2 M 
lithium sulfate, 0.1 M Bis-Tris-HCl (pH 6.5), and 25% (w/v) PEG3350, plus 10 mM 
CdCl2. These crystals were cryoprotected and flash-cooled in liquid nitrogen before they 
were analyzed in the synchrotron X-ray beam at the Structural Biology Center (SBC), 
sector 19-ID at the Advanced Photon Source (APS; Argonne National Laboratory). The 
proteins with ampicillin and zinc, manganese, or cadmium were crystallized in the same 
space group (P212121) with similar cell dimensions of a = 39.1–39.2, b = 78.6 –79.2, c = 
133.7–134.5 Å, although they were grown under two different conditions. However, 
Δ30-far-Cd crystallized in a different space group (C2) with cell dimensions of a = 
145.63, b = 39.32, c = 75.37 Å and γ = 99.96°.  
 
Data collection 
 All diffraction data were collected at 100 K at the 19-ID beamline of the SBC at 
the APS, using the ADSC Q315r detector. The high-resolution data to 1.05 Å resolution 
for the co-crystal of Δ30-amp-Zn were collected at 0.5166 Å with the detector distance 
of 200 mm from a rectangular crystal (0.1 x 0.06 x 0.03 mm) by exposing for 20 s/frame 
of 1.0° rotation on  over 150° in 2 wedges (100 and 50°) from 2 different places of the 
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same crystal. For the Δ30-amp-Mn crystal, the data at 0.9793 to 1.5 Å were collected 
from a single protein crystal (0.10 x 0.04 x 0.05 mm). The crystal was exposed for 3 
s/1.0° rotation of ω with a crystal-to-detector distance of 280 mm. The data were 
obtained by scanning 160° on ω. The Δ30-far-Cd and Δ30-amp-Cd data were collected 
similarly at 0.9793 Å by exposing a crystal for 3 s/1.0° rotation frame over 200° on ω up 
to 2.5 Å for Δ30-far-Cd and by exposing a crystal for 3 s/1.0° rotation frame over 170° 
on ω for Δ30-amp-Cd. The detailed data collection statistics are shown in Appendix 
Table A5. 
 
Structure determination and refinement 
 All structures were determined by molecular replacement using HKL-3000 (23), 
and Molrep with the Protein Data Bank identification (PDB ID) 3Q6X structure as a 
search model. Iterative manual adjustment using Coot
293
 and phenix.refine
156
 refinement 
made the models converge to the final Rwork and Rfree values of 14.7 and 16.8%, 
respectively, for Δ30-amp-Mn; 20.4 and 25.1% for Δ30-far-Cd; 12.7 and 16.7% for Δ30-
amp-Cd; and 13.3 and 15.7% for the 1.05 Å 30-amp-Zn (Appendix Table A5). In the 
Δ30-amp-Zn structure, 2 zinc ions were found in the active site, although no additional 
zinc was included during purification and crystallization. The presence of Zn, Mn, and 
Cd ions was confirmed by the residual anomalous difference electron density map, 
metal-metal distances, metal-N (or O) distances, and/or fluorescence emission spectra 
(Zn K 1, 8.6 keV; Mn K 1, 5.9 keV; Cd K 1, 4.0 keV). 
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Validation and deposition 
 The stereochemistry of the structures was checked with PROCHECK 
294
 and a 
Ramachandran plot. The main-chain torsion angles for nearly all residues are in allowed 
regions: for Δ30-amp-Zn, 98.7% of all residues in favored region with 1 outlier; for Δ30-
amp-Mn, 98.7% with 2 outliers; for Δ30-amp-Cd, 98.9% with 3 outliers; for Δ30-far-Cd, 
97.6% with 3 outliers.  
 
Molecular dynamics  
 Molecular dynamics simulations were performed with the code NAMD
295
, 
developed by the Theoretical and Computational Biophysics Group at the Beckman 
Institute for Advanced Science and Technology (University of Illinois at Urbana-
Champaign, Urbana-Champaign, IL, USA). The CHARMM 27 force field
296
 parameters 
were used. Parameters for the ampicillin and imipenem substrates were developed using 
the standard methodology. Analysis of dynamics trajectories and preparation of figures 
was conducted with the program VMD
297
. Initial coordinates for protein atoms were 
obtained from the crystal structures. Missing atom coordinates (hydrogens) were defined 
with the PSFGEN module of VMD, which was also used to solvate the protein and 
neutralize the total charge of the simulation model. The solvation box was extended for 
10 Å beyond the protein. With a 12-Å cutoff for electrostatic interactions, the box 
dimensions ensured a “diffuse” simulation model, in which no protein atoms interacted 
directly with protein atoms in the periodic images. Electrostatic interactions were 
computed using a smooth particle-mesh Ewald method
298
, with a grid size of ~1-Å 
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spacing. Simulations began with a small amount of minimization (1000 steps) and then 
utilized typically 100,000 steps of NVT dynamics and 100,000 steps of NPT dynamics 
run with 1-fs time steps to equilibrate the system. Constant temperature was maintained 
by a Langevin method
299
, and constant pressure conditions were enforced through a 
modified version of the Langevin piston
300
and Hoover
301,302
  methods. Typical 
production runs were of 10 ns duration and were conducted using NPT dynamics with 2-
fs time steps, recording coordinate information at 1-ps intervals. Simulations were 
conducted for the dimeric conformation of the protein, as observed in the crystal 
structure. There were ~50,000 atoms in the simulations, in a box of nominal dimensions, 
65 x 68 x 102 Å.  
 
QM/MM studies 
 To study energetics along the proposed reaction pathway, we performed 
QM/MM calculations with the program NWChem
303
. We utilized a nudged elastic band 
(NEB) method
286
  implemented recently. Initial coordinates for reactant states were 
taken from snapshots of the dynamics trajectories in which the attacking water molecule 
was positioned in what we would describe as a near attack conformation
285
. The 
quantum partitions for all simulations included the side chains of residues His120, 
His122, Asp124, His189, Cys208, and His250. Also treated quantum mechanically were 
the penem moiety of the imipenem substrate (excluding the R1and R2 substituents), the 
zinc or cadmium ions, the attacking water, and additional waters that were coordinated 
to the zinc or cadmium ions. Atoms beyond 15 Å from the target carbon atom of the 
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substrate were frozen in place, and only atoms within that spherical region were allowed 
to move. The reactant state was defined by optimizing the original model using the 
density functional method B3LYP
304
  and a 6–31 + + G** basis set for all atoms except 
zinc and cadmium and a 6–31G**(2s,2f) basis set for the zinc ions and a def2-tzvp basis 
set for the cadmium ions. The def2 basis set includes an effective core potential (ECP) 
for 28 electrons. An initial estimate of the reaction pathway was constructed by 
optimizing intermediate structures subject to constraints. For example, the distance 
between the water molecule oxygen atom and the substrate carbonyl carbon atom would 
be systematically reduced from its original value of ~3 Å to a final value of 1.4 Å. The 
product-state geometry was then obtained by removing all constraints and reoptimizing 
the geometry, starting from the last step along the pathway. The pathways produced 
utilized between 10 and 15 intermediate structures to represent the initial pathway guess. 
The initial pathways were subjected to further NEB optimizations to define an optimal 
QM pathway. Free energy calculations were then conducted for some pathways, using 
the (static) reference geometries of the QM partition atoms and allowing the MM 
partition atoms to move dynamically. Typical simulations utilized 30 ps of dynamics, 
and the free energy values reported represent the average values obtained by neglecting 
the initial (equilibration) 10 ps of the trajectories. Trajectories were examined visually 
for stability and s.d. of all results were < 2 kJ/mol. 
 
Enzymatic studies 
 pH dependence of NDM-1 activity was assayed at 25°C in a reaction buffer 
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containing 50 mM Bis-Tris (pH 5.5, 6.5, 7.5) or 50 mM Tris (pH 8.5), 100 mM NaCl, 
and 50 µM ZnCl2, varying concentrations of CENTA substrate (EMD Biosciences, San 
Diego, CA, USA), and 2 nM NDM-1. Steady-state hydrolysis of the β-lactam ring by 
NDM-1 was monitored by increase in max: 405 nm during the linear portion of the 
reaction initial velocity. The extinction coefficient of CENTA was experimentally 
determined (ε=1767 M -1 cm-1). The rate of spontaneous hydrolysis of the β-lactam ring 
was determined in absence of enzyme at each pH and was subtracted from the initial 
velocities determined with NDM-1. Metal dependence of NDM-1 activity was assayed 
at 25°C using ampicillin as a substrate in reaction buffer containing 50 mM Tris (pH 
6.5), 100 mM NaCl, and varying concentrations of ZnCl2 and CdCl2. Hydrolysis of the 
β-lactam ring by NDM-1 was monitored by decrease of the lactam chromophore max: 
235 nm (ε = 900 M -1 cm -1) during the linear portion of the reaction initial velocity. 
Kinetic parameters were determined by plotting the initial velocities against substrate 
concentration and curve fitting with the Michaelis-Menten equation using KaleidaGraph 
4.0 (Synergy Software, Reading, PA, USA). 
 
 
 
 151 
 
CHAPTER VII  
 
CONCLUSION AND FUTURE DIRECTIONS 
  
 β-lactams have received a great deal attention with respect to their potential to be 
used for TB treatment
69,70,97,98,101,102,144
. Carbapenems are very effective β-lactam 
antibiotics because of their inhibitor activity against serine β-lactamases99, which allows 
them to be used against otherwise β-lactam resistant bacteria. The primary mechanism of 
Mtb resistance β-lactam antibiotics is the extended spectrum β-lactamase BlaC96,305. 
Inhibition of BlaC by carbapenems and clavulanate is sufficient to re-sensitize Mtb to β-
lactams
98
. However, these molecules are β-lactams that are hydrolyzed by BlaC. 
Unfortunately, the inhibitory activity is only transient
69,70
. Once they become hydrolyzed 
by BlaC, they are permanently inactivated, and can no longer function to inhibit their 
cell wall biosynthetic PBP targets or BlaC. 
 Ideally, a β-lactam could selectively inhibit the cell wall PBP targets and not bind 
to BlaC. However, BlaC is evolutionally related to the cell wall PBPs, so they can 
naturally bind similar molecules. Therefore, the similarity of BlaC to PBP targets 
precludes designing a target selective β-lactam. To identify target selective β-lactams, 
the antibacterial activities of β-lactam antibiotics on Mtb cells in presence and absence of 
active BlaC enzyme was compared to quantify the contribution of BlaC to Mtb 
resistance to these β-lactams. As expected, the antibiotic activities of carbapenems are 
less affected by the presence of BlaC than other β-lactams that are rapidly hydrolyzed by 
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BlaC. Interestingly, faropenem (a penem) was less affected by the presence of BlaC than 
the carbapenems. The structure activity relationship of BlaC with multiple β-lactams 
provided insight into faropenem’s ability to evade BlaC structure activity relationship 
more than other β-lactams, and reveals desirable structural features for the future design 
of target selective β-lactams with reduced binding to BlaC. 
 Faropenem, biapenem, and tebipenem were biochemically and biophysically 
characterized with BlaC. Inhibition kinetics demonstrated that faropenem has less 
affinity for BlaC than structurally similar carbapenems: biapenem and tebipenem. Mass 
spectrometry demonstrated that faropenem formed a transient acyl-intermediate complex 
with BlaC, as did biapenem, tebipenem, and other carbapenems
98,144
. This result is 
unique because the BlaC-faropenem complex was less stable than biapenem and 
tebipenem. These results showed that faropenem’s ability to evade BlaC more than other 
β-lactams is due to having a weaker affinity for the enzyme. The acyl-intermediate 
crystal structures of BlaC with faropenem, biapenem, and tebipenem elucidated the 
intermolecular interactions that are responsible for binding to BlaC and for the stability 
of the acyl-intermediates. The defining feature that likely distinguishes tighter binding 
carbapenems, biapenem and tebipenem, from faropenem is hydrophobic interaction with 
the side chain of Ile105 that borders the active site upon binding. Biapenem and 
tebipenem have R2 methyl groups that mediate this contact. The R2 methyl group is 
absent in faropenem, preventing hydrophobic interaction between faropenem and Ile105, 
which decreases the affinity of faropenem for the BlaC active site. This ultimately yields 
a measurable decrease in β-lactamase mediated resistance of Mtb to faropenem relative 
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to other β-lactams. This feature can be exploited in future efforts to rationally design 
selectivity into novel β-lactams to evade BlaC mediated resistance while maintaining 
potent activity against Mtb. The importance of the hydrophobic patch created by Ile105 
in ligand binding to BlaC is further demonstrated by the structure activity relationship 
between BlaC and boronic acid inhibitors. 
 In addition to using structure-based design to improve the activities of β-lactams 
for use against tuberculosis, BlaC inhibitors are of particular interest.  The FDA 
approved β-lactamase inhibitor clavulanic acid potentiates the activities of β-lactams by 
inhibiting BlaC
69,98
. However, clavulanic acid is inactivated by BlaC and the β-lactamase 
activity is eventually restored
70
.  More stable inhibitors of BlaC are a topic of current 
investigation
70
. In addition, the low micromolar affinity of clavulanic acid for BlaC is 
modest compared to recently designed boronic acids for class C β-lactamase AmpC, 
which have reached subnanomolar binding constants and are effective in vivo
81-84
.  
Designing a more potent and stable BlaC inhibitor may improve β-lactam activity 
against Mtb. 
 Benzoxaboroles are a relatively new class of β-lactamase inhibitor that have 
demonstrated activity against class A and class C β-lactamases85 including TEM-1, 
CMY-2-, KPC-2, and AmpC P99. They function by forming reversible covalent bonds 
with the active site serine
81-84
, and are stable to β-lactamase hydrolysis unlike β-lactam-
based inhibitors. Only enzymatic data has been reported for optimization of the 
benzoxaborole scaffold as β-lactamase inhibitors; therefore, structural data for 
benzoxaboroles is of great interest for rational design. To gain insight into the binding 
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and inhibition of benzoxaboroles with BlaC, a boronic acid inhibitor library from Anacor 
Pharmaceuticals was enzymatically screened, which revealed that the benzoxaborole 
scaffold also inhibits BlaC. To identify structural features of the BlaC active site that can 
be exploited for inhibitor design, we generated a structure activity relationship with 
derivative benzoxaboroles and BlaC. Co-crystal structures of BlaC with derivative 
benzoxaborole inhibitors provided insight into the inhibition of β-lactamases by 
benzoxaboroles by revealing key intermolecular interactions that govern binding to the 
active site. The structure activity relationship enabled us to visualize how specific 
modifications to the benzoxaborole scaffold either increased or decreased the potency of 
BlaC inhibition, and provided a platform for the design of improved BlaC inhibitors. 
 Three locations on the benzoxaborole scaffold were chemically modified to 
probe for BlaC inhibition. A carboxymethyl group at the 3’ position was determined to 
be indispensable for tight binding and inhibition. Electrostatic surface potential maps of 
BlaC generated from the co-crystal structures show that the carboxylate binds in a 
positively charged region of the active site (next to the oxyanion hole), which is the 
same location that the carboxylate group of substrate β-lactams binds98,144. In this 
manner, the 3’ carboxylate seems to mimic β-lactam substrates. The 4’ position of the 
benzoxaborole tolerated small and large modifications without drastically affecting the 
binding or inhibition of BlaC because the 4’ position mostly faces open solvent. 
However, the general trend of the enzymatic data shows that more hydrophobic 
modifications at this position increase potency. Examination of the crystal structures 
showed that the nearby hydrophobic side chain of Ile105 is responsible for the 
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preference for hydrophobic groups. This observation lends credence to the previous 
observation that substrates biapenem and tebipenem bind tighter to BlaC than faropenem 
by hydrophobically interacting with Ile 105 upon binding. Substitutions made to the 
benzoxaborole 6’ position reached into the distal cavity of the BlaC active site bordered 
by the substrate specificity loop. Each of the 6’ modifications interacted with the 
backbone amide nitrogen of Ile105 either directly or through a solvent bridge, which 
further confirms the importance of Ile105 in ligand recognition by BlaC. The other 
contacts made by 6’ derivative benzoxaboroles were hydrogen bonds with the side chain 
of Asp240. 
 From this investigation, it seems that the best place to probe for additional potent 
modifications to the benzoxaborole scaffold resides with the 6’ position, which is 
proximal to the BlaC substrate specificity loop in crystal structures. Importantly, 
hydrogen bonding donors and acceptors stem from the side chains of residues in the 
substrate specificity loop (Asn170, Glu166). Asn170 and Glu166 are conserved because 
of their role in binding β-lactam substrates like amoxicillin and their essential role in 
catalysis. Theoretically, these residues, especially Glu166, will be less tolerant to 
mutations because they would decrease activity of BlaC. Therefore, a logical strategy for 
inhibitor design would be to make additional interactions with Glu166. The effectiveness 
of this strategy is exemplified by the interruption of catalysis by carbapenems
69,99,144
. 
Although, the inhibitors characterized in this investigation did not bind directly to these 
residues, the crystal structures illustrate the potential for modifications at the 6’ 
benzoxaborole position that would facilitate hydrogen bonding to the substrate 
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specificity loop, and increase potency for BlaC inhibition. In addition, further 
characterization of the inhibitory activity of benzoxaboroles with modifications at the 5’ 
and 7’ positions remain to be investigated. 
 According to the W.H.O., rapid spreading of drug resistant tuberculosis 
infections across the globe particularly in resource limited environments in South Africa, 
India, and southeast Asia demands the development of newer and more rapid diagnostic 
strategies to reduce transmission and decrease mortality. One of the main hurdles to 
detecting tuberculosis is the slow growth rate of the pathogen, which prevents rapid 
detection because of the long time required to culture the bacilli. Furthermore, the 
conventional methods of detection including smear microscopy, skin tests and chest x-
rays are not sensitive or conclusive enough to diagnose tuberculosis infection
105,106,188
. 
Newer nucleic acid-based and fluorescence based techniques are improving the 
sensitivity and specificity of detection
170,181,306
. Amplification of signal is ideal for 
detecting very small concentrations of pathogen, which offers a distinct advantage for 
the early detection of tuberculosis. The fact that BlaC is a constitutively expressed and 
secreted enzyme facilitates detection of the Mtb in vitro and in vivo through the use of β-
lactam fluorogenic probes
103,181
 .  
 The challenge that is posed by using β-lactam-based probes is the possibility for 
false positives due to normal flora or other pathogens that infect the respiratory tract and 
secrete β-lactamases. This challenge can be met by increasing the specificity of β-lactam 
probes for BlaC relative to other similar class A β-lactamases. The TEM family of β-
lactamases is the most prevalent plasmid encoded family of β-lactamases found in the 
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clinic
57
, and the active site is nearly identical to BlaC
97
. Therefore, TEM-1 was selected 
as a model enzyme for comparison of probe specificity relative to BlaC. The 
cephalosporin β-lactam was selected for probe design because of its ability to release a 
fluorescent leaving group upon hydrolysis by β-lactamase. The cephalosporin scaffold 
was modified at the side chain of the 7’ amino group (R1) or at the 7’ position of the β-
lactam ring. BlaC is known for its large active site relative to other class A β-
lactamases
97
. In order to see if extension of the R1 side chain would confer specificity of 
the probes for BlaC relative to TEM, modifications made to the R1 position increased in 
size from methyl to benzyl and then to the extended side chain of cefoperazone
103
. This 
resulted in probes that were hydrolyzed by both β-lactamases and exhibited slightly 
more selectivity for the TEM-1 enzyme because of increased turnover relative to BlaC.  
However, selectivity of the probes for BlaC was generated by modification of the 7’ 
position of the β-lactam ring with methoxy and ethoxy groups.  BlaC and TEM were 
able to hydrolyze the 7’-methoxy modified probe. Addition of the larger ethoxy group 
decreased turnover for BlaC by 100 fold, but abolished turnover by TEM-1. The 7’-
methoxy probe (CDC-OMe) exhibited over 3 orders of magnitude selectivity for BlaC 
(kcat/Km = 2.1× 10
4
 s
-1
 M
-1
) over TEM-1 (kcat/Km = 16 s
-1
 M
-1
). These observations 
show that increasing the size of the modification at the 7’-postion of the β-lactam ring is 
sufficient to generate selectivity of fluorogenic probes for BlaC over the very similar 
TEM-1 enzyme
103
. 
 To identify the structural basis behind the observed selectivity of CDC-OMe for 
BlaC over TEM-1, acyl-intermediate crystal structures of BlaC were solved with the 
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selective probe CDC-OMe and the non-selective probe CDC-1
103
. The crystal structures 
showed probes bound in the same orientation as substrates, forming conserved 
interactions with substrate recognition residues. Superimposition of these structures with 
the TEM-1 crystal structure showed that the main structural difference between the BlaC 
active site and the TEM-1 active site was the flexible nature of the BlaC substrate 
specificity loop relative to TEM-1
97,186
.  BlaC and TEM-1 share 3 conserved salt bridges 
that serve to stabilize the conformation of the substrate specificity loops for catalysis. 
The R164 side chain increases the rigidity of the TEM-1 substrate specificity loop 
relative to BlaC by making 3 additional salt bridges. This residue is A164 in BlaC, 
which increases the flexibility of BlaC substrate specificity loop allowing it to expand 
the active site and facilitate Glu166 to adopt a catalytically competent conformation for 
reaction completion. The structural basis for decreased turnover of 7’-methoxy 
substituted fluorogenic probes by BlaC and TEM-1 was revealed by the acyl-
intermediate crystal structure of BlaC with CDC-OMe. The structure showed that the 7’-
methoxy group was positioned directly in the path of catalytic base Glu166, preventing 
hydrolytic water coordination for hydrolysis. This observation supports the hypothesis 
that the flexibility of BlaC substrate specificity loop relative to TEM-1 facilitates 
selectivity for BlaC by allowing Glu166 to sample more conformations for reaction 
completion
103
.  
 The selectivity of CDC-OMe was further demonstrated with whole E. coli cells 
expressing either TEM-1 or BlaC. Further optimization of the fluorescent leaving group 
led to an additional >10 fold increase in specificity for BlaC, resulting in greater than 
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four orders of magnitude selectivity for BlaC over TEM in vitro
103
. The sensitivity and 
specificity of the final probe was also demonstrated with raw unprocessed human 
sputum that contained Mtb var. bovis BCG or other β-lactamase producing bacteria 
including E. coli, P. aeruginosa, M. smegmatis, and S. aureus. The final probe was able 
to detect down to 10 mycobacteria in 200 µL of human sputum.  Furthermore, there are 
still positions of the β-lactam probe scaffold  that have yet to be chemically explored, 
which offers possibility for design of even more specific and selective biosensors for a 
rapid and cost effective method for early tuberculosis detection
103
. 
 The recent discovery and rapid dissemination of the New Delhi Metallo-β-
lactamase (NDM-1) foreshadows a future where β-lactam antibiotics are no longer 
effective against pathogenic bacteria
107,133,194,277
. The NDM-1 gene isolated from a 
patient carrying K. pneumonia was characterized by susceptibility testing with β-lactam 
antibiotics. NDM-1 carrying E. coli and K. pneumonia displayed extended spectrum 
resistance to β-lactam antibiotics including several cephalosporins and carbapenems. In 
order to understand the contribution of NDM-1 to the observed extended spectrum 
antibiotic resistance due to NDM-1, the truncated NDM-1 enzyme lacking the N-
terminal signal peptide was over-expressed in non-pathogenic E. coli and purified to 
homogeneity
108,279
. Biochemical characterization of purified NDM-1 in vitro revealed 
that NDM-1 is a potent MBL enzyme with a very broad and non-specific substrate 
profile. Furthermore, it has the ability to non-discriminately bind and hydrolyze 
cephalosporin, cephamycin, and carbapenem and penem classes of β-lactams108,279.  
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 To identify the mechanism of NDM-1 promiscuity in substrate recognition and 
hydrolysis, the crystal structure of NDM-1 was solved in apo, monometalated 
108
 and 
dimetalated forms. About the same time, several other investigators published the 
structure of NDM-1 with slightly different N-terminal truncations in dimetalated forms, 
and with the hydrolyzed β-lactam substrate ampicillin46,47,49. Comparison of the apo, 
monometalated, dimetalated NDM-1 revealed the structural plasticity of five active site 
loops, and the preserved fold in absence or presence of cofactors
108
. The two zinc co-
factors are coordinated via two catalytic triads (His, His, His / His, Asp, Cys); the triad 
residues are donated from five flexible active site loops. The HHH triad is the higher 
affinity site, which is evident by its presence in the three monometalated NDM-1 
structures
108
 and consistency with other structurally characterized MBLs
126
. Binding of 
the second zinc co-factor orders the second catalytic HDC triad by pulling the residues 
into closer proximity, and stabilizes the active site in a catalytically competent 
conformation for substrate recognition and hydrolysis
108,236
. The most important 
structural feature of NDM-1 that contributes to promiscuous substrate recognition and 
hydrolysis is the enlarged active site formed by the five flexible active site loops. The 
enlarged active site is partially due to insertions in the active site loops, and substitution 
of the large hydrophobic residues in other MBL active sites with alanines in NDM-1. 
These features allow for decreased rigidity of the active site loops and increased volume 
of the NDM-1 active site, facilitating the acceptance of structurally diverse substrates
108
. 
The crystal structures of NDM-1 with hydrolyzed substrates showed that the substrate R 
groups extended into the open cavities of the active site, and the oxygen atoms of the β-
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lactam carbonyl and carboxylate moieties were recognized by the zinc co-factors
47,52,236
. 
Active site loop 1 has the most conformational variability, and is flexed outward to 
expand the active site cavity when liganded
46,48,52
. The hydrophobic surface area formed 
by active site loop 1 is hypothesized to non-specifically recognize substrates for 
hydrolysis
46,50,52
. 
 The MBL mechanism is generally accepted to function through assisted catalysis 
from zinc co-factor(s) that activate an ordered solvent molecule for nucleophilic attack 
of the lactam, and the specific details of the reaction mechanism have been the subject of 
investigation
45,127
. The catalytic base is important to note.  It has been suggested that the 
conserved aspartate in the second zinc binding site serves as the catalytic base, but 
mutational studies confirmed that this residue is not absolutely essential for 
catalysis
128,129
. Spectroscopic studies of the NDM-1 reaction show three reactions 
species that were hypothesized to represent substrate, ring-opened intermediate, and 
product
51
. Protonation of the ring-opened lactam nitrogen is required for product 
formation, but the exact origin of the proton is still at question.  In addition, no data 
suggests whether or not the ordered solvent molecule coordinated by the zinc co-
factor(s) is a water molecule or hydroxide ion.  
 To gain insight into the pH dependence of the reaction mechanism of NDM-1, 
the activity of NDM-1 at pH ranging from 5.5-8.5 was examined. NDM-1 was 
approximately 5-fold more catalytically active at higher pH
52
. The ability of NDM-1 to 
function in acidic and basic environments suggests that the zinc-ordered catalytic solvent 
molecule is a hydroxide ion at high pH and a water molecule at low pH. Molecular 
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dynamics simulations predicted that the NDM-1 zinc-zinc distance is theoretically 5.6 Å, 
when an ordered water molecule is bound and 3.6 Å when an ordered hydroxide ion is 
bound
52
. Consistent with the biochemical and computational data, examination of the 
available structural data for NDM-1 showed that the variation in the distance between 
the zinc co-factors was pH dependent
46,47,49,50,52,108
. In general, greater zinc-zinc 
distances were observed in low pH conditions, consistent with an ordered water 
molecule, and shorter zinc-zinc distances at higher pH, consistent with an ordered 
hydroxide. In the high resolution (1.05 Å) crystal structure of NDM-1 solved at pH 6.5, 
the zinc-zinc distance was 4.6 Å, suggesting partial occupancy by a hydroxide ion and 
water molecule
52
. In another study, data collected at pH 7.6 suggested a 3.38 Å zinc-zinc 
distance, consistent with an ordered hydroxide.  In summary, these observations 
suggested that the NDM-1 reaction mechanism can proceed with a zinc ordered water or 
hydroxide, in a pH dependent manner
52
. 
 Metal dependence studies showed that NDM-1 was almost completely 
inactivated when the zinc co-factor was replaced by cadmium, which enabled structure 
determination of NDM-1 with unhydrolyzed and partially hydrolyzed ampicillin. Zinc 
liganded structures of NDM-1 with ampicillin only yielded hydrolyzed product
52
. To 
gain further insight into the NDM-1 reaction mechanism, computational studies were 
conducted using the aforementioned substrate-liganded NDM-1 structures as starting 
points
52
. The simulations estimated the energy along the reaction coordinate of NDM-1 
reaction using the previously proposed model that uses active site aspartate as the 
general base, and investigated other potential mechanisms where the coordinated solvent 
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(water or hydroxide) serves as the catalytic base. These simulations revealed that the 
most energetically favorable NDM-1 reaction mechanism used the zinc ordered solvent 
molecule (hydroxide at high pH, or water at low pH) as the catalytic base to activate a 
water molecule from bulk solvent for attack of the β-lactam ring. Subsequent to ring 
opening, the lactam nitrogen is protonated by translocation through a bulk solvent 
mediated proton shuttle
52
.  Cumulatively, the biochemical, biophysical, and 
computational data support that NDM-1 is a promiscuous MBL due to its expanded 
active site cavity that enables it to indiscriminately bind structurally diverse substrates 
through recognition of the β-lactam core by zinc co-factors and hydrolyze them with a 
pH-dependent proton shuttle based mechanism. 
 From the BlaC studies, we see that single interactions or active site features are 
able to distinguish rapidly and poorly hydrolyzed β-lactam substrates, increase the 
affinity of β-lactamase inhibitors, or enhance the selectivity of β-lactam based 
fluorogenic probes, while the majority of the interactions involved in ligand recognition 
remain the same. This implies that resistance to inhibitors, expanded enzymatic activity, 
or loss of probe selectivity can easily arise from single point mutations, and that future 
design efforts should target interactions with residues that will be less likely to tolerate 
mutations.  
 On the other hand, NDM-1 retains promiscuous enzymatic activity primarily 
through recognition of the core of β-lactam substrates, and a lack of specific interactions 
that confer substrate specificity. The mechanistic details of the NDM-1 reaction 
described in this record of study will aid in the future design of specific NDM-1 
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inhibitors. Inhibitors will likely be non-specifically recognized by the catalytic zinc co-
factors as are many existing MBL inhibitors
61
. Additional specificity and potency will 
have to be rationally designed by making additional interactions with the hydrophobic 
pocket formed by active site loop 1, or other hydrogen bonding residues that extend 
along the active site cavity of NDM-1. These inhibitor structure activity relationship 
studies are underway. 
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Figure A1. Raw FTICR-MS time course spectra of the BlaC reaction with (a) biapenem, (b) tebipenem, 
and (c) faropenem. Reaction species are labeled according to their respective mass (Da) and colored (blue) 
free enzyme, (purple) acyl-intermediate (M), and (orange) M – 44 Da. (left) Time of reaction quenching in 
seconds. 
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Table A1. Crystallographic data collection and refinement statistics of BlaC-acyl-intermediate complexes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 E166A  
Amoxicillin 
E166A 
Cefoperazone 
E166A 
Cefotaxime 
Data collection    
Space group P21 P21 P21 
    
a, b, c (Å) 79.6, 96.7, 109.8 78.3, 95.6, 108. 7 78.8, 96.2, 107.1 
)  90.0, 107.5, 90.0 90.0, 107.2, 90.0 90.0, 106.3, 90.0 
Resolution (Å) 47-2.85 (2.93-2.85)* 47-2.25 (2.25-2.28) * 45-2.30 (2.34-2.29)* 
Rmerge 0.20 (0.87) 0.09 (0.55) 0.11 (0.63) 
I / σI 12.0 (2.1) 20.0 (2.2) 13.0 (2.0) 
Completeness (%) 99 (99) 99 (99) 98 (81) 
Redundancy 5.1 (5.1) 3.6 (3.6) 3.6 (3.5) 
Wavelength (Å)  0.91990 0.97929 0.91959 
Refinement    
Resolution (Å) 47.26 - 2.85  47 - 2.19 45 - 2.29 
No. reflections 36,965 71,884 67,526 
Rwork/ Rfree  .21/.24 .21/.22 .21/.24 
No. atoms 7864 8026 7948 
Protein   7784 7667  7730 
    Adduct 50 74  52 
    PO4 30 40 45 
    Water 0 245 121 
B-factors    
    Protein 60.49 39.07 38.06 
    Adduct 62.37 53.90 60.86 
    PO4 110.2 82.24 67.90 
    Water n/a 48.91 39.69 
R.m.s deviations    
    Bond lengths (Å)  0.017 0.026 0.006 
    Bond angles (º) 1.662 1.521 0.818 
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Table A1 continued. Crystallographic data collection and refinement statistics of BlaC-acyl-intermediate 
complexes. 
 
 
 
 
 
 
 E166A 
Faropenem 
WT 
Biapenem  
WT 
Tebipenem 
Data collection    
Space group P21  P21 P21 
    
a, b, c (Å) 78.5, 97.0, 110.0 78.5, 97.0, 110.0 78.5, 96.3, 110.2 
)  90.0, 108.7, 90.0 90.0, 108.7, 90.0 90.0, 108.3, 90.0 
Resolution (Å) 47-2.10 (2.15-
2.11)* 
37-1.72 (1.75-
1.72)* 
47-2.04(2.09-2.05)* 
Rmerge 0.13 (0.84) 0.06 (0.71) 0.07 (0.51) 
I / σI 16.1 (2.3) 20.9 (2.1) 24.14 (2.6) 
Completeness (%) 98 (74) 100 (99) 98 (86) 
Redundancy 5.1 (4.5) 2.5 (2.5) 3.6 (2.7) 
Wavelength (Å) 0.91990 0.97926 0.97740 
Refinement    
Resolution (Å) 47-2.10  37-1.72 47-2.04  
No. reflections 89,625 157,565 97,020 
Rwork/ Rfree .17/.20 .17/.18 .17/.21 
No. atoms 8380 8823 8622 
Protein 7874 7912 7906 
    Adduct 38 48 50 
    PO4 40 40 30 
    Water 428 823 636 
B-factors    
    Protein 29.65 24.08 29.88 
    Adduct 53.62 53.89 49.77 
    PO4 64.14 41.36 52.76 
    Water 38.32 41.43 44.44 
R.m.s deviations    
    Bond lengths (Å)  0.015 0.008 0.015 
    Bond angles (º) 1.494 1.303 1.617 
 196 
 
             
Figure A2. Benzoxaborole scaffold (a) and lead inhibitor AN4715 (b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b 
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Table A2. BlaC-benzoxaborole crystallographic data collection and refinement statistics. 
 
 
 
 
 
 
 BlaC AN4715 BlaC AN4845 BlaC AN4967 
Data collection    
Space group P21  P21 P21 
    
a, b, c (Å) 78.9, 96.8, 110.9 78.5, 96.7, 109.6 78.3, 96.2, 110.1 
)  90.0, 108.2, 90.0 90.0, 107.9, 90.0 90.0, 108.4, 90.0 
Resolution (Å) 47-2.4 (2.44-2.40) 47-2.23 (2.26-2.23) 47-2.34(2.37-2.34) 
Rmerge 0.15 (0.61) 0.14 (0.86) 0.18 (0.97) 
I / σI 13.8 (2.0) 15.2 (2.3) 10.6 (2.4) 
Completeness (%) 99 (88) 97 (43) 99 (90) 
Redundancy 7.0 (5.3) 5.9 (5.8) 5.5 (5.7) 
Wavelength (Å) 0.95380 0.97947 0.97947 
Refinement    
Resolution (Å) 47-2.40  37-1.72 47-2.34  
No. reflections 61,695 73,601 61,269 
Rwork/ Rfree 0.16/0.20 0.16/0.19 0.18/0.22 
No. atoms 8427 8378 8351 
Protein 7961 7952 7972 
    Adduct 46 58 54 
    PO4 40 40 35 
    Water 380 328 290 
B-factors    
    Protein 24.82 35.86 34.40 
    Adduct 37.70 64.18 50.43 
    PO4 49.72 61.62 63.16 
    Water 28.65 38.57 36.30 
R.m.s deviations    
    Bond lengths (Å)  0.007 0.007 0.008 
    Bond angles (º) 1.193 1.133 1.163 
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Table A3. BlaC-fluorogenic probe crystallographic data collection and refinement statistics. 
a
 Values in 
parentheses are for highest-resolution shell. Each dataset was collected from a single crystal. 
b
 Due to the 
difference in the disorder of the substrate specificity loop and resolution, the protein atom number in both 
structures is different.  
 
 
 
 
 
 
 
 
 
 
 BlaC CDC-1 BlaC CDC-3 
Data collection   
Space group P21  P21 
   
a, b, c (Å) 79.40, 97.46, 110.96  78.5, 97.0, 110.0 
)  90.0, 108.37, 90.0  90.0, 107.69, 90.0  
 
Resolution (Å) 50-2.60 (2.60-2.64) 
a
  50-2.80 (2.80-2.85) 
a
  
Rmerge 0.15 (0.72)  0.12 (0.80)  
I / σI 12.0 (2.1)  11.7 (1.2)  
Completeness (%) 99 (98)  99.1 (99.9)  
Redundancy 4.0 (3.9)  4.1 (4.1)  
Wavelength (Å) 0.97929  0.91943  
Refinement   
Resolution (Å) 47.26 - 2.57  47.16 - 2.77  
No. reflections 49,807  38,850  
Rwork/ Rfree 0.22/0.25  0.24/0.25  
No. atoms 8124  7409  
Protein 7928 
b
  7285 
b 
 
    Adduct 46  96  
    PO4 35  15  
    Water 114  13  
B-factors   
    Protein 49.19  72.59  
    Adduct 90.41  93.64  
    PO4 77.61  103.98  
    Water 43.17  66.12  
R.m.s deviations   
    Bond lengths (Å)  0.010  0.011  
    Bond angles (º) 1.176  1.297  
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Table A4. Summary of the NDM-1 crystallographic data. a Rmerge = ΣhklΣi  Ii  - < I >  / ΣhklΣi  < I > 
, where Ii is the intensity for the ith measurement of an equivalent reflection with indices h, k, and l. b 
Numbers in parentheses are values for the highest-resolution bin. c Refined using PHENIX. 
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Table A5. NDM-1 Data collection, phasing, and refinement statistics. Values in parentheses are for 
highest-resolution shell. 
 
 
